WO2022196701A1 - 濾胞性t細胞を用いた新規医療技術 - Google Patents
濾胞性t細胞を用いた新規医療技術 Download PDFInfo
- Publication number
- WO2022196701A1 WO2022196701A1 PCT/JP2022/011710 JP2022011710W WO2022196701A1 WO 2022196701 A1 WO2022196701 A1 WO 2022196701A1 JP 2022011710 W JP2022011710 W JP 2022011710W WO 2022196701 A1 WO2022196701 A1 WO 2022196701A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disease
- cells
- follicular
- subject
- level
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 304
- 230000003325 follicular Effects 0.000 title claims abstract description 265
- 238000000034 method Methods 0.000 title claims abstract description 153
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 550
- 201000010099 disease Diseases 0.000 claims abstract description 544
- 208000015181 infectious disease Diseases 0.000 claims description 105
- 229960005486 vaccine Drugs 0.000 claims description 88
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 85
- 208000023275 Autoimmune disease Diseases 0.000 claims description 81
- 238000011156 evaluation Methods 0.000 claims description 74
- 206010028980 Neoplasm Diseases 0.000 claims description 71
- 238000009826 distribution Methods 0.000 claims description 54
- 238000012360 testing method Methods 0.000 claims description 50
- 201000011510 cancer Diseases 0.000 claims description 48
- 239000003153 chemical reaction reagent Substances 0.000 claims description 47
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 claims description 44
- 208000035415 Reinfection Diseases 0.000 claims description 43
- 238000000684 flow cytometry Methods 0.000 claims description 41
- 208000035473 Communicable disease Diseases 0.000 claims description 36
- 239000003814 drug Substances 0.000 claims description 36
- 239000003795 chemical substances by application Substances 0.000 claims description 33
- 238000004458 analytical method Methods 0.000 claims description 29
- 238000003556 assay Methods 0.000 claims description 28
- 208000036142 Viral infection Diseases 0.000 claims description 25
- 230000009385 viral infection Effects 0.000 claims description 25
- 206010020751 Hypersensitivity Diseases 0.000 claims description 24
- 238000005259 measurement Methods 0.000 claims description 22
- 208000026935 allergic disease Diseases 0.000 claims description 21
- 230000007815 allergy Effects 0.000 claims description 21
- 229940124597 therapeutic agent Drugs 0.000 claims description 20
- 230000002068 genetic effect Effects 0.000 claims description 17
- 238000012744 immunostaining Methods 0.000 claims description 17
- 238000010249 in-situ analysis Methods 0.000 claims description 17
- 238000003745 diagnosis Methods 0.000 claims description 15
- 230000001681 protective effect Effects 0.000 claims description 15
- 238000012502 risk assessment Methods 0.000 claims description 15
- 230000001575 pathological effect Effects 0.000 claims description 14
- 230000007170 pathology Effects 0.000 claims description 14
- 230000000069 prophylactic effect Effects 0.000 claims description 12
- 229940045207 immuno-oncology agent Drugs 0.000 claims description 11
- 239000002584 immunological anticancer agent Substances 0.000 claims description 11
- 230000003449 preventive effect Effects 0.000 claims description 7
- 238000012335 pathological evaluation Methods 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 154
- 239000000427 antigen Substances 0.000 description 100
- 108091007433 antigens Proteins 0.000 description 98
- 102000036639 antigens Human genes 0.000 description 98
- 210000004027 cell Anatomy 0.000 description 95
- 102000004196 processed proteins & peptides Human genes 0.000 description 78
- 108090000623 proteins and genes Proteins 0.000 description 72
- 239000000203 mixture Substances 0.000 description 57
- 235000001014 amino acid Nutrition 0.000 description 56
- 229940024606 amino acid Drugs 0.000 description 56
- 150000001413 amino acids Chemical class 0.000 description 55
- QVVFNJUJKXWFAU-SAYMMRJXSA-N 4,6-O-[(1R)-1-carboxyethylidene]-alpha-D-galactose Chemical compound O1[C@H](O)[C@H](O)[C@@H](O)[C@H]2O[C@](C)(C(O)=O)OC[C@H]21 QVVFNJUJKXWFAU-SAYMMRJXSA-N 0.000 description 45
- 108091008874 T cell receptors Proteins 0.000 description 42
- 229920001184 polypeptide Polymers 0.000 description 41
- 239000000523 sample Substances 0.000 description 34
- 210000002865 immune cell Anatomy 0.000 description 32
- 102000004169 proteins and genes Human genes 0.000 description 29
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 27
- 235000018102 proteins Nutrition 0.000 description 27
- 108091034117 Oligonucleotide Proteins 0.000 description 24
- 150000007523 nucleic acids Chemical class 0.000 description 24
- 102000040430 polynucleotide Human genes 0.000 description 24
- 108091033319 polynucleotide Proteins 0.000 description 24
- 239000002157 polynucleotide Substances 0.000 description 24
- 230000014509 gene expression Effects 0.000 description 23
- 108010074108 interleukin-21 Proteins 0.000 description 23
- 102000039446 nucleic acids Human genes 0.000 description 23
- 108020004707 nucleic acids Proteins 0.000 description 23
- 239000008194 pharmaceutical composition Substances 0.000 description 23
- 230000000875 corresponding effect Effects 0.000 description 22
- 230000015654 memory Effects 0.000 description 22
- 210000003719 b-lymphocyte Anatomy 0.000 description 21
- 230000000694 effects Effects 0.000 description 21
- 230000006870 function Effects 0.000 description 21
- 125000003275 alpha amino acid group Chemical group 0.000 description 20
- 102100031673 Corneodesmosin Human genes 0.000 description 19
- 101710139375 Corneodesmosin Proteins 0.000 description 19
- 239000000126 substance Substances 0.000 description 19
- 108700028369 Alleles Proteins 0.000 description 18
- 102210047362 DRB1*15:01 Human genes 0.000 description 18
- 210000000612 antigen-presenting cell Anatomy 0.000 description 18
- 230000036039 immunity Effects 0.000 description 18
- 210000005259 peripheral blood Anatomy 0.000 description 17
- 239000011886 peripheral blood Substances 0.000 description 17
- 238000011282 treatment Methods 0.000 description 17
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 16
- 230000000890 antigenic effect Effects 0.000 description 16
- 229910052804 chromium Inorganic materials 0.000 description 16
- 239000011651 chromium Substances 0.000 description 16
- 238000004891 communication Methods 0.000 description 16
- 239000002609 medium Substances 0.000 description 16
- 239000013642 negative control Substances 0.000 description 16
- 241001678559 COVID-19 virus Species 0.000 description 15
- 241000700605 Viruses Species 0.000 description 15
- 230000009258 tissue cross reactivity Effects 0.000 description 15
- 102000004127 Cytokines Human genes 0.000 description 14
- 108090000695 Cytokines Proteins 0.000 description 14
- 230000028993 immune response Effects 0.000 description 14
- 230000004044 response Effects 0.000 description 13
- 239000002299 complementary DNA Substances 0.000 description 12
- 238000001514 detection method Methods 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 230000009257 reactivity Effects 0.000 description 12
- 208000025721 COVID-19 Diseases 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 11
- 102210012675 DRB1*15 Human genes 0.000 description 11
- 238000011510 Elispot assay Methods 0.000 description 11
- 230000004913 activation Effects 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 11
- 230000000638 stimulation Effects 0.000 description 11
- 238000006467 substitution reaction Methods 0.000 description 11
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 10
- 239000003124 biologic agent Substances 0.000 description 10
- 241000712461 unidentified influenza virus Species 0.000 description 10
- 230000003612 virological effect Effects 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 9
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 9
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 9
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 9
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 9
- 239000013566 allergen Substances 0.000 description 9
- 230000005809 anti-tumor immunity Effects 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 230000002458 infectious effect Effects 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- -1 ICOS Proteins 0.000 description 8
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- QSHGUCSTWRSQAF-FJSLEGQWSA-N s-peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C1=CC=C(OS(O)(=O)=O)C=C1 QSHGUCSTWRSQAF-FJSLEGQWSA-N 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 230000004071 biological effect Effects 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 6
- 238000003559 RNA-seq method Methods 0.000 description 6
- 239000012980 RPMI-1640 medium Substances 0.000 description 6
- 230000005867 T cell response Effects 0.000 description 6
- 208000006673 asthma Diseases 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 210000002443 helper t lymphocyte Anatomy 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 239000012678 infectious agent Substances 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 description 5
- 244000309467 Human Coronavirus Species 0.000 description 5
- 102000043131 MHC class II family Human genes 0.000 description 5
- 108091054438 MHC class II family Proteins 0.000 description 5
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 229940030156 cell vaccine Drugs 0.000 description 5
- 239000000032 diagnostic agent Substances 0.000 description 5
- 229940039227 diagnostic agent Drugs 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 230000016784 immunoglobulin production Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000035800 maturation Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 description 4
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 4
- 206010012438 Dermatitis atopic Diseases 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 description 4
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 4
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 4
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 240000003829 Sorghum propinquum Species 0.000 description 4
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 201000008937 atopic dermatitis Diseases 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 230000009266 disease activity Effects 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000028996 humoral immune response Effects 0.000 description 4
- 230000004727 humoral immunity Effects 0.000 description 4
- 208000026278 immune system disease Diseases 0.000 description 4
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000010606 normalization Methods 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 description 3
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 3
- 241001225321 Aspergillus fumigatus Species 0.000 description 3
- 102100032937 CD40 ligand Human genes 0.000 description 3
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 3
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 3
- 244000281762 Chenopodium ambrosioides Species 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 241000711573 Coronaviridae Species 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 3
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 description 3
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 206010039085 Rhinitis allergic Diseases 0.000 description 3
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 201000010105 allergic rhinitis Diseases 0.000 description 3
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 235000003484 annual ragweed Nutrition 0.000 description 3
- 229940091771 aspergillus fumigatus Drugs 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008827 biological function Effects 0.000 description 3
- 235000006263 bur ragweed Nutrition 0.000 description 3
- 235000003488 common ragweed Nutrition 0.000 description 3
- 238000004590 computer program Methods 0.000 description 3
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 235000009736 ragweed Nutrition 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000004043 responsiveness Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 210000001082 somatic cell Anatomy 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 241001529453 unidentified herpesvirus Species 0.000 description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- 240000004731 Acer pseudoplatanus Species 0.000 description 2
- 235000002754 Acer pseudoplatanus Nutrition 0.000 description 2
- 208000026872 Addison Disease Diseases 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000027932 Collagen disease Diseases 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 2
- 241001333951 Escherichia coli O157 Species 0.000 description 2
- 206010061126 Escherichia infection Diseases 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 2
- 101001010621 Homo sapiens Interleukin-21 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 2
- 208000005647 Mumps Diseases 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 206010034277 Pemphigoid Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 235000006485 Platanus occidentalis Nutrition 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 241000315672 SARS coronavirus Species 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- 208000002474 Tinea Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 244000078534 Vaccinium myrtillus Species 0.000 description 2
- 241000700647 Variola virus Species 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 241000907316 Zika virus Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 230000033289 adaptive immune response Effects 0.000 description 2
- 230000004721 adaptive immunity Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000009824 affinity maturation Effects 0.000 description 2
- 201000009961 allergic asthma Diseases 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 238000006664 bond formation reaction Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 208000000594 bullous pemphigoid Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 208000020612 escherichia coli infection Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 230000012178 germinal center formation Effects 0.000 description 2
- 238000011194 good manufacturing practice Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 230000009390 immune abnormality Effects 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 239000000677 immunologic agent Substances 0.000 description 2
- 229940124541 immunological agent Drugs 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 239000006194 liquid suspension Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 208000010805 mumps infectious disease Diseases 0.000 description 2
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 238000007481 next generation sequencing Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 208000005987 polymyositis Diseases 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 238000011191 terminal modification Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000000439 tumor marker Substances 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
- 125000000134 2-(methylsulfanyl)ethyl group Chemical group [H]C([H])([H])SC([H])([H])C([H])([H])[*] 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- UJBCLAXPPIDQEE-UHFFFAOYSA-N 5-prop-1-ynyl-1h-pyrimidine-2,4-dione Chemical group CC#CC1=CNC(=O)NC1=O UJBCLAXPPIDQEE-UHFFFAOYSA-N 0.000 description 1
- 244000101408 Abies amabilis Species 0.000 description 1
- 235000014081 Abies amabilis Nutrition 0.000 description 1
- 208000016026 Abnormality of the immune system Diseases 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 241000208140 Acer Species 0.000 description 1
- 240000002767 Acer grandidentatum Species 0.000 description 1
- 235000010319 Acer grandidentatum Nutrition 0.000 description 1
- 235000010328 Acer nigrum Nutrition 0.000 description 1
- 235000002629 Acer saccharinum Nutrition 0.000 description 1
- 235000010157 Acer saccharum subsp saccharum Nutrition 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 241001093951 Ailanthus altissima Species 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 241000223600 Alternaria Species 0.000 description 1
- 244000237956 Amaranthus retroflexus Species 0.000 description 1
- 235000013479 Amaranthus retroflexus Nutrition 0.000 description 1
- 235000004135 Amaranthus viridis Nutrition 0.000 description 1
- 241000208841 Ambrosia trifida Species 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 241000256837 Apidae Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 235000015701 Artemisia arbuscula Nutrition 0.000 description 1
- 235000002657 Artemisia tridentata Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000228193 Aspergillus clavatus Species 0.000 description 1
- 241000228197 Aspergillus flavus Species 0.000 description 1
- 241000351920 Aspergillus nidulans Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241001465318 Aspergillus terreus Species 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 208000011594 Autoinflammatory disease Diseases 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 206010060999 Benign neoplasm Diseases 0.000 description 1
- 244000274847 Betula papyrifera Species 0.000 description 1
- 235000009113 Betula papyrifera Nutrition 0.000 description 1
- 235000009109 Betula pendula Nutrition 0.000 description 1
- 235000010928 Betula populifolia Nutrition 0.000 description 1
- 235000002992 Betula pubescens Nutrition 0.000 description 1
- 241000219495 Betulaceae Species 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 241000228405 Blastomyces dermatitidis Species 0.000 description 1
- 241001674044 Blattodea Species 0.000 description 1
- 206010005913 Body tinea Diseases 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 241000589567 Brucella abortus Species 0.000 description 1
- 241001509299 Brucella canis Species 0.000 description 1
- 241001148106 Brucella melitensis Species 0.000 description 1
- 241001148111 Brucella suis Species 0.000 description 1
- 241000722910 Burkholderia mallei Species 0.000 description 1
- 241001136175 Burkholderia pseudomallei Species 0.000 description 1
- 240000001432 Calendula officinalis Species 0.000 description 1
- 235000005881 Calendula officinalis Nutrition 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000144583 Candida dubliniensis Species 0.000 description 1
- 241000222173 Candida parapsilosis Species 0.000 description 1
- 241000222178 Candida tropicalis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 1
- 241000723418 Carya Species 0.000 description 1
- 235000009025 Carya illinoensis Nutrition 0.000 description 1
- 244000068645 Carya illinoensis Species 0.000 description 1
- 240000008444 Celtis occidentalis Species 0.000 description 1
- 235000018962 Celtis occidentalis Nutrition 0.000 description 1
- 241001619326 Cephalosporium Species 0.000 description 1
- 241000422842 Chamaecyparis pisifera Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 235000009344 Chenopodium album Nutrition 0.000 description 1
- 235000005484 Chenopodium berlandieri Nutrition 0.000 description 1
- 235000009332 Chenopodium rubrum Nutrition 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 241001647372 Chlamydia pneumoniae Species 0.000 description 1
- 241001647378 Chlamydia psittaci Species 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010056979 Colitis microscopic Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241001522864 Cryptococcus gattii VGI Species 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- 241000223208 Curvularia Species 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 241000209210 Dactylis Species 0.000 description 1
- 241000222175 Diutina rugosa Species 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 235000017643 Elaeagnus angustifolia Nutrition 0.000 description 1
- 244000307545 Elaeagnus angustifolia Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- 206010060742 Endocrine ophthalmopathy Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 241001492222 Epicoccum Species 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- 235000010099 Fagus sylvatica Nutrition 0.000 description 1
- 240000000731 Fagus sylvatica Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000234642 Festuca Species 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 241000589602 Francisella tularensis Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101710114810 Glycoprotein Proteins 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 206010061187 Haematopoietic neoplasm Diseases 0.000 description 1
- 206010061190 Haemophilus infection Diseases 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 240000004153 Hibiscus sabdariffa Species 0.000 description 1
- 235000001018 Hibiscus sabdariffa Nutrition 0.000 description 1
- 241001539176 Hime Species 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 1
- 241001428935 Human coronavirus OC43 Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010022491 Insulin resistant diabetes Diseases 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 235000013740 Juglans nigra Nutrition 0.000 description 1
- 244000184861 Juglans nigra Species 0.000 description 1
- 241000721662 Juniperus Species 0.000 description 1
- 241000721668 Juniperus ashei Species 0.000 description 1
- 235000014556 Juniperus scopulorum Nutrition 0.000 description 1
- 235000014560 Juniperus virginiana var silicicola Nutrition 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 241000589929 Leptospira interrogans Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000735234 Ligustrum Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000034762 Meningococcal Infections Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 241000893980 Microsporum canis Species 0.000 description 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 235000003805 Musa ABB Group Nutrition 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 206010028470 Mycoplasma infections Diseases 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 description 1
- 208000037538 Myelomonocytic Juvenile Leukemia Diseases 0.000 description 1
- 241001443590 Naganishia albida Species 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 241001263478 Norovirus Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010030111 Oedema mucosal Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000222051 Papiliotrema laurentii Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 108010043958 Peptoids Proteins 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 240000003889 Piper guineense Species 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 235000015266 Plantago major Nutrition 0.000 description 1
- 208000035109 Pneumococcal Infections Diseases 0.000 description 1
- 241000233872 Pneumocystis carinii Species 0.000 description 1
- 241000142787 Pneumocystis jirovecii Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000002500 Primary Ovarian Insufficiency Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 241001494501 Prosopis <angiosperm> Species 0.000 description 1
- 235000001560 Prosopis chilensis Nutrition 0.000 description 1
- 235000014460 Prosopis juliflora var juliflora Nutrition 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 208000010362 Protozoan Infections Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 235000008572 Pseudotsuga menziesii Nutrition 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 241000219492 Quercus Species 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 241000235527 Rhizopus Species 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 206010067470 Rotavirus infection Diseases 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 235000017848 Rubus fruticosus Nutrition 0.000 description 1
- 235000005291 Rumex acetosa Nutrition 0.000 description 1
- 235000008691 Sabina virginiana Nutrition 0.000 description 1
- 241000119565 Salix gooddingii Species 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000607760 Shigella sonnei Species 0.000 description 1
- 206010049416 Short-bowel syndrome Diseases 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 240000006021 Solidago canadensis Species 0.000 description 1
- 235000003657 Solidago canadensis Nutrition 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- 101710167605 Spike glycoprotein Proteins 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- 241001149963 Sporothrix schenckii Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241001147691 Staphylococcus saprophyticus Species 0.000 description 1
- 206010041956 Stasis syndrome Diseases 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 1
- 244000204900 Talipariti tiliaceum Species 0.000 description 1
- 208000033878 Tertiary Lymphoid Structures Diseases 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 206010043781 Thyroiditis chronic Diseases 0.000 description 1
- 240000007313 Tilia cordata Species 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000007712 Tinea Versicolor Diseases 0.000 description 1
- 201000010618 Tinea cruris Diseases 0.000 description 1
- 206010067719 Tinea faciei Diseases 0.000 description 1
- 206010043870 Tinea infections Diseases 0.000 description 1
- 206010043871 Tinea nigra Diseases 0.000 description 1
- 206010056131 Tinea versicolour Diseases 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- 241000223229 Trichophyton rubrum Species 0.000 description 1
- 241001480048 Trichophyton tonsurans Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241001149163 Ulmus americana Species 0.000 description 1
- 241000417365 Ulmus davidiana var. japonica Species 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 244000274883 Urtica dioica Species 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 201000006449 West Nile encephalitis Diseases 0.000 description 1
- 206010057293 West Nile viral infection Diseases 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 208000027207 Whipple disease Diseases 0.000 description 1
- 208000026589 Wolman disease Diseases 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 241000222126 [Candida] glabrata Species 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000021029 blackberry Nutrition 0.000 description 1
- 208000005634 blind loop syndrome Diseases 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229940056450 brucella abortus Drugs 0.000 description 1
- 229940038698 brucella melitensis Drugs 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229940074375 burkholderia mallei Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 208000032343 candida glabrata infection Diseases 0.000 description 1
- 229940055022 candida parapsilosis Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 208000029771 childhood onset asthma Diseases 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 1
- 208000013507 chronic prostatitis Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 208000008609 collagenous colitis Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 229940029030 dendritic cell vaccine Drugs 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 208000007784 diverticulitis Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000002570 electrooculography Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 230000000369 enteropathogenic effect Effects 0.000 description 1
- 230000000688 enterotoxigenic effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 229940118764 francisella tularensis Drugs 0.000 description 1
- 239000013569 fungal allergen Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 125000003712 glycosamine group Chemical group 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 230000009033 hematopoietic malignancy Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 201000002250 liver carcinoma Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000004341 lymphocytic colitis Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 108010081910 neoplasm-associated factor Proteins 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 206010036601 premature menopause Diseases 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 150000003291 riboses Chemical class 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 235000001520 savin Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 235000003513 sheep sorrel Nutrition 0.000 description 1
- 229940115939 shigella sonnei Drugs 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229940083538 smallpox vaccine Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000012069 sugar maple Nutrition 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 229940036185 synagis Drugs 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000005057 thyrotoxicosis Diseases 0.000 description 1
- 201000009642 tinea barbae Diseases 0.000 description 1
- 201000003875 tinea corporis Diseases 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 206010044697 tropical sprue Diseases 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M1/00—Apparatus for enzymology or microbiology
- C12M1/34—Measuring or testing with condition measuring or sensing means, e.g. colony counters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
Definitions
- This disclosure relates to novel medical technology using follicular T cells. More specifically, it relates to a technique that uses follicular T cells as an indicator for diagnosing diseases.
- the present disclosure applicants found that when an infectious factor (such as a virus) is present, there is a public TfhTCR specific to the infectious factor common to various patients. By rearranging the TCR ⁇ and ⁇ chains, the present inventors confirmed that the antigens presented by the frequent alleles are T cell epitopes. The present inventors have found that this TCR clonotype can be used for diagnostic purposes.
- an infectious factor such as a virus
- (Item 1) A method for assessing a disease in a subject comprising measuring the level or amount of follicular T cells reactive to a disease-associated factor of the disease in the subject. (Item 2) Evaluation of the history of the disease, evaluation of the efficacy of a prophylactic agent or vaccine against the disease, evaluation of the efficacy of a therapeutic agent against the disease, evaluation of protective ability against re-infection of the disease, based on the results of the measurement; The method according to any one of the above items, further comprising performing at least one selected from the group consisting of pathological condition evaluation of the disease and risk of contracting the disease. (Item 3) The method of any of the preceding items, further comprising testing for or diagnosing said disease in said subject.
- the method of any of the preceding items further comprising assessing the subject's history of infection with the disease.
- the method according to any of the above items further comprising assessing vaccine efficacy against said disease in said subject and assessing ability to protect against reinfection.
- the method according to any of the above items further comprising evaluating the efficacy of an immuno-oncology agent for the disease in the subject.
- the disease-associated factor is an autoimmune disease-associated factor, and the measuring includes measuring the level or amount of follicular T cells reactive to the autoimmune disease-associated factor, and autoantibody-associated autoantibody The method according to any of the above items, further comprising risk assessment and pathological evaluation of immune diseases.
- the measurement is performed by ELISPOT, flow cytometry, restimulation assay of peripheral blood mononuclear cells (PBMC), next-generation sequencer/genetic test (repertoire analysis), immunostaining (histopathological test), in situ analysis, Any method described.
- PBMC peripheral blood mononuclear cells
- next-generation sequencer/genetic test repertoire analysis
- immunostaining histopathological test
- in situ analysis Any method described.
- the level, spatial distribution or amount of follicular T cells reactive with the disease-associated factor measured is compared with the level, spatial distribution of follicular T-cells reactive with the disease-associated factor in disease-free subjects. or a method according to any of the preceding items, further comprising comparing to the mean or median amount.
- (Item 11) The method according to any of the preceding items, wherein the disease is a viral infection.
- the disease is an allergy or an autoimmune disease.
- Reagents or devices for assessing a disease in a subject including reagents or devices that measure the level, spatial distribution or amount of follicular T cells reactive to disease-associated factors of the disease in the subject.
- said reagent or device comprises a reagent that specifically reacts with follicular T cells.
- PBMC peripheral blood mononuclear cells
- next generation sequencer/genetic test repertoire analysis
- immunostaining histopathological test
- in situ analysis A reagent or device according to any of the above items, which is (Item 16) The reagent or device according to any of the preceding items, wherein the disease is an infectious disease or cancer. (Item 17) The reagent or device of any of the preceding items, wherein the disease is a viral infection. (Item 18) The reagent or device of any of the preceding items, wherein the disease is an allergy or an autoimmune disease.
- a reagent or device for measuring the level, spatial distribution or quantity of follicular T cells reactive to disease-related factors of disease in a subject comprising an evaluation unit that evaluates the results of measurement by the reagent or device for the disease.
- the evaluation unit evaluates the history of the disease, evaluates the effectiveness of a preventive agent or vaccine against the disease, evaluates the effectiveness of a therapeutic agent against the disease, evaluates the protective ability against re-infection of the disease,
- the system according to any one of the above items, which is configured to perform at least one selected from the group consisting of pathological condition evaluation and morbidity risk evaluation of the disease.
- (Item 21) The system according to any one of the above items, further comprising an examination/diagnosis unit that examines or diagnoses the disease in the subject.
- (Item 22) The system according to any of the above items, further comprising an infection history evaluation unit that evaluates an infection history of the disease of the subject.
- (Item 23) The system according to any one of the above items, further comprising a vaccine effectiveness evaluation/reinfection protective ability evaluation unit that evaluates the vaccine effectiveness evaluation/reinfection protective ability against the disease of the subject.
- (Item 24) The system according to any one of the above items, further comprising a cancer immunodrug efficacy evaluation unit that evaluates efficacy of the cancer immunodrug for the disease of the subject.
- the disease-related factor is an autoimmune disease-related factor, and a follicular T cell measuring unit that measures the level, spatial distribution or amount of follicular T cells reactive to the autoimmune disease-related factor, and the subject
- a system according to any of the preceding items comprising an autoimmune disease risk assessment involving autoantibodies of , an autoimmune disease risk assessment for assessing pathology, and a pathology assessment unit.
- the reagent or device comprises a reagent that specifically reacts with follicular T cells.
- (Item 27) Devices for performing ELISPOT, flow cytometry, restimulation assay of peripheral blood mononuclear cells (PBMC), next generation sequencer/genetic test (repertoire analysis), immunostaining (histopathological test), and in situ analysis
- PBMC peripheral blood mononuclear cells
- next generation sequencer/genetic test repertoire analysis
- immunostaining histopathological test
- in situ analysis The system according to any of the preceding items, wherein (Item 28)
- the level, spatial distribution or amount of follicular T cells reactive with the disease-associated factor measured is compared with the level, spatial distribution of follicular T-cells reactive with the disease-associated factor in disease-free subjects. or the system according to any of the preceding items, further comprising a comparator that compares with the average or median value of the amount.
- (Item 29) The system according to any of the preceding items, wherein the disease is an infectious disease or cancer.
- the disease is a viral infection.
- (Item 31) A system according to any of the preceding items, wherein the disease is an allergy or an autoimmune disease.
- (Item 32) providing information about the level, spatial distribution or quantity of follicular T cells reactive to disease-associated factors of the disease in the subject; Evaluating information regarding the level, spatial distribution or quantity of said follicular T cells for said disease.
- the step of evaluating includes evaluating the history of the disease, evaluating the efficacy of a prophylactic agent or vaccine against the disease, evaluating the efficacy of a therapeutic agent against the disease, evaluating the ability to protect against re-infection of the disease, and evaluating the disease. and evaluating the risk of contracting the disease.
- a method according to any of the preceding items comprising assessing the infection history of the disease in the subject.
- the method according to any of the above items comprising evaluating the efficacy of an immuno-oncology agent for the disease in the subject.
- the disease-associated factor is an autoimmune disease-associated factor
- the measuring includes measuring the level or amount of follicular T cells reactive to the autoimmune disease-associated factor, and autoantibody-associated autoantibody
- the step of providing the information includes ELISPOT, flow cytometry, restimulation assay of peripheral blood mononuclear cells (PBMC), next-generation sequencer/genetic test (repertoire analysis), immunostaining (histopathological test), and in situ analysis.
- a method according to any of the preceding items which is carried out.
- (Item 39) providing information regarding the level, spatial distribution or quantity of follicular T cells reactive to a disease-associated factor of a disease in said subject;
- (Item 40) The method according to any of the preceding items, wherein the disease is an infectious disease or cancer.
- the disease is a viral infection.
- (Item 42) The method of any of the preceding items, wherein the disease is an allergy or an autoimmune disease.
- (Item 43) providing information about the level, spatial distribution or quantity of follicular T cells reactive to disease-associated factors of the disease in the subject; evaluating information regarding the level, spatial distribution or quantity of said follicular T cells for said disease. program containing.
- the step of evaluating includes evaluating the history of the disease, evaluating the efficacy of a prophylactic agent or vaccine against the disease, evaluating the efficacy of a therapeutic agent against the disease, evaluating the ability to protect against re-infection of the disease, and evaluating the disease. and evaluating the risk of contracting the disease.
- the disease-associated factor is an autoimmune disease-associated factor, the method comprising: measuring the level or amount of follicular T cells reactive to the autoimmune disease-associated factor; The program according to any one of the above items, including risk assessment and pathological evaluation of autoimmune diseases associated with antibodies.
- the step of providing the information includes ELISPOT, flow cytometry, restimulation assay of peripheral blood mononuclear cells (PBMC), next-generation sequencer/genetic test (repertoire analysis), immunostaining (histopathological test), and in situ analysis.
- PBMC peripheral blood mononuclear cells
- next-generation sequencer/genetic test repertoire analysis
- immunostaining histopathological test
- in situ analysis A program according to any of the preceding items, which is carried out.
- the method comprises providing information regarding the level, spatial distribution or quantity of follicular T cells reactive to a disease-associated factor of disease in said subject, A program according to any of the preceding items, further comprising comparing the information regarding the level, spatial distribution or quantity of follicular T cells reactive to the mean or median value.
- (Item 51) A program according to any of the preceding items, wherein the disease is an infectious disease or cancer.
- (Item 52) A program according to any of the preceding items, wherein the disease is a viral infection.
- (Item 53) A program according to any of the preceding items, wherein the disease is an allergy or an autoimmune disease.
- (Item 54) A computer-readable recording medium storing the program according to any one of the above items.
- (Item 55) A computer-readable recording medium storing the program according to any one of the above items.
- This disclosure also provides the following items.
- (Item A1) A pharmaceutical composition for treating or preventing a disease comprising a disease-associated factor or a portion or functional equivalent thereof capable of inducing follicular T cells reactive to the disease-associated factor of said disease.
- (Item A2) A vaccine against said disease comprising said disease-associated factor or a part or functional equivalent thereof capable of eliciting follicular T-cells reactive with said disease-associated factor.
- (Item A3) The composition or vaccine of any of the preceding items, wherein said composition or vaccine preferentially induces follicular T cells.
- (Item A4) A pharmaceutical composition for treating or preventing said disease, comprising follicular T cells reactive with said disease-associated factor.
- (Item A5) A cellular vaccine against said disease comprising follicular T cells reactive with said disease-associated factor.
- (Item A6) A composition or vaccine according to any of the preceding items, wherein follicular T cells reactive with said disease-associated factor are reactive with at least said disease-associated factor.
- compositions or vaccine of any of the preceding items, wherein the disease is an infectious disease or cancer.
- compositions or vaccine of any of the preceding items, wherein the disease is a viral infection.
- composition according to any of the preceding items, wherein the composition induces follicular T cells in an HLA type-specific manner.
- disease-associated factor or part or functional equivalent thereof comprises up to 20 amino acids.
- the composition of any of the preceding items, wherein the follicular T cells are public follicular T cells.
- a method of screening for follicular T cells reactive to said disease comprising: A) providing a population of follicular T cells; B) contacting said population of follicular T cells with said disease-associated agent; C) measuring the responsiveness of said follicular T cells to said disease-associated factor; D) selecting follicular T cells exhibiting a predetermined level or more of reactivity to the disease-related factor from the population of follicular T cells.
- the step of measuring C) is performed by ELISPOT, flow cytometry, or peripheral blood mononuclear cell (PBMC) restimulation assay.
- (Item B1) A polypeptide for presenting said disease-associated factor or a portion or functional equivalent thereof, which has the ability to elicit follicular T-cells responsive to said disease-associated factor.
- (Item B2) A polypeptide according to any of the preceding items, wherein the polypeptide preferentially induces follicular T cells.
- (Item B3) A polypeptide according to any of the preceding items, wherein follicular T cells reactive with said disease-associated factor are reactive with at least said disease-associated factor.
- (Item B5) The polypeptide according to any of the preceding items, wherein the disease is a viral infection.
- (Item B6) The polypeptide according to any of the preceding items, wherein the polypeptide induces follicular T cells in an HLA type-specific manner.
- (Item B7) A polypeptide according to any of the preceding items, wherein said disease-associated factor or part or functional equivalent thereof comprises up to 20 amino acids.
- (Item B8) The polypeptide of any of the preceding items, wherein said follicular T cells are public follicular T cells.
- (Item C1) An antibody that specifically binds to a TCR that interacts with said disease-associated factor or a portion or functional equivalent thereof, having the ability to elicit follicular T-cells reactive with said disease-associated factor.
- (Item C2) The antibody of any of the preceding items, wherein the antibody preferentially induces follicular T cells.
- (Item C3) The antibody of any of the preceding items, wherein follicular T cells reactive with said disease-associated factor are reactive with at least said disease-associated factor.
- (Item C4) The antibody according to any of the preceding items, wherein the disease is an infectious disease or cancer.
- (Item C5) The antibody of any of the preceding items, wherein the disease is a viral infection.
- (Item C6) The antibody according to any of the preceding items, wherein the antibody induces follicular T cells in an HLA type-specific manner.
- (Item C7) The antibody of any of the preceding items, wherein said disease-associated factor or part or functional equivalent thereof comprises up to 20 amino acids.
- (Item C8) The antibody of any of the preceding items, wherein said follicular T cells are public follicular T cells.
- (Item D1) A pharmaceutical composition for diagnosing a disease, wherein the disease-related factor, a part thereof, or a functional equivalent thereof, which has the ability to induce follicular T cells reactive to the disease-related factor, is used as an index.
- (Item D2) The pharmaceutical composition according to any of the preceding items, wherein the pharmaceutical composition preferentially induces follicular T cells.
- (Item D3) The pharmaceutical composition according to any of the preceding items, wherein the follicular T cells reactive with the disease-related factor are reactive with at least the disease-related factor.
- (Item D4) The pharmaceutical composition according to any of the preceding items, wherein the disease is an infectious disease or cancer.
- (Item D6) The pharmaceutical composition according to any of the preceding items, wherein the pharmaceutical composition induces follicular T cells in an HLA type-specific manner.
- (Item D7) A pharmaceutical composition according to any of the preceding items, wherein said disease-associated factor or part or functional equivalent thereof comprises at most 20 amino acids.
- (Item D8) The pharmaceutical composition according to any of the preceding items, wherein the follicular T cells are public follicular T cells.
- (Item E1) A composition for enhancing acquisition of immunity against said disease, comprising follicular T cells reactive with said disease-associated factor.
- (Item E2) A composition or vaccine according to any of the preceding items, wherein follicular T cells reactive with said disease-associated factor are reactive with at least said disease-associated factor.
- (Item E3) The composition or vaccine of any of the preceding items, wherein the disease is an infectious disease or cancer.
- (Item E4) The composition or vaccine of any of the preceding items, wherein the disease is a viral infection.
- (Item E5) The composition of any of the preceding items, wherein the follicular T cells are public follicular T cells.
- (Item X1) determining the level or amount of follicular T cells reactive to a disease-associated factor of the disease in the subject, and comparing the level or amount to a predetermined standard. method for testing.
- (Item X2) Said criteria consist of a history of said disease, efficacy of a prophylactic or vaccine against said disease, efficacy of a therapeutic agent against said disease, ability to protect against re-occurrence of said disease, condition of said disease and risk of contracting said disease.
- (Item X3) The method of any of the preceding items, wherein said criteria are criteria for said disease in said subject.
- (Item X4) A method according to any of the preceding items, wherein the criteria are criteria relating to the infection history of the disease in the subject.
- (Item X5) The method according to any of the above items, wherein the criterion is a criterion regarding vaccine efficacy/protection against reinfection of the disease in the subject.
- (Item X6) The method according to any of the preceding items, wherein said criterion is a criterion relating to the efficacy of an immuno-oncology agent for said disease in said subject.
- the disease-associated factor is an autoimmune disease-associated factor
- the measuring comprises measuring the level or amount of follicular T cells reactive to the autoimmune disease-associated factor
- the criterion is The method according to any of the above items, which is a criterion for the risk, condition of autoimmune disease associated with autoantibodies.
- the measurement is performed by ELISPOT, flow cytometry, restimulation assay of peripheral blood mononuclear cells (PBMC), next-generation sequencer/genetic test (repertoire analysis), immunostaining (histopathological test), in situ analysis, Any method described.
- (Item X9) Said comparison compares the measured level, spatial distribution or quantity of follicular T cells reactive with said disease-associated factor to the level of follicular T-cells reactive with said disease-associated factor in a disease-free subject. , the method according to any of the preceding items, further comprising comparing to the mean or median of the spatial distribution or amount.
- the method according to any of the preceding items, wherein the disease is an infectious disease or cancer.
- (Item X11) The method according to any of the preceding items, wherein the disease is a viral infection.
- (Item X12) The method of any of the preceding items, wherein the disease is an allergy or an autoimmune disease.
- Reagents or devices for assessing a disease in a subject including reagents or devices that measure the level, spatial distribution or amount of follicular T cells reactive to disease-associated factors of the disease in the subject.
- Reagents or devices for assessing a disease in a subject including reagents or devices that measure the level, spatial distribution or amount of follicular T cells reactive to disease-associated factors of the disease in the subject.
- PBMC peripheral blood mononuclear cells
- next generation sequencer/genetic test repertoire analysis
- immunostaining histopathological test
- in situ analysis A reagent or device according to any of the above items, which is (Item X16) The reagent or device according to any of the preceding items, wherein the disease is an infectious disease or cancer. (Item X17) The reagent or device of any of the preceding items, wherein the disease is a viral infection. (Item X18) The reagent or device of any of the preceding items, wherein the disease is an allergy or an autoimmune disease.
- a reagent or device for measuring the level, spatial distribution or quantity of follicular T cells reactive to disease-related factors of disease in a subject a comparison unit that compares the results of measurements by the reagents or devices with a predetermined standard for testing the subject for the disease-related matter.
- the criteria are based on the history of the disease, the efficacy of a prophylactic agent or vaccine against the disease, the efficacy of a therapeutic agent against the disease, the ability to protect against re-disease of the disease, the pathological condition evaluation of the disease, and the risk of contracting the disease.
- a system according to any of the preceding items which is a criterion for at least one selected from the group consisting of: (Item X21) The system of any of the preceding items, wherein the criteria are criteria relating to the disease in the subject. (Item X22) The system of any of the preceding items, wherein the criteria are criteria relating to the subject's history of infection with the disease. (Item X23) The system according to any of the above items, wherein the criteria are criteria relating to vaccine efficacy/protection against reinfection of the disease in the subject. (Item X24) The system according to any of the preceding items, wherein the criteria are criteria relating to efficacy of an immuno-oncology agent for the disease in the subject.
- the disease-related factor is an autoimmune disease-related factor, further comprising a follicular T cell measuring unit that measures the level, spatial distribution or amount of follicular T cells reactive to the autoimmune disease-related factor,
- the system according to any of the preceding items, wherein the criteria are criteria relating to the subject's risk of autoimmune disease associated with autoantibodies, pathology.
- the reagent or device comprises a reagent that specifically reacts with follicular T cells.
- the comparison unit compares the measured level, spatial distribution or amount of follicular T cells reactive with the disease-associated factor to the level, spatial distribution or amount of follicular T cells reactive with the disease-associated factor in the disease-free subject.
- the comparison unit compares the measured level, spatial distribution or amount of follicular T cells reactive with the disease-associated factor to the level, spatial distribution or amount of follicular T cells reactive with the disease-associated factor in the disease-free subject.
- the level, spatial distribution or quantity is compared to the mean or median.
- (Item X29) The system according to any of the preceding items, wherein the disease is an infectious disease or cancer.
- (Item X30) The system according to any of the preceding items, wherein the disease is a viral infection.
- (Item X31) A system according to any of the preceding items, wherein the disease is an allergy or an autoimmune disease.
- (Item X32) providing information about the level, spatial distribution or quantity of follicular T cells reactive to disease-associated factors of the disease in the subject; and comparing information regarding the level, spatial distribution or quantity of said follicular T cells to predetermined criteria.
- the criteria are the history of the disease, the efficacy of a prophylactic agent or vaccine against the disease, the efficacy of a therapeutic agent against the disease, the ability to protect against re-disease of the disease, the pathologic evaluation of the disease, and the risk of contracting the disease.
- a method according to any of the preceding items, wherein the criteria are criteria relating to the infection history of the disease in the subject.
- the criterion is a criterion relating to the efficacy of an immuno-oncology agent for said disease in said subject.
- the disease-associated factor is an autoimmune disease-associated factor
- the measuring comprises measuring the level or amount of follicular T cells reactive to the autoimmune disease-associated factor
- the criterion is The method according to any of the above items, which is a criterion for the risk, condition of autoimmune disease associated with autoantibodies.
- the step of providing the information includes ELISPOT, flow cytometry, restimulation assay of peripheral blood mononuclear cells (PBMC), next-generation sequencer/genetic test (repertoire analysis), immunostaining (histopathological test), and in situ analysis.
- PBMC peripheral blood mononuclear cells
- next-generation sequencer/genetic test repertoire analysis
- immunostaining histopathological test
- in situ analysis A method according to any of the preceding items, which is carried out.
- Said comparison provides information regarding the level, spatial distribution or quantity of follicular T cells reactive with a disease-associated factor of a disease in said subject to a disease-associated factor of a disease in a subject without said disease
- (Item X40) The method according to any of the preceding items, wherein the disease is an infectious disease or cancer.
- (Item X41) The method according to any of the preceding items, wherein the disease is a viral infection.
- (Item X42) The method of any of the preceding items, wherein the disease is an allergy or an autoimmune disease.
- (Item X43) providing information about the level, spatial distribution or quantity of follicular T cells reactive to disease-associated factors of the disease in the subject; and comparing information regarding the level, spatial distribution or quantity of said follicular T cells to predetermined criteria.
- the criteria are the history of the disease, the efficacy of a prophylactic agent or vaccine against the disease, the efficacy of a therapeutic agent against the disease, the ability to protect against re-disease of the disease, the pathologic evaluation of the disease, and the risk of contracting the disease.
- the disease-associated factor is an autoimmune disease-associated factor
- the method wherein the measuring comprises measuring the level or amount of follicular T cells reactive to the autoimmune disease-associated factor
- the criterion is the The program according to any of the above items, which is a criterion for the risk and condition of an autoimmune disease associated with autoantibodies in a subject.
- the step of providing the information includes ELISPOT, flow cytometry, restimulation assay of peripheral blood mononuclear cells (PBMC), next-generation sequencer/genetic test (repertoire analysis), immunostaining (histopathological test), and in situ analysis.
- PBMC peripheral blood mononuclear cells
- next-generation sequencer/genetic test repertoire analysis
- immunostaining histopathological test
- in situ analysis A program according to any of the preceding items, which is carried out.
- (Item X50) Said comparison provides information regarding the level, spatial distribution or quantity of follicular T cells reactive with a disease-associated factor of a disease in said subject to a disease-associated factor of a disease in a subject in a subject without disease
- (Item X51) A program according to any of the preceding items, wherein the disease is an infectious disease or cancer.
- (Item X52) A program according to any of the preceding items, wherein the disease is a viral infection.
- (Item X53) A program according to any of the preceding items, wherein the disease is an allergy or an autoimmune disease.
- (Item X54) A computer-readable recording medium storing the program according to any one of the above items.
- the present disclosure is based on the discovery of public TfhTCRs specific to disease factors common to various patients. Provides specific follicular helper T cells (Tfh).
- FIG. 1 shows identified TCRs expressed in Tfh cells from COVID-19 patients.
- the standard Tfh cell markers CD200, ICOS, CD40LG, PDCD1, CXCL13, CXCR5 were used to label the Tfh clusters displayed in the UMAP plots.
- Figure 2 shows the alignment of the TCR CDR3 sequences of clone 1 and clone 2.
- Figure 3 shows that TCRs cloned from patient Tfh cells are reactive with peptides derived from the SARS-CoV-2 S protein.
- T-cell hybridomas expressing TCRs of clonotype 1/2 do not stimulate in the presence (A) or absence (B) of APC from the corresponding donor for 20 hours.
- intact (filled histograms) or inactivated virus equivalent to S protein 1 ⁇ g/ml
- recombinant S protein (1 ⁇ g/ml
- S peptide pool and M+N peptide pool both 1 ⁇ g/ml per peptide
- Clones 1 and 2 were stimulated with S-peptide pools #1 and #2 (1 ⁇ g/ml per peptide) for 20 hours in the presence of cognate APCs (Fig. 3C). Clones 1 and 2 were stimulated with S-peptide pool #2 and S-peptide pool PepTivator® (both at 0.3 ⁇ g/ml per peptide) for 20 hours in the presence of APCs of the same origin and then CD69 was stimulated. stained (Fig. 3D). Clones 1 and 2 were stimulated with S peptide pool #2 (1 ⁇ g/ml per peptide) for 20 hours in the presence of APCs from different donors and then analyzed for CD69 expression (Fig. 3E). FIG. 4 shows the relative positions of the coverage of peptide pools. FIG.
- FIG. 5 shows the identified HLA and S protein peptides recognized by S protein-responsive TCRs.
- T-cell hybridomas expressing TCRs of clonotype 1/2 (clone 1 and clone 2, respectively) in the presence of APCs from other donor PBMCs with the same DP or DR/DQ alleles with the original individual were stimulated with S peptide pool #2 (0.3 ⁇ g/ml per peptide) (Fig. 5A).
- Clones 1 and 2 were stimulated with S-peptide pool #2 (0.3 ⁇ g/ml per peptide) in the presence of HEK293T cells expressing the indicated HLA (Fig. 5B).
- FIG. 5 shows the identified HLA and S protein peptides recognized by S protein-responsive TCRs.
- S864-882 is a SARS-CoV-2-specific peptide that is widely recognized by healthy populations and convalescent COVID-19 patients.
- T-cell hybridomas expressing TCRs of clonotype 1/2 (clone 1 and clone 2, respectively) were co-cultured with peptide pools derived from APC and HCoV-OC43 S protein (0.3 ⁇ g/ml per peptide) (Fig. 6A). Sequence alignment of the corresponding region of S 864-882 human coronavirus to SARS-CoV-2 (Fig. 6B).
- S864-882 is a SARS-CoV-2-specific peptide that is widely recognized by healthy populations and convalescent COVID-19 patients. Clones 1 and 2 were stimulated with a single peptide in the presence of APC with DRB1*15:02 and analyzed for CD69 expression (Fig. 6D). Distribution of clonotype 1/2 in public databases of healthy donors and convalescent COVID-19 patients.
- FIG. 8 is a diagram showing an example of the configuration of system 1000.
- FIG. 9 is a diagram showing an example of the configuration of the user device 100.
- FIG. 10 shows an example of the configuration of the server device 200.
- FIG. 8 is a diagram showing an example of the configuration of system 1000.
- follicular T cells refer to helper T cells with a shared TCR that regulate B cell maturation and activation, and antibody production. Also referred to as follicular helper T cells, follicular T cells are used interchangeably herein to mean the same as follicular helper T cells.
- telomere binding means that an antibody or fragment thereof or a cell containing them recognizes and binds a target with higher affinity than any other target.
- follicular T cells refers to follicular T cells that react and activate at least the subject, and irrespective of whether they are reactive with anything other than their target (cross-reactive) and those with low (preferential) or no reactivity with their specific to the subject).
- preferentially induce means to induce a subject at a high rate, for example, 50% or more, 55% or more, 60% or more, 65% or more, 70% or more, 75% or more % or more, 80% or more, 85% or more, 90% or more, 95% or more, or 100%.
- disease factor includes not only infection sources such as viruses, but also neoplasms such as cancer, and factors that cause immune abnormalities in the case of autoimmune diseases.
- an “epitope” is a molecule or portion recognized by the immune system, such as an antibody, B cell or T cell, also known as an antigenic determinant, or to which an antibody or lymphocyte receptor binds. It can also refer to a site in an antigen molecule.
- an “epitope” is a molecule capable of binding with a binding moiety (eg, an antibody or antigen-binding fragment thereof) as described herein. Epitopes usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics.
- epitopes are well known in the art, and such epitopes can be determined by those skilled in the art using such well-known and conventional techniques once a nucleic acid or amino acid primary sequence is provided. can do.
- antigen refers to any substrate that can be specifically bound by an antibody molecule.
- immunogen refers to an antigen capable of initiating lymphocyte activation resulting in an antigen-specific immune response.
- probe presenting an epitope to HLA refers to a probe for presenting an epitope to HLA. It is possible to examine the presence or absence of the establishment of Although it is a probe, HLA and an epitope peptide may be integrated as a polypeptide, but there may be cases where HLA is not integrated and the peptide is on top of it.
- TCR T cell receptor
- enhancing acquisition of immunity refers to promoting acquisition of immunity such as natural immunity and acquired immunity against antigens, for example, maturation and activation of B cells by follicular T cells, Examples include promotion of control of antibody production.
- protective antibody refers to an antibody responsible for immunity against infectious pathogens, particularly the ability to block viral infection, observed in active or passive immunity.
- public follicular T cells refer to helper T cells with a TCR shared between individuals that control maturation and activation of B cells and antibody production. Public follicular helper T cells, used interchangeably with public Tfh cells.
- operably linked means that a polypeptide encoded by a nucleic acid is linked to an element such that it is expressed under the control of an element such as a promoter in a state in which the polypeptide exhibits biological activity.
- disease is used interchangeably with “disorder” and “condition” in the present disclosure, and interpreted in a broader sense to It refers to any condition that is not specifically defined and cannot be said to be a healthy condition, such as illness, disorder, various symptoms, etc.
- the term "evaluation" of a disease refers to determining the value or significance of certain aspects of the target disease by investigating the good or bad of things, properties, abilities, etc. For example, the disease evaluation of the history of disease, evaluation of the efficacy of prophylactic agents or vaccines against diseases, evaluation of the efficacy of therapeutic agents against diseases (e.g., cancer immunological agents such as immune checkpoint agents in the case of cancer), disease re-infection (e.g., re-infection in the case of infectious diseases), evaluation of pathological conditions of diseases (e.g., cancer, infectious diseases, autoimmune diseases and allergies), and evaluation of the risk of contracting said diseases, etc. not.
- diseases e.g., cancer immunological agents such as immune checkpoint agents in the case of cancer
- disease re-infection e.g., re-infection in the case of infectious diseases
- pathological conditions of diseases e.g., cancer, infectious diseases, autoimmune diseases and allergies
- evaluation of the risk of contracting said diseases etc. not.
- disease-related factor refers to a factor that directly causes a disease, a factor that causes the disease directly, a factor that causes the disease directly, a factor that causes the disease directly, a consequential factor that occurs in parallel
- a factor, a correlated factor, etc. refers to any factor that causes a change in a subject's disease state compared to when the disease state is not present.
- a factor that causes a disease is called a "disease-causing factor”. Examples include immunogenic substances (causative substances) such as allergens, tumor cells in the case of neoplasms, and toxic substances.
- a factor resulting from a disease is also referred to as a "disease outcome factor", and in this case includes factors, metabolites, etc. related to an immune response in a subject.
- follicular T cells reactive to disease-related factors refers to conditions in which follicular T cells can interact with disease-related factors. A change in another factor in the presence of that factor compared to its absence. A follicular T cell reactive to a disease-related factor means that the follicular T-cell undergoes some positive or negative change when placed in a state capable of interacting with the disease-related factor.
- the “level” of follicular T cells means the degree of function of the T cells
- the “quantity” of follicular T cells means the degree of physical quantity of the T cells. do.
- viral antigen refers to a part or all of a virus that is intended to elicit an immune response, and refers to an antigen that elicits an immune response when administered to a host. Peptides, whole (lysate), etc. can be used. Alternatively, virus-like particles (VLPs) may be formed and utilized.
- Viral antigen targets include HIV, hepatitis B virus, hepatitis C virus, coronavirus, norovirus, rotavirus, rabies virus, West Nile virus, papillomavirus, Zika virus, rubella virus, cytomegalovirus, influenza virus, Examples include, but are not limited to, avian influenza virus antigens.
- bacterial antigen refers to part or all of a bacterium that is the target for which an immune response is to be induced, and that elicits an immune response when administered to a host. Peptides, whole (lysate), etc.
- fungal antigen refers to a part or all of the fungus that is the target for eliciting an immune response, and refers to an antigen that elicits an immune response when administered to a host. Peptides, whole (lysate), etc.
- immune abnormality refers to any disease, disorder or condition caused or suspected to be caused at least partially by an abnormality of the immune system.
- Immune disorders include, but are not limited to, allergies, autoimmune diseases, and the like. When it is directed against one's own antigens, it is generally called an autoimmune disease, and when it is directed against foreign antigens, it is called an allergy.
- a strong immune response results in an autoimmune disease state to self antigens and an allergic state to non-self antigens, while a weak immune response results in hypersensitivity to self antigens. It can be said that it becomes a cancerous state and becomes infectious to non-self antigens.
- infectious disease can be any infectious disease, including viral infections (including any form of virus such as single-stranded or double-stranded DNA viruses, RNA viruses), bacterial infections, protozoan infections, , mycoplasma infection, and any type of infection, including tuberculosis, coronavirus, malaria, yellow fever virus, smallpox virus, smallpox vaccine, measles/rubella, polio, mumps/ MUMPS, rotavirus infection, chickenpox, yellow fever, Ebola, West Nile fever, Hib infection, pneumococcal infection, whooping cough, Japanese encephalitis, meningococcal infection, salmonella infection, pathogenicity E.
- Herpes virus type 1 Herpes virus type 1
- EBV/Epstein-Barr virus Herpes virus type 4
- CMV/Cytomegalovirus Herpes virus type 5
- Influenza MARS, Rabies and Diphtheria.
- cancer is used in the same sense as commonly used in the art, and is strongly atypical, proliferates faster than normal cells, and can destructively invade surrounding tissues or metastasize. Refers to a possible malignant tumor or the presence of such a malignant tumor.
- cancer includes, but is not limited to, solid tumors and hematopoietic malignancies, and is used interchangeably herein with “neoplasm” and “tumor.” Cancers, neoplasms and tumors are intended to include hematopoietic neoplasms as well as solid neoplasms.
- neoplasms include melanoma, non-small cell lung, small cell lung, lung, liver carcinoma, retinoblastoma, astrocytoma, glioblastoma, gingiva, tongue, leukemia, neuroblastoma, head cervical, cervical, breast, pancreatic, prostate, renal, bone, testicular, ovarian, mesothelioma, sarcoma, cervical, gastrointestinal, lymphoma, brain, colon, bladder, myeloma, or other malignant or benign neoplasms including but not limited to.
- neoplasms include acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia, juvenile myelomonocytic leukemia, multiple myeloma, and chronic lymphoid leukemia. It may be a hematopoietic neoplasm selected from the group consisting of sexual leukemia.
- autoimmune disease refers to the detection of autoantibodies (e.g., anti-Sm antibody, anti-dsDNA antibody, rheumatoid factor) against self-components (e.g., immunoglobulins), and autoimmunity is involved in pathology. refers to the disease Autoimmune diseases include organ-specific autoimmune diseases (e.g., chronic thyroiditis, primary mucosal edema, thyrotoxicosis, pernicious anemia, Goodpasture's syndrome, acute progressive glomerulonephritis, myasthenia gravis, vulgaris vulgaris).
- autoantibodies e.g., anti-Sm antibody, anti-dsDNA antibody, rheumatoid factor
- self-components e.g., immunoglobulins
- autoimmunity is involved in pathology. refers to the disease
- Autoimmune diseases include organ-specific autoimmune diseases (e.g., chronic thyroiditis, primary mu
- Rheumatoid arthritis systemic lupus erythematosus, discoid lupus erythematosus, polymyositis, scleroderma and mixed connective tissue disease are known as collagen diseases. That is, collagen diseases are included in systemic autoimmune diseases.
- allergen refers to an excessive immune reaction against a specific non-self antigen, and is a disease in which an immune reaction occurs against an “allergen.”
- allergen refers to an antigen that can react with the antibody of a subject with an allergic disease, and allergens derived from pollen of trees (acacia, alder, velvet aodamonium, beech, white birch, maple, mountain cedar, red cedar, cottonwood) , cypress, American elm, Japanese elm, Toga sawara, rubber tree, eucalyptus tree, hackberry, hickory, linden, sugar maple, mesquite, cassava, Quercus, olive, pecan, pepper, pine, privet, Russian olive, sycamore, Ailanthus, black walnut, black willow, etc.), allergens derived from the pollen of plants (cotton, sycamore, longhorn, sorghum, corn,
- allergy include but are not limited to: Representative diseases of "allergy” include atopic dermatitis, allergic rhinitis (hay fever, etc.), allergic conjunctivitis, allergic gastroenteritis, bronchial asthma, childhood asthma, food allergy, drug allergy, or urticaria. mentioned.
- inflammatory disease refers to a disease or condition characterized by abnormal inflammation (e.g., elevated levels of inflammation compared to controls, such as healthy individuals not suffering from the disease).
- inflammatory diseases include atopy, asthma, autoinflammatory diseases, hypersensitivity, childhood allergic asthma, allergic asthma, inflammatory bowel disease, celiac disease, Crohn's disease, colitis, ulcerative colitis.
- HLA restrictions should also be considered.
- cytotoxic (killer) T cells recognize disease factors and eliminate them by damaging them, complexes of disease factor antigen-derived peptides recognized by killer T cells and HLA class I molecules have been identified. and can use information from such classes.
- Certain disease agents have common HLA types for common antigens, and this approach can be used to identify antigenic peptides for use in specific cohorts of dendritic cell preparations of the present disclosure. After immunizing transgenic mice of this particular HLA type with these synthetic peptides, peptides capable of inducing an immune response in killer T cells can be identified and utilized.
- a viral antigen that binds to can be identified, and using the dendritic cell vaccine of the present disclosure produced using a method of inducing differentiation of dendritic cells from human ES cells expressing these HLAs, killer T cells is activated in an antigen-specific manner, and is expected to prevent aggravation due to cytokine storms.
- Exemplary antigenic peptides used in this disclosure can be HLA-restricted or HLA-nonrestricted.
- a single peptide can be used for restriction, but it is preferable to use multiple overlapping peptides or electroporate a viral nucleic acid for non-restriction.
- CD8+ T cells there are roughly two types of T cells.
- CD8+ T cells recognize peptides, typically nine amino acids, bound to a class of HLA (MHC) called Class I.
- CD4+ T cells recognize peptides bound to MHC called class II.
- the length of peptides that bind to HLA (MHC) class II are considered to be, by way of example and not limitation, 15-24 amino acids.
- HLA (MHC) class I molecules are expressed in all somatic cells and bind and present protein fragments produced by self cells.
- HLA (MHC) class II molecules are expressed in limited cells such as antigen-presenting cells such as macrophages and dendritic cells, and B cells. Unlike normal somatic cells, antigen-presenting cells take in proteins from the outside, degrade them, and present them in combination with HLA (MHC) class I and II molecules. Thus, CD8+ T cells primarily recognize endogenous HLA (MHC) class I-restricted antigens on somatic cells, while CD4+ T cells recognize exogenous HLA (MHC) class II-restricted antigens on antigen-presenting cells. . In humans, MHC class I is HLA A, B, C, and MHC class II is HLA DR, DQ, DP.
- the dosage form of "pharmaceutical (composition)” is not particularly limited, and may be solid, semi-solid, or liquid preparations, and can be selected according to the purpose of use. . Cell preparations are usually provided as liquid preparations, but may be provided frozen or freeze-dried.
- the dosage form of the pharmaceutical composition includes, for example, the dosage form described in the Japanese Pharmacopoeia 17th Edition, General Rules for Formulations or equivalents in each country.
- the term "vaccine” includes antigens or cells, and is administered in vivo to refer to factors capable of producing antibodies, factors capable of enhancing cell-mediated immunity, or substances capable of producing such factors.
- Antigen refers to a selected substance and a composition for eliciting an immune response in a vertebrate, such as a human, against that substance.
- agent As used herein, “agent”, “agent” or “factor” (both equivalent to the English equivalent of agent) are used broadly and interchangeably to describe any agent capable of achieving its intended purpose. It may be matter or other elements (eg, energy such as light, radiation, heat, electricity, etc.).
- Such substances include, for example, proteins, polypeptides, oligopeptides, peptides, polynucleotides, oligonucleotides, nucleotides, nucleic acids (including DNA such as cDNA and genomic DNA, RNA such as mRNA), poly Saccharides, oligosaccharides, lipids, organic small molecules (e.g., hormones, ligands, signaling substances, organic small molecules, molecules synthesized by combinatorial chemistry, small molecules that can be used as pharmaceuticals (e.g., small molecule ligands, etc.), etc.) , including but not limited to these complex molecules.
- proteins proteins, polypeptides, oligopeptides, peptides, polynucleotides, oligonucleotides, nucleotides, nucleic acids (including DNA such as cDNA and genomic DNA, RNA such as mRNA), poly Saccharides, oligosaccharides, lipids, organic small
- treatment means healing or improvement of disease or symptoms, or suppression of symptoms. Prevent, preferably maintain, more preferably alleviate, and even more preferably eliminate the deterioration of such a disease or disorder when such a condition occurs, and is associated with the patient's disease or disease It includes the ability to exhibit symptom-ameliorating effects or preventive effects for one or more symptoms. Preliminary diagnosis and appropriate treatment are called “companion therapy” or “tailor-made therapy”, and the diagnostic agent for that purpose is sometimes called “companion diagnostic agent”.
- prevention means to prevent the manifestation of disease or symptoms.
- treatment means any treatment for a disease or symptom, and includes therapy and prophylaxis.
- diagnosis refers to identifying various parameters associated with a disease, disorder, condition (e.g., cancer, viral infection, etc.) in a subject, and It means judging the future.
- conditions within the body can be investigated, and such information can be used to determine the disease, disorder, condition, treatment or prophylactic formulation to be administered in a subject.
- various parameters such as method can be selected.
- diagnosis in a narrow sense means diagnosing the current situation, but in a broader sense it includes “early diagnosis”, “predictive diagnosis”, “pre-diagnosis” and the like.
- the diagnostic method of the present disclosure is industrially useful because, in principle, it can use what comes out of the body and can be performed without the hands of medical professionals such as doctors.
- "predictive diagnosis, preliminary diagnosis or diagnosis” is sometimes referred to as "assisting”.
- the term "subject (person)” refers to a subject to be diagnosed, detected, or treated according to the present disclosure (e.g., organisms such as humans or cells taken from organisms, blood, serum, etc.). .
- sample refers to any substance obtained from a subject, etc., and includes, for example, serum.
- sample refers to any substance obtained from a subject, etc., and includes, for example, serum.
- a person skilled in the art can appropriately select a preferable sample based on the description of this specification.
- kits refers to a unit that provides parts (e.g., test agents, diagnostic agents, therapeutic agents, antibodies, labels, instructions, etc.) to be provided, usually divided into two or more compartments.
- parts e.g., test agents, diagnostic agents, therapeutic agents, antibodies, labels, instructions, etc.
- This kit form is preferred when the purpose is to provide a composition that should not be provided in a mixed form for reasons such as stability, and is preferably used in a mixed form immediately before use.
- kits preferably include the parts provided (e.g., instructions or instructions describing how to use the test, diagnostic, therapeutic agent, or how to handle the reagents).
- the kit When the kit is used as a reagent kit in the present specification, the kit usually includes an instruction manual describing how to use the test agent, diagnostic agent, therapeutic agent, antibody, etc. is included.
- the term "instructions” describes instructions for a physician or other user on how to use the present disclosure.
- the instructions describe the detection method of the present disclosure, how to use the diagnostic agent, or instructions for administering medicine or the like.
- the instructions may include words that instruct oral administration or esophageal administration (for example, by injection) as the administration site.
- This instruction is prepared in accordance with the format prescribed by the regulatory authority of the country in which this disclosure is implemented (for example, the Ministry of Health, Labor and Welfare in Japan, the Food and Drug Administration (FDA) in the United States, etc.) and is approved by the regulatory authority.
- FDA Food and Drug Administration
- package inserts which are usually provided in paper form, but are not limited to that, for example, in the form of electronic media (e.g., homepages provided on the Internet, e-mail). can also be provided.
- a “disease-associated factor” or functional equivalent of a portion thereof is not the disease-associated factor or portion thereof per se, but a variant or variant (e.g., nucleic acid analogue, amino acid analogue, sequence variants, etc.) that have the biological action of the disease-associated factor or part thereof and, at the time of action, the disease-associated factor or part thereof itself or this disease-associated factor or part thereof (e.g., a nucleic acid encoding a disease-associated factor or part thereof itself or a variant or variant of a disease-associated factor or part thereof, and a vector comprising the nucleic acid, viruses, liposomes, cells, etc.).
- a variant or variant e.g., nucleic acid analogue, amino acid analogue, sequence variants, etc.
- Bio searches include stringent hybridization, macroarrays in which genomic DNA is attached to a nylon membrane or the like or microarrays attached to a glass plate (microarray assay), PCR and in situ hybridization. Not limited.
- genes used in this disclosure are intended to include corresponding genes identified by such electronic and biological searches.
- protein As used herein, "protein”, “polypeptide”, “oligopeptide” and “peptide” are used interchangeably herein and refer to polymers of amino acids of any length.
- the polymer may be linear, branched, or cyclic.
- Amino acids may be naturally occurring or non-naturally occurring, and may be modified amino acids.
- the term can also include multiple polypeptide chains assembled into a complex.
- the term also includes natural or artificially modified amino acid polymers. Such modifications include, for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation or any other manipulation or modification (eg, conjugation with a labeling component).
- amino acid is a general term for organic compounds having an amino group and a carboxyl group.
- amino acid sequence may be chemically modified.
- any amino acid in the amino acid sequence may form a salt or solvate.
- any amino acid in the amino acid sequence may be L-type or D-type.
- the protein according to the embodiment of the present disclosure can be said to contain the above-mentioned "specific amino acid sequence".
- chemical modifications that amino acids contained in proteins undergo in vivo include N-terminal modifications (e.g., acetylation, myristoylation, etc.), C-terminal modifications (e.g., amidation, glycosylphosphatidylinositol addition, etc.), or side chains. Modification (for example, phosphorylation, sugar chain addition, etc.) and the like are known. Amino acids can be natural or non-natural as long as they fulfill the purposes of this disclosure.
- polynucleotide As used herein, “polynucleotide”, “oligonucleotide” and “nucleic acid” are used interchangeably herein and refer to polymers of nucleotides of any length. The term also includes “oligonucleotide derivatives” or “polynucleotide derivatives.” “Oligonucleotide derivative” or “polynucleotide derivative”, used interchangeably, refer to oligonucleotides or polynucleotides that contain derivatives of nucleotides or that have unusual linkages between nucleotides.
- oligonucleotides include, for example, 2'-O-methyl-ribonucleotides, oligonucleotide derivatives in which phosphodiester bonds in oligonucleotides are converted to phosphorothioate bonds, and phosphodiester bonds in oligonucleotides.
- nucleic acid sequence also includes conservatively modified variants (e.g., degenerate codon substitutions) and complementary sequences thereof, as well as sequences explicitly indicated. is intended to include Specifically, degenerate codon replacements create sequences in which the third position of one or more selected (or all) codons is replaced with mixed bases and/or deoxyinosine residues.
- degenerate codon replacements create sequences in which the third position of one or more selected (or all) codons is replaced with mixed bases and/or deoxyinosine residues.
- gene refers to a factor that defines a hereditary trait, and “gene” may refer to "polynucleotide”, “oligonucleotide” and “nucleic acid”.
- the term "homology" of a gene refers to the degree of identity of two or more gene sequences to each other. Generally, having “homology” means having a high degree of identity or similarity. Say. Therefore, the higher the homology between two genes, the higher the identity or similarity of their sequences. Whether two types of genes have homology can be determined by direct sequence comparison or, in the case of nucleic acids, hybridization under stringent conditions. When two gene sequences are directly compared, the DNA sequences are typically at least 50% identical, preferably at least 70% identical, more preferably at least 80%, 90% identical between the gene sequences. , 95%, 96%, 97%, 98% or 99% identical, then the genes are homologous.
- a “homologue” or “homologous gene product” as used herein therefore refers to a protein in another species, preferably a mammal, that performs the same biological function as the protein component of the complex further described herein. means Such homologues may also be referred to as “orthologous gene products.” It is understood that such homologues, homologous gene products, orthologous gene products, etc. can also be used so long as they are consistent with the objectives of the present disclosure.
- Amino acids may be referred to herein by either their commonly known three-letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides may also be referred to by their commonly recognized one-letter code.
- BLAST a tool for sequence analysis, using default parameters. Identity searches can be performed, for example, using NCBI's BLAST 2.2.28 (published April 2, 2013 or more recent).
- the value of identity in the present specification generally refers to the value when aligned under the default conditions using the above BLAST. However, if a higher value is obtained by changing the parameters, the highest value is taken as the identity value. When identity is evaluated in multiple regions, the highest value among them is taken as the identity value. Similarity is a number that takes into account similar amino acids in addition to identity.
- Several in an embodiment of the present disclosure may be, for example, 8, 7, 6, 5, 4, 3, or 2, or may be any value or less. It is known that polypeptides in which one or several amino acid residues have been deleted, added, inserted, or substituted with other amino acids retain their biological activity (Mark et al., Proc. Natl Acad Sci USA.1984 Sep;81(18):5662-5666., Zoller et al., Nucleic Acids Res.1982 Oct.25;10(20):6487-6500., Wang et al., Science.1984 Jun. 29;224(4656):1431-1433.). Whether or not they are functional equivalents can be determined by measuring the activity by an appropriate method with deletion or the like.
- “90% or more” may be, for example, 90, 95, 96, 97, 98, 99, or 100% or more, and within any two of those values good too.
- the above "homology” may be calculated by calculating the ratio of the number of homologous amino acids in two or more amino acid sequences according to methods known in the art. Prior to calculating percentages, the amino acid sequences of the amino acid sequences to be compared are aligned and gaps are introduced into portions of the amino acid sequences if necessary to maximize the percentage of identical amino acids. Alignment methods, ratio calculation methods, comparison methods, and computer programs related thereto are conventionally well known in the art (eg, BLAST, GENETYX, etc.).
- homology can be expressed as a value measured by NCBI BLAST unless otherwise specified. Blastp can be used with default settings as an algorithm for comparing amino acid sequences with BLAST. Measurement results are quantified as Positives or Identities.
- a substance of the present disclosure may be purified, and as used herein a “purified” substance or biological agent (e.g., nucleic acid or protein, etc.) refers to It means that at least part of the factors associated with is removed. Thus, the purity of the biological agent in a purified biological agent is generally higher (ie, more concentrated) than the state in which the biological agent is normally present.
- the term "purified” as used herein preferably refers to at least 75%, more preferably at least 85%, even more preferably at least 95%, and most preferably at least 98% by weight of It means that the same type of biological agent is present.
- a substance or biological agent used in this disclosure is preferably a "purified" substance.
- an "isolated" substance or biological agent e.g., nucleic acid or protein, etc.
- isolated does not necessarily have to be expressed in terms of purity, as it varies according to its purpose, but if necessary, preferably at least 75% by weight, more preferably means that at least 85%, even more preferably at least 95%, and most preferably at least 98% by weight of the same type of biological agent is present.
- Materials used in the present disclosure are preferably “isolated" materials or biological agents.
- a "corresponding" amino acid or nucleic acid or portion refers to a polypeptide or polynucleotide molecule (e.g., a polynucleotide encoding a spike protein, etc.) that is a reference polypeptide or polynucleotide for comparison.
- an antisense molecule can be the same portion in an ortholog that corresponds to a particular portion of the antisense molecule.
- the corresponding amino acid is, for example, cysteinylated, glutathionylated, S—S bond formation, oxidized (e.g. of the methionine side chain), formylated, acetylated, phosphorylated, glycosylated, myristylated, etc. can be an amino acid of Alternatively, the corresponding amino acid may be the amino acid responsible for dimerization.
- Such "corresponding" amino acids or nucleic acids may be regions or domains spanning a range. Accordingly, such cases are referred to herein as "corresponding" regions or domains. Such corresponding regions or domains are useful when designing composite molecules herein.
- a "corresponding" gene e.g., polynucleotide sequence or molecule
- a gene e.g, a polynucleotide sequence or molecule
- a gene corresponding to a gene can be an ortholog of that gene.
- each specific gene in humans can find corresponding specific genes in other animals, especially mammals.
- Such corresponding genes can be identified using techniques well known in the art.
- a corresponding gene in an animal can be derived from the reference gene (e.g., S protein, etc.) of the corresponding gene by using the sequence of the reference gene as a query sequence. can be found by searching databases containing
- fragment refers to a polypeptide or polynucleotide having a sequence length of 1 to n-1 relative to a full-length polypeptide or polynucleotide (length is n).
- the length of the fragment can be changed as appropriate according to its purpose.
- the lower limit of the length of the polypeptide is 15, 20, 25, 30, 40, 50 and more amino acids are included, and integer lengths not specifically recited herein (eg, 11, etc.) are also suitable as lower limits. obtain.
- integer lengths not specifically recited herein eg, 11, etc.
- polynucleotides 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 75, 100 and more nucleotides are included, specifically recited herein.
- a length expressed as a non-integer integer may also be suitable as a lower bound.
- such fragments fall within the scope of the present disclosure, for example, if the full-length function as a marker or target molecule, the fragment itself also functions as a marker or target molecule. is understood.
- activity refers to the function of a molecule in the broadest sense and can be taken into consideration in evaluating functional equivalents.
- Activity generally includes, but is not limited to, any biological, biochemical, physical or chemical function of the molecule. Activities include, for example, activating, promoting, stabilizing, inhibiting, repressing, or destabilizing enzymatic activity, ability to interact with other molecules, and functions of other molecules. stability, ability to localize to specific subcellular locations. Where applicable, the term also relates to the function of protein complexes in the broadest sense.
- biological function refers to a specific function that the gene, nucleic acid molecule or polypeptide can have in vivo when referring to a gene or a nucleic acid molecule or polypeptide related thereto. Examples include, but are not limited to, generation of specific antibodies, enzymatic activity, imparting resistance, and the like.
- biological activity refers to the activity that a certain factor (e.g., polynucleotide, protein, etc.) can have in vivo, and various functions (e.g., ability to induce follicular T cells) includes, for example, activities in which interaction with one molecule activates or inactivates another molecule.
- a certain factor e.g., polynucleotide, protein, etc.
- various functions e.g., ability to induce follicular T cells
- the biological activity can be the binding between the two molecules and the resulting biological change and, for example, one molecule was precipitated using an antibody. Two molecules are considered bound when sometimes other molecules also co-precipitate. Therefore, observing such coprecipitation is one method of determination.
- an agent is an enzyme
- its biological activity includes its enzymatic activity.
- Another example includes binding to the receptor to which the ligand corresponds when the agent is a ligand.
- Such biological activity can be measured by techniques well known in the art.
- "activity” indicates or reveals binding (either directly or indirectly); affecting a response (i.e., having a measurable effect in response to some exposure or stimulus);
- Refers to various measurable indicators, such as the affinity of a compound that binds directly to a polypeptide or polynucleotide of the present disclosure, or, for example, the amount of upstream or downstream protein after some stimulus or event or other Measures of similar function are included.
- expression of a gene, polynucleotide, polypeptide, etc. refers to the transformation of the gene into a different form after undergoing a certain action in vivo.
- genes, polynucleotides, etc. are transcribed and translated into a polypeptide form, but transcription to produce mRNA is also an aspect of expression.
- expression product includes such polypeptides or proteins, or mRNA. More preferably, such polypeptide forms may be post-translationally processed.
- insertions, substitutions or deletions of one or more amino acids in the amino acid sequence, or additions to one or both ends thereof can be used.
- "insertion, substitution or deletion of one or more amino acids in an amino acid sequence, or addition to one or both ends thereof” refers to well-known techniques such as site-directed mutagenesis. It means that it has been modified by a method or by natural mutation, such as substitution of a plurality of amino acids to the extent that it can occur naturally.
- Modified amino acid sequences are, for example, insertions, substitutions, or deletions of 1 to 30, preferably 1 to 20, more preferably 1 to 9, even more preferably 1 to 5, and particularly preferably 1 to 2 amino acids.
- the modified amino acid sequence preferably has one or more (preferably one or several or one, two, three, or four) conservative substitutions in the amino acid sequence of the viral S protein, etc. It may be an amino acid sequence.
- conservative substitution means replacement of one or more amino acid residues with another, chemically similar amino acid residue that does not substantially alter the function of the protein. For example, replacing one hydrophobic residue with another hydrophobic residue, replacing one polar residue with another polar residue having the same charge, and the like. Functionally similar amino acids with which such substitutions can be made are known in the art for each amino acid.
- nonpolar (hydrophobic) amino acids include alanine, valine, isoleucine, leucine, proline, tryptophan, phenylalanine, methionine, and the like.
- Polar (neutral) amino acids include glycine, serine, threonine, tyrosine, glutamine, asparagine, cysteine, and the like.
- positively charged (basic) amino acids include arginine, histidine, and lysine.
- negatively charged (acidic) amino acids include aspartic acid and glutamic acid.
- the present disclosure provides methods for assessing a disease in a subject, including measuring the level or amount of follicular T cells reactive to a disease-associated factor of the disease in the subject, and compositions related thereto. , systems, programs, and recording media that store them.
- the medical technology of the present disclosure is based on the results of measuring the level or amount of follicular T cells reactive to disease-related factors, assessing the history of the disease, efficacy of preventive agents or vaccines against the disease, at least one selected from the group consisting of evaluation of sexuality, evaluation of efficacy of a therapeutic agent for the disease, evaluation of protective ability against re-infection of the disease, evaluation of the pathology of the disease, and evaluation of the risk of contracting the disease. further including
- these evaluations include, for example, evaluation of infection history, evaluation of vaccine efficacy (presence or absence of Tfh induction), evaluation of ability to protect against reinfection, evaluation of efficacy of cancer immunodrugs (immune checkpoints, etc.) , risk assessment for autoimmune diseases associated with autoantibodies (before disease), pathological assessment, etc., but are not limited to these.
- the present disclosure provides a process for identifying a disease-associated factor or portion thereof having the ability to elicit follicular T cells specific for the disease-associated factor of a disease; and obtaining follicular T cells specific for the disease using do.
- the present disclosure provides a method of screening for disease-reactive follicular T cells comprising: A) providing a population of follicular T cells; C) measuring the responsiveness of said follicular T cells to said disease-associated factor or a portion or functional equivalent thereof; Selecting follicular T cells exhibiting a predetermined level or more of reactivity to the disease-related factor.
- the step of A) providing a population of follicular T cells can be performed by collecting blood from the subject, biopsy, or the like.
- the step of B) contacting said population of follicular T cells with a disease-associated factor or a portion or functional equivalent thereof comprises, for example, adding a medium in which the population of follicular T cells is cultured to the disease It can be carried out by adding a relevant factor or a part thereof or a functional equivalent, and then culturing, incubating or standing, if necessary.
- C) measuring the reactivity of said follicular T cells to said disease-associated factor or part or functional equivalent thereof is performed by ELISPOT, flow cytometry, peripheral blood mononuclear cells (PBMC) restimulation assay, next-generation sequencing/genetic testing (repertoire analysis), immunostaining (histopathological examination), and in situ analysis.
- the predetermined value may be the mean or median reactivity of follicular T cells to a disease-associated factor or a portion or functional equivalent thereof in subjects not suffering from the disease. . ⁇ Diagnosis>
- the present disclosure provides a method for testing or diagnosing disease comprising measuring the level or amount of follicular T cells reactive to a disease-associated factor.
- the present disclosure includes measuring the level or amount of follicular T cells reactive to a disease-associated factor of a disease in a subject, and comparing the level or amount to a predetermined standard, A method is provided for testing said disease on said subject.
- the predetermined criterion can be the mean or median level or amount of follicular T cells in healthy individuals. In other embodiments, the predetermined criterion may be the reference value of the article.
- the present disclosure provides a method for evaluating the infection history of a disease, a method for evaluating the efficacy of a vaccine for a disease and the ability to protect against reinfection, a cancer immune drug for a disease (immune checkpoint etc.) to provide a method for evaluating efficacy, a method for evaluating the risk of autoimmune diseases associated with autoantibodies (before disease), and a method for evaluating pathology.
- These methods involve measuring the level or amount of follicular T cells reactive with disease-associated factors.
- the measurement is ELISPOT, flow cytometry, restimulation assay of peripheral blood mononuclear cells (PBMC), next-generation sequencing/genetic testing (repertoire analysis), immunostaining (histopathology), in It may be done by in situ analysis.
- PBMC peripheral blood mononuclear cells
- next-generation sequencing/genetic testing repertoire analysis
- immunostaining histopathology
- measuring the level or amount of follicular T cells reactive to a disease-related factor can be performed, for example, as follows.
- Peripheral blood derived from a subject can be contacted with a probe containing an epitope specific to an infectious agent, and the amount of follicular T cells in the peripheral blood that binds to the probe can be measured by ELISPOT or flow cytometry. and flow cytometry are exemplified elsewhere herein.
- the ELISPOT assay used in the present disclosure can be used.
- the ELISPOT assay used here uses plates coated with antibodies capable of detecting IL-21 produced by follicular T cells.
- Peripheral blood mononuclear cells (PBMC) are added to the wells and stimulated with source-derived antigen for 36 hours.
- Secreted IL-21 binds to capture antibodies in the vicinity of producing cells.
- a cytokine antibody for detection is added to detect the spots.
- an assay without source-derived antigen stimulation is performed.
- flow cytometry can be utilized, which stimulates peripheral blood mononuclear cells (PBMC) with source-derived antigens for 36 hours.
- PBMC peripheral blood mononuclear cells
- a sample not stimulated with an infection source-derived antigen is used as a negative control for comparison.
- the disease is detected by comparing the measured level or amount of follicular T cells reactive to a disease-related factor with a predetermined value (e.g., negative control measurement value or healthy subject measurement value). can be tested or diagnosed.
- a predetermined value e.g., negative control measurement value or healthy subject measurement value.
- the present disclosure provides methods for assessing disease infection history, including measuring the level or amount of follicular T cells reactive to disease-associated factors.
- Antibody-based evaluation of infection history is often performed, but specific immune cells are maintained longer than antibodies, so identifying source-specific immune cells is beneficial in investigating infection history. .
- measuring the level or amount of follicular T cells reactive with a disease-associated factor can be performed, for example, as follows.
- Peripheral blood derived from a subject can be contacted with a probe containing an epitope specific to an infectious agent, and the amount of follicular T cells in the peripheral blood that binds to the probe can be measured by ELISPOT or flow cytometry. and flow cytometry are exemplified elsewhere herein.
- comparing the measured level or amount of follicular T cells reactive to a disease-associated factor with a predetermined value e.g., negative control measurement value or healthy subject measurement value
- Infection history can be assessed.
- the present disclosure provides a method for assessing vaccine efficacy and ability to protect against reinfection of a disease, comprising measuring the level or amount of follicular T cells reactive to a disease-associated factor.
- a method for assessing vaccine efficacy and ability to protect against reinfection of a disease comprising measuring the level or amount of follicular T cells reactive to a disease-associated factor.
- measuring the level or amount of follicular T cells reactive to a disease-associated factor is performed, for example, as follows: can be implemented.
- Peripheral blood derived from a subject can be contacted with a probe containing an epitope specific to an infectious agent, and the amount of follicular T cells in the peripheral blood that binds to the probe can be measured by ELISPOT or flow cytometry. and flow cytometry are exemplified elsewhere herein.
- comparing the measured level or amount of follicular T cells reactive to a disease-associated factor with a predetermined value e.g., negative control measurement value or healthy subject measurement value
- a predetermined value e.g., negative control measurement value or healthy subject measurement value
- the present disclosure assesses the efficacy of cancer immunopharmaceuticals (such as immune checkpoints) in disease comprising measuring the level or amount of follicular T cells reactive to cancer-associated factors. provide a method for
- measuring the level or amount of follicular T cells reactive to a cancer-associated factor is performed, for example, by: can be implemented.
- Peripheral blood derived from a subject can be contacted with a probe containing an epitope specific to an infectious agent, and the amount of follicular T cells in the peripheral blood that binds to the probe can be measured by ELISPOT or flow cytometry. and flow cytometry are exemplified elsewhere herein.
- comparing the measured level or amount of follicular T cells reactive to a disease-associated factor with a predetermined value e.g., negative control measurement value or healthy subject measurement value
- the present disclosure provides risk assessment of autoimmune diseases associated with autoantibodies (before disease), disease states, including measuring the level or amount of follicular T cells reactive to autoimmune disease-associated factors.
- autoimmune diseases are associated with autoantibodies.
- diseases in which autoantibodies are thought to be pathogenic e.g., ANCA-associated vasculitis
- follicular T cells that interact with autoantibody-producing B cells are involved. Presence/absence/increase/decrease may lead to onset and aggravation/relapse of pathology associated with maturation of B cells.
- measuring the level or amount of follicular T cells reactive to an autoimmune disease-associated factor is performed, for example, by: can be implemented as follows:
- Peripheral blood derived from a subject can be contacted with a probe containing an epitope specific to an infectious agent, and the amount of follicular T cells in the peripheral blood that binds to the probe can be measured by ELISPOT or flow cytometry. and flow cytometry are exemplified elsewhere herein.
- autoantibody It is possible to assess the risk of autoimmune diseases associated with
- diagnosis or testing can be performed by measuring the various amounts or levels described above.
- Efficacy evaluation of cancer immunodrugs (immune checkpoints, etc.) 5.Risk assessment of autoimmune diseases with autoantibodies (pre-disease), pathological assessment
- the present disclosure can provide infection history assessment techniques. Antibody-based evaluation of infection history is often performed, but specific immune cells are maintained longer than antibodies, so identifying source-specific immune cells is beneficial in investigating infection history. .
- a T cell detection method using a probe containing an epitope specific to an infectious agent is useful as a simple method for detecting immune cells established and maintained after infection. The presence or absence of probe-reactive T cells can be easily detected by ELISPOT using peripheral blood mononuclear cells (PBMC) or a system using flow cytometry. If probe-reactive T cells are detected, past infection can be determined. In addition, past infection can be determined if a larger number of probe-reactive T cells are detected compared to healthy subjects.
- PBMC peripheral blood mononuclear cells
- ⁇ Application to diagnosis of infection It is known that a specific response by immune cells is established within a few days to two weeks after infection and is maintained for a long period thereafter. Therefore, with selected epitopes, it is possible to determine the infection history from the immune status after infection, after the pathogen of the infectious disease has been cleared from the body, or even when the immune system is suppressed to an undetectable level.
- ⁇ Specific procedure for evaluation of infection history Using epitopes related to specific infectious diseases and specimens that are considered to have acquired immunity against specific infectious diseases in patients or recovered individuals, reactivity of follicular T cells is evaluated. Confirm and identify epitopes that induce follicular T cells.
- sequence conservation of the epitope with other infectious disease antigens and disease-related antigens preferably actual specimens and epitope-reactive T cells is used to assess cross-reactivity and select epitopes specific for the particular infection of interest. As a result, it is ensured that only those who have a history of infection with a specific infectious disease will respond to the selected epitope, and this can be used to evaluate the history of infection.
- the present disclosure provides assessment of vaccine efficacy/protection against reinfection.
- Infectious source-specific immune cells are maintained for a longer period of time than antibodies, and the protective ability of immune cells can be evaluated in that they can rapidly respond to reinfection.
- follicular T cells are important fractions for the induction and enhancement of humoral immunity (affinity maturation), so they contain epitopes that specifically induce follicular T cells.
- Subjects with probe-reactive T cells are judged to have a stronger or qualitatively superior defense against infection. Since the specific response by immune cells reacts only with vaccine antigens, it is possible to determine the presence or absence and strength of immunity against vaccine target diseases after vaccination by observing the reactivity with the epitope.
- ⁇ Vaccine efficacy evaluation Specific procedures for protection against reinfection Among the T cell epitopes contained in the vaccine, specimens that are considered to have acquired immunity against the vaccine target disease in patients or recoverers of the vaccine target disease is used to confirm follicular T cell reactivity and identify epitopes that induce follicular T cells.
- sequence conservation of the epitope with other infectious disease antigens and disease-related antigens preferably, actually test specimens and epitope-reactive T cells to assess cross-reactivity and select follicular T-cell epitopes specific for the vaccine.
- the vaccine can be used to evaluate the efficacy of vaccines, as it is guaranteed that the vaccine will respond to epitopes selected only for those who have a history of infection with vaccine target diseases and who have been vaccinated. Since the specific response by immune cells reacts only with vaccine antigens, it is possible to determine the presence or absence and strength of immunity against vaccine target diseases after vaccination by observing the reactivity with the epitope. This makes it possible to evaluate the effectiveness of the vaccine and the ability to protect against reinfection.
- ELISPOT and flow cytometry can be used for evaluation in the same manner as described above. These methods can also be used to detect whether the T cells responding to the epitope probe were in fact follicular T cells, and to what extent, by altering the cytokines detected or combining surface antigen probes.
- the experimental system can be designed according to the detection sensitivity and judgment criteria.
- Follicular T cells are characterized by the surface antigens and cytokines they release. Therefore, ELISPOT detects follicular T cell-specific cytokines, specifically IL-21, released from the cells after reaction with the epitope, and flow cytometry detects follicular T cells such as CXCR5. By capturing a cell-specific cell surface antigen, it can be confirmed whether the reacted T cells were follicular T cells. In addition, the predominance of follicular T cells in T cells induced by epitopes can be evaluated by capturing other T cell-specific cytokines and surface antigens together. Here, the released cytokines are compared with those before epitope stimulation and with a positive/negative control prepared in advance to evaluate the ability to induce the epitope-specific follicular T cells. , the immunity established after infection or after vaccination can be assessed.
- the ability to protect against reinfection can be evaluated.
- the present disclosure provides an efficacy evaluation for immuno-oncology agents (immune checkpoints, etc.).
- Tumor-specific T cells from individual patients are extremely small in the periphery and are very difficult to detect ex vivo. Responses can be detected. Since it is assumed that the response of cytotoxic (CD8+) T cells will be stronger, CD4+ T cells and antigen-presenting cells (such as immortalized B cells) are removed from the periphery, and the patient tumor or Tumor-specific follicular T cell responses can be visualized by co-culturing with patient-derived tumor cell lines, and a subject's anti-tumor immunity can be assessed based on measurements of the level or amount of follicular T cell responses. can.
- cytotoxic (CD8+) T cells will be stronger
- CD4+ T cells and antigen-presenting cells such as immortalized B cells
- ex vivo evaluation of follicular T cells present in the tumor locality or tumor microenvironment can be performed using surgical or biopsy specimens performed before administration of cancer immunodrugs.
- chemokines such as CXCL13, which are thought to induce follicular T cells in the future, and IL associated with tertiary lymphoid structures that are suggested to have a good correlation with prognosis.
- Efficacy can be evaluated with higher accuracy by also evaluating the levels of inhibitory cytokines such as -7 and IL-10, which suggests a negative correlation.
- T cells obtained from tumor biopsy specimens and peripheral blood with epitope probes By evaluating the reactivity of T cells obtained from tumor biopsy specimens and peripheral blood with epitope probes, it is possible to evaluate the activity of the subject's anti-tumor immunity and use it to select treatment methods.
- epitope probes and flow cytometry to evaluate the activation and exhaustion of epitope-specific follicular T cells (tumor-specific follicular T cells) during drug administration, the activity of anti-tumor immunity is maintained. It is expected to find out if This is effective in determining whether immune checkpoint inhibitors will continue to be effective, or whether treatment should be discontinued and other treatment methods should be sought.
- the activation of individual follicular T cells is evaluated, for example, by the expression of IL-21 and ICOS, and the production of IL-21.
- the degree of exhaustion is generally evaluated by PD-1, but other exhaustion markers such as LAG3, TIM3, and TIGIT can also be used.
- the present disclosure provides risk assessment (pre-disease) and pathological assessment of autoimmune diseases associated with autoantibodies.
- autoimmune diseases are associated with autoantibodies.
- diseases in which autoantibodies are thought to be pathogenic e.g., ANCA-associated vasculitis
- follicular T cells that interact with autoantibody-producing B cells are involved. Presence/absence/increase/decrease may lead to onset and aggravation/relapse of pathology associated with maturation of B cells. Therefore, by detecting follicular T cells that present epitopes derived from disease-specific self-antigens, it is considered possible to evaluate disease risk (before onset) and disease activity.
- Peptides and the like of the present disclosure can be produced using various methods such as chemical synthesis, genetic engineering, and production by microorganisms.
- antigens can be generated either in vitro or in vivo.
- An antigen may be produced in vitro as a peptide or polypeptide, which may then be formulated into a personalized neoplastic vaccine or immunogenic composition and administered to a subject.
- in vitro production involves, for example, peptide synthesis or peptide/peptide synthesis from DNA, p, or RNA molecules in any of a variety of bacterial, eukaryotic, or viral recombinant expression systems.
- the antigen may be produced in vivo by introducing an antigen-encoding molecule (eg, DNA, RNA, viral expression system, etc.) into a subject, followed by expression of the encoded antigen.
- an antigen-encoding molecule eg, DNA, RNA, viral expression system, etc.
- Methods of in vitro and in vivo production of antigens are also further described herein as it relates to methods of delivery of pharmaceutical compositions and combination therapies.
- Proteins or peptides may be synthesized by standard molecular biology techniques, expression of the protein, polypeptide or peptide, isolation of the protein from natural sources, in vitro translation, or isolation of the peptide or synthesis of the protein or peptide. It can be made by any technique known to those of skill in the art, including chemical synthesis. Nucleotide and protein, polypeptide and peptide sequences corresponding to various genes have been previously disclosed and can be referred to computerized databases known to those skilled in the art. One such database is the Genbank and GenPept databases of the National Center for Biotechnology Information at the National Institutes of Health website. Coding regions of known genes can be amplified and/or expressed using techniques disclosed herein or as known to those of skill in the art. Alternatively, various commercially available protein, polypeptide and peptide preparations are known to those skilled in the art.
- Peptides can be readily chemically synthesized using reagents that do not contain contaminating bacteria or animal substances (Merrifield RB: Solid Phase Peptide Synthesis I. Synthesis of Tetrapeptides. The synthesis of a tetrapeptide". J. Am. Chem. Soc. 85:2149-54, 1963).
- the preparation of antigenic peptides comprises (1) parallel solid-phase synthesis on a multichannel instrument using homogeneous synthesis and cleavage conditions; (2) purification by column stripping on an RP-HPLC column; followed by (3) analysis by the most informative, limited set of assays.
- a good manufacturing practice (GMP) footprint can be defined, thus requiring a suite switching procedure only between different patient peptide syntheses. be.
- antigenic peptides may be generated in vitro using nucleic acids (eg, polynucleotides) encoding antigenic peptides of the present disclosure.
- Polynucleotides include, for example, DNA, cDNA, PNA, CNA, RNA, either single-stranded and/or double-stranded, or in native or stabilized forms of polynucleotides, such as having a phosphorothioate backbone. It may be a polynucleotide, etc., or a combination thereof, and may or may not contain introns, so long as it encodes a peptide.
- in vitro translation is used to generate peptides.
- Retic Lysate IVT kit Life Technologies, Waltham, Mass.
- an expression vector capable of expressing a polypeptide can also be prepared.
- Expression vectors for various cell types are well known in the art and can be selected without undue experimentation.
- the DNA is inserted into an expression vector, such as a plasmid, in proper orientation and correct reading frame for expression.
- the DNA may be ligated to appropriate transcriptional and translational regulatory control nucleotide sequences recognized by the desired host (eg, bacteria), but such controls are generally available on the expression vector.
- the vector is then introduced into a host bacterium for cloning using standard techniques (e.g., Sambrook et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. .).
- Antigenic peptides may be provided in the form of RNA or cDNA molecules that encode the desired antigenic peptide.
- One or more antigenic peptides of this disclosure may be provided by a single expression vector.
- the present disclosure comprises measuring the level or amount of follicular T cells reactive to a disease-associated factor of a disease in a subject, and comparing the level or amount to a predetermined standard.
- a method is provided for testing for the disease in a subject.
- the criteria consist of history of disease, efficacy of prophylactic agents or vaccines against disease, efficacy of therapeutic agents against disease, ability to protect against re-occurrence of disease, disease status and risk of contracting disease. Criteria for at least one selected from the group.
- the reference is a reference for said disease in said subject, and as a reference the mean or median level or amount of follicular T cells reactive to a disease-associated factor of disease in healthy humans can be used. If higher than the reference, the subject is likely to have the disease.
- the criteria are criteria relating to the subject's history of infection with the disease, and the presence or absence of infection-source-specific immune cells can be used as the criteria. If there are source-specific immune cells, there may be a history of infection.
- the criteria are criteria regarding vaccine efficacy and ability to protect against reinfection of the disease of the subject, and the presence or absence of infection source-specific immune cells can be used as the criteria. If there are source-specific immune cells, it can be determined that the vaccine is effective and has the ability to protect against reinfection.
- the criterion is a criterion relating to the efficacy of an immuno-oncology agent for said disease in said subject, and the level of immune cells with anti-tumor (epitope) activity can be used as a criterion, and the epitope Activation and exhaustion of specific follicular T cells (tumor-specific follicular T cells) can also be used as criteria. If the activity of epitope-specific follicular T cells is increased, it can be judged that the cancer immunodrug is effective.
- the disease-associated factor is an autoimmune disease-associated factor
- the measuring comprises measuring the level or amount of follicular T cells reactive with the autoimmune disease-associated factor
- the criterion is It is a criterion relating to the risk of autoimmune diseases associated with autoantibodies and pathological conditions of the subject.
- the presence or absence of autoimmune disease-related factor-specific immune cells can be used as a criterion. If there are autoimmune disease-related factor-specific immune cells, it may be an autoimmune disease.
- the present disclosure provides a reagent or device for measuring the level, spatial distribution or amount of follicular T cells reactive to a disease-related factor of a disease in a subject, and a predetermined A system for testing for the disease related to the subject is provided, including a comparator that compares to a reference.
- the present disclosure provides information about the level, spatial distribution or amount of follicular T cells reactive to a disease-related factor of a disease in a subject; and comparing distribution or amount information to predetermined criteria.
- the present disclosure provides information about the level, spatial distribution or amount of follicular T cells reactive to a disease-related factor of a disease in a subject;
- the present disclosure provides a computer-readable recording medium storing the above program.
- the present disclosure provides polypeptides for presenting a disease-associated factor or portion thereof that have the ability to elicit follicular T cells specific for the disease-associated factor.
- polypeptides can be used in the tests or diagnostics of the disclosure and are also referred to as probes.
- the disclosure provides antibodies that specifically bind to a TCR that interacts with a disease-associated factor or a portion thereof that have the ability to elicit follicular T cells specific for the disease-associated factor.
- Such antibodies can be used for testing or diagnosis of the present disclosure and are also referred to as probes.
- the present disclosure can be provided as a medicament.
- a component included in a medicament or pharmaceutical composition may be referred to as a drug and the like.
- the medicaments of the disclosure may be provided as vaccines (including cellular vaccines) or probes.
- the present disclosure provides a pharmaceutical composition for treating or preventing a disease comprising a disease-associated factor or part thereof that has the ability to elicit follicular T cells specific for the disease-associated factor. .
- the present disclosure provides a vaccine against disease comprising a disease-associated factor or part thereof that has the ability to elicit follicular T cells specific for the disease-associated factor.
- compositions for treating or preventing diseases comprising follicular T cells specific for disease-related factors.
- the present disclosure can provide cellular vaccines against disease comprising follicular T cells specific for disease-associated factors.
- the disease can be an infection or cancer. In another embodiment, the disease can be a viral infection. In certain embodiments, the compositions of the present disclosure are capable of inducing follicular T cells in an HLA type-specific manner.
- disease-associated agents can be amino acids, nucleic acids, viruses, or cells.
- a disease-associated factor may be a factor that directly or indirectly causes the disease, or may be a factor that results from the development of the disease. For example, if the disease is a viral disease, the disease-associated agent can be a virus that causes the viral disease. In some embodiments, the disease-associated factor or portion thereof comprises up to 20 amino acids.
- follicular T cells of the present disclosure can be public follicular T cells.
- the present disclosure relates to TCR-T cell therapy.
- compositions for enhancing immunity against disease comprising follicular T cells specific for disease-associated factors.
- the present disclosure provides a medicament for treating or preventing a disease comprising a disease-associated factor or a portion or functional equivalent thereof that has the ability to elicit follicular T cells reactive to the disease-associated factor.
- a composition is provided.
- the present disclosure provides a vaccine against disease comprising a disease-associated factor, or a portion or functional equivalent thereof, capable of eliciting follicular T cells reactive to the disease-associated factor.
- the composition or vaccine may preferentially induce follicular T cells, or may induce follicular T cells while inducing cells other than follicular T cells.
- the present disclosure provides pharmaceutical compositions for treating or preventing disease, comprising follicular T cells reactive to disease-related factors.
- the present disclosure provides cellular vaccines against disease comprising follicular T cells reactive with disease-associated factors.
- the present disclosure provides that the follicular T cells reactive with the disease-associated factor are reactive with at least the disease-associated factor.
- the disease is an infection or cancer.
- the disease is a viral infection.
- the composition induces follicular T cells in an HLA type-specific manner.
- the follicular T cells are public follicular T cells.
- formulations for oral administration may be formulated as liquids such as oral solutions, suspensions, emulsions, syrups, etc., or may be formulated as dry formulations that are redissolved at the time of use. may
- parenteral administration it may be formulated in a unit dose ampoule or contained in a multi-dose container or tube, and additives such as stabilizers, buffers, preservatives, and tonicity agents may also be added. may be included.
- formulations for parenteral administration may be formulated into powders that can be redissolved in a suitable carrier (sterilized water, etc.) at the time of use.
- the term "active ingredient” refers to a component contained in an amount necessary to obtain the desired effect of the composition of the present disclosure, such as treatment, prevention, or inhibition of progression, and the effect is less than the desired level. Other ingredients may also be included as long as they are not compromised.
- the medicaments, compositions, etc. of the present disclosure may be formulated.
- the administration route of the medicament, composition, etc. of the present disclosure may be either oral or parenteral, and can be appropriately set according to the form of the preparation.
- salts are, for example, inorganic acid salts (such as hydrochlorides, hydrobromides, phosphates, and sulfates), or salts of organic acids (acetates, propionates, malonates, and benzoate, etc.) may be used.
- inorganic acid salts such as hydrochlorides, hydrobromides, phosphates, and sulfates
- organic acids acetates, propionates, malonates, and benzoate, etc.
- compositions further contain liquids (water, saline, glycerol and ethanol). Additionally, auxiliary substances such as wetting agents, emulsifying agents or pH buffering agents can be present in compositions. Carriers enable the pharmaceutical composition to be formulated as tablets, pills, dragees, liquids, gels, syrups, slurries and suspensions, to be ingested by a subject.
- compositions present in some form of administration include suitable forms for parenteral administration, such as injection or infusion (e.g., bolus or continuous infusion).
- parenteral administration such as injection or infusion (e.g., bolus or continuous infusion).
- parenteral administration such as injection or infusion (e.g., bolus or continuous infusion).
- parenteral administration such as injection or infusion (e.g., bolus or continuous infusion).
- parenteral administration such as injection or infusion (e.g., bolus or continuous infusion).
- parenteral administration such as injection or infusion (e.g., bolus or continuous infusion).
- parenteral administration such as injection or infusion (e.g., bolus or continuous infusion).
- formulatory agents suspending, stabilizing and/or dispersing agents
- it may be in dry form, for reconstitution prior to use with a suitable sterile liquid.
- compositions of this disclosure can be administered directly to a subject.
- the composition is adapted for administration to a mammal (eg, human subject).
- compositions of this disclosure may be administered by any number of routes (oral, intravenous, intramuscular, intraarterial, intramedullary, intraperitoneal, intrathecal, intraventricular, transdermal, transdermal, topical, including but not limited to subcutaneous, intranasal, enteral, sublingual, intravaginal, or rectal routes).
- routes oral, intravenous, intramuscular, intraarterial, intramedullary, intraperitoneal, intrathecal, intraventricular, transdermal, transdermal, topical, including but not limited to subcutaneous, intranasal, enteral, sublingual, intravaginal, or rectal routes.
- a hypospray can also be used to administer the pharmaceutical compositions of this disclosure.
- the therapeutic compositions are prepared as injectables, either as liquid solutions or suspensions. Solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection can be prepared.
- Direct delivery of the composition is generally accomplished by subcutaneous, intraperitoneal, intravenous, intramuscular injection, or delivered to the interstitial space of the tissue.
- the composition can be administered to the lesion. Dosage treatment may be a single dose regimen or a multiple dose regimen.
- the pharmaceutical will provide instructions relating to the frequency of administration (eg, whether to be delivered daily, weekly, monthly, etc.). Also, frequency and dose may depend on the severity of symptoms.
- compositions of the present disclosure can be prepared in various forms.
- the compositions can be prepared as injectables, either as liquid solutions or suspensions.
- Solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection can be prepared (lyophilized compositions, such as Synagis, for reconstitution with sterile water containing a preservative). registered trademark) and Herceptin®, etc.)).
- the composition may be prepared for topical administration eg as an ointment, cream or powder.
- the composition may be prepared for oral administration eg as a tablet or capsule, as a spray, or as a syrup (optionally flavored).
- the composition may be prepared for pulmonary administration as an inhaler, eg, using a fine powder or spray.
- the composition may be prepared as a suppository or pessary.
- the composition may be prepared for nasal, aural, or ocular administration, eg, as drops.
- the composition may be in the form of a kit, designed such that a combined composition is reconstituted immediately prior to administration to a subject.
- lyophilized antibodies can be provided in kit form with sterile water or sterile buffer.
- the present disclosure can be provided as a vaccine. And, in some aspects, the present disclosure provides methods of preventing diseases and the like using vaccines and the like.
- the pharmaceutical composition of the present disclosure can be a vaccine composition for administration to humans to enhance immunity.
- a vaccine composition may further comprise one or more adjuvants. Examples of adjuvants that may be included in vaccine compositions are provided herein below.
- vaccine compositions may include cell vaccines.
- suitable adjuvants include: (1) oil-in-water emulsion formulations (with or without certain other immunostimulatory substances such as muramyl polypeptides or bacterial cell wall components); For example, MF59TM (containing 5% squalene, 0.5% Tween 80, and 0.5% sorbitan trioleate) and SAF (10% squalene, 0.4% Tween 80, 5% Pluronic®) (2) a saponin adjuvant such as QS21, STIMULONTM (Cambridge Bioscience, Worcester, Mass.), Abisco® (Isconova, Sweden), or Iscomatrix® (Commonwealth Serum Laboratories, Australia), (3) Complete Freund's Adjuvant (CFA) and Incomplete Freund's Adjuvant (IFA), (4) contains a CpG motif in which cytosines are unmethylated, i.e.
- CFA Complete Freund's Adjuvant
- IFA Incomplete Freund's Adjuvant
- At least one CG Oligonucleotides containing dinucleotides e.g., Krieg, Vaccine (2000) 19:618-622; Krieg, CurrOpinMolTher (2001) 3:15-24; WO98/40100, WO98/55495, WO98/37919, and WO98/ 52581), and (5) metal salts, including aluminum salts (alum, aluminum phosphate, aluminum hydroxide, etc.), (6) saponins and oil-in-water emulsions (eg, WO99/11241).
- a medicament for treating or preventing a disease comprising the disease-associated factor or a portion or functional equivalent thereof capable of inducing follicular T cells reactive to the disease-associated factor of the present disclosure
- the disease can be treated or prevented by administering the composition to a subject having or at risk of having the disease.
- the treatment or prophylaxis of the present disclosure involves binding identified follicular T cell epitopes, or functional equivalents thereof, to 1. other vaccine antigens/nucleic acids for purposes such as B cell induction, or 2. viral 3.
- Vaccines are designed by combining antigens other than B cells + Tfh, such as cytotoxic T cell epitopes, that are intended to induce immunity separately from B cells + Tfh.
- Vaccine efficacy is determined by optimizing the above combinations, the number and balance of antigens to be presented, and adjuvants to be combined with HLA-humanized mice. Although drug efficacy can be evaluated to some extent in animal models, it is difficult to completely reproduce human immunity, which is a difficult point when targeting T cells.
- the treatment or prevention of this disclosure is 1) binding the identified follicular T cell epitopes, or those containing functional equivalents thereof, to other vaccine antigens/nucleic acids or independently expressing them in viral vectors or VLPs; 2) mixing with something that provokes immunity separate from B cells or Tfh (such as a cytotoxic T cell epitope); 3) can be implemented by performing a step of administering the product obtained by 2)
- Computer program of technology for evaluating the disease for a subject or a recording medium storing the same, and a system or a user device that constitutes a part of the system In one aspect of the present disclosure, a method for evaluating the disease in a subject, a computer program for realizing the method or a recording medium storing the same, a system or a user device that constitutes a part of the system, etc. provided.
- the system 1000 includes at least one user device 100, a server device 200 connected to the at least one user device 100 via a network 400, and a database section 300 connected to the server device 200 (FIG. 8). ).
- the user device 100 can be any terminal device such as a smartphone, tablet computer, smart watch, laptop computer, desktop computer, medical wearable device, etc., in addition to dedicated medical equipment.
- User device 100 can communicate with server device 200 via network 400 .
- the type of network 400 does not matter.
- the user device 100 may communicate with the server device 200 via the Internet, or may communicate with the server device 200 via a LAN.
- three user devices 100 are depicted in FIG. 8, the number of user devices 100 is not limited to this.
- the number of user devices 100 can be any number greater than or equal to one, which can be the same or different.
- the server device 200 can communicate with at least one user device 100 via the network 400 . Also, the server device 200 can communicate with the database unit 300 connected to the server device 200 .
- the database unit 300 connected to the server device 200 can store pre-obtained information on follicular T cells of multiple subjects, arbitrary health and medical information on the subject, and the like.
- the stored information may be used, for example, to build a trained model.
- the database unit 300 may store the built learned model.
- FIG. 9 shows an example of the configuration of the user device 100.
- the user device 100 includes a communication interface section 110 , an input section 120 , a display section 130 , a memory section 140 and a processor section 150 .
- the communication interface unit 110 controls communication via the network 400.
- the processor unit 150 of the user device 100 can receive information from outside the user device 100 and can transmit information to the outside of the user device 100 via the communication interface unit 110 .
- the processor unit 150 of the user device 100 can receive information from the server device 200 via the communication interface unit 110 and can transmit information to the server device 200 .
- Communication interface section 110 may control communications in any manner.
- the input unit 120 allows the user to input information into the user device 100 . It does not matter in what manner the input unit 120 enables the user to input information to the user device 100 . For example, if the input unit 120 is a touch panel, the user may input information by touching the touch panel. Alternatively, if the input unit 120 is a mouse, the user may input information by operating the mouse. Alternatively, if the input unit 120 is a keyboard, the user may input information by pressing keys on the keyboard. Alternatively, if the input unit 120 is a microphone, the user may input information by voice.
- the display unit 130 can be any display for displaying information.
- the memory unit 140 stores programs for executing processes in the user device 100, data required for executing the programs, and the like.
- the memory unit 140 stores, for example, evaluation of the history of the subject's disease, evaluation of the effectiveness of a preventive agent or vaccine against the disease, evaluation of the effectiveness of a therapeutic agent against the disease, evaluation of the protective ability against re-infection of the disease, evaluation of the disease Stores part or all of a program for evaluating medical technology for pathological condition evaluation and disease morbidity risk evaluation.
- the memory unit 140 may store applications that implement arbitrary functions.
- the memory unit 140 may store an application for obtaining information about the level or amount of follicular T cells, for example, by measuring biochemical information about the follicular T cells.
- the user device 100 has a part that realizes measurement of information on follicular T cells.
- the memory unit 140 may store, for example, an application for obtaining information on the level or amount of follicular T cells from biochemical information on follicular T cells.
- the user device 100 has a part that implements the function of measuring the electro-oculography.
- the memory unit 140 may store an application for obtaining eyeball information by other means.
- the program may be pre-installed in memory unit 140 .
- the program may be installed in memory unit 140 by being downloaded via network 400 .
- Memory unit 140 may be implemented by any storage means.
- the processor unit 150 controls the operation of the user device 100 as a whole.
- the processor unit 150 reads a program stored in the memory unit 140 and executes the program. This allows the user device 100 to function as a device that executes desired steps.
- the processor unit 150 may be implemented by a single processor or multiple processors.
- the user device 100 can include a data acquisition unit 160 in addition to the configuration described above.
- the data acquisition unit 160 is any means for acquiring biochemical information on follicular T cells, exemplified by biochemical means such as ELISA.
- the data acquisition unit 160 is, for example, a device that implements ELISA.
- the data acquisition unit 160 may be, for example, light absorption means built into the user device 100 or external FACS equipment attached to the user device 100 .
- the user device 100 can include additional information acquisition means 170 in addition to the configuration described above, or in place of or in addition to the data acquisition section 160 described above.
- Additional information acquisition means 170 is any means for acquiring additional information.
- the additional information acquisition means 170 is means for acquiring information on infectious diseases, vaccines, cancers, allergies, and autoimmune diseases, for example.
- the additional information acquisition means 170 may be biotechnology equipment such as PCR for identifying infectious diseases in the user device 100 or may be an antigen-antibody reaction measuring device attached to the user device 100 .
- the other medical equipment can be used as the additional information acquisition means 170 .
- each component of the user device 100 is provided in the user device 100 in the example shown in FIG. 9, the present disclosure is not limited to this. Any of the components of user device 100 may be provided external to user device 100 .
- each hardware component is connected via an arbitrary network. may be At this time, the type of network does not matter.
- Each hardware component may be connected via a LAN, wirelessly, or wired, for example.
- User device 100 is not limited to a particular hardware configuration.
- the configuration of the user device 100 is not limited to those described above as long as its functions can be realized.
- FIG. 10 shows an example of the configuration of the server device 200.
- FIG. 10 shows an example of the configuration of the server device 200.
- the server device 200 includes a communication interface section 210 , a memory section 220 and a processor section 230 .
- the communication interface unit 210 controls communication via the network 400. Communication interface section 210 also controls communication with database section 300 .
- the processor unit 230 of the server device 200 can receive information from outside the server device 200 via the communication interface unit 210 and can transmit information to the outside of the server device 200 .
- the processor unit 230 of the server device 200 can receive information from the user device 100 via the communication interface unit 210 and can transmit information to the user device 100 .
- Communication interface unit 210 may control communications in any manner.
- the memory unit 220 stores programs required for executing the processes of the server device 200, data required for executing the programs, and the like. For example, part or all of a program for analyzing follicular T cells and evaluating diseases based thereon is stored.
- the memory unit 220 stores, for example, an application for obtaining information on the level or amount of follicular T cells, an evaluation of the history of the disease of interest, an evaluation of the effectiveness of a preventive agent or vaccine against the disease, and a therapeutic agent against the disease. Applications may be stored for evaluating medical techniques for efficacy assessment, protection against re-infection, disease pathology assessment, and disease morbidity risk assessment.
- the memory unit 220 may, for example, store applications for obtaining follicular T cell or other medical technology information by other means. Memory unit 220 may be implemented by any storage means.
- the processor unit 230 controls the operation of the server device 200 as a whole.
- the processor unit 230 reads a program stored in the memory unit 220 and executes the program. This allows the server device 200 to function as a device that executes desired steps.
- the processor unit 230 may be implemented by a single processor or multiple processors.
- each component of the server device 200 is provided in the server device 200 in the example shown in FIG. 10, the present disclosure is not limited to this. Any one of the components of server device 200 may be provided outside server device 200 .
- each hardware component may be connected via an arbitrary network. At this time, the type of network does not matter.
- Each hardware component may be connected via a LAN, wirelessly, or wired, for example.
- Server device 200 is not limited to a specific hardware configuration.
- the configuration of the server device 200 is not limited to the above as long as the functions can be realized.
- the database unit 300 is provided outside the server device 200, but the present disclosure is not limited to this. It is also possible to provide the database unit 300 inside the server device 200 .
- the database section 300 may be implemented by the same storage means as the storage means in which the memory section 220 is implemented, or by a storage means different from the storage means in which the memory section 220 is implemented.
- database unit 300 is configured as a storage unit for server device 200 .
- the configuration of database unit 300 is not limited to a specific hardware configuration.
- the database unit 300 may be configured with a single hardware component, or may be configured with a plurality of hardware components.
- the database unit 300 may be configured as an external hard disk device of the server device 200, or configured as a cloud storage connected via a network. (general technology)
- Example 1 Virus case (general case)
- SARS-CoV-2-specific T-cell subsets and their clonotypes are analyzed using a single-cell-based RNA sequencing platform (10xGenomics, Chromium).
- Peripheral blood mononuclear cells are prepared from 6 individuals, including healthy donors and virally infected patients (eg influenza virus infected patients). Preparation is carried out as follows. Whole blood was collected in heparin-coated tubes and centrifuged at 1500 rpm for 10 minutes to separate cell fractions and plasma. Plasma is removed from the cell pellet and stored at -80°C. PBMCs are then separated by density gradient sedimentation and erythrocytes are lysed using ACK lysis buffer. The isolated PBMCs are cryopreserved at -80°C in a STEM-CELLBANKER (Zenoaq Resource).
- STEM-CELLBANKER STEM-CELLBANKER
- Cryopreserved PBMCs are thawed and washed with RPMI1640 medium supplemented with 5% human AB serum.
- 5 x 10 5 PBMCs were immunized with 1 ⁇ g/ml S protein, recombinant S protein (1 ⁇ g/ml), S peptide pool (1 ⁇ g/ml/peptide) or M+N peptide pool (1 ⁇ g/ml).
- Stimulate with activated virus eg, influenza virus.
- the stimulating protein is appropriately selected depending on the virus.
- the protein of the recombinant virus is prepared based on known literature).
- PepMix influenza virus variant proteins
- CD3+CD69+ or CD3+CD137+ cells are sorted by cell sorter SH-800S cells (SONY) and analyzed for TCR sequences along with RNA expression by single-cell VDJ-RNA-seq analysis as described below.
- a single-cell suspension containing approximately 2 ⁇ 10 cells is loaded onto a Chromium microfluidic chip and a Chromium controller (10XGenomics) is used to generate single-cell gel-bead-in-emulsions according to the manufacturer's instructions.
- Barcoded cell-derived RNA for each sample was then reverse transcribed in a gel bead-in-emulsion using a Veriti Thermal Cycler (Thermo Fisher Scientific), and all subsequent transcriptions to generate single-cell libraries were performed.
- the steps are performed according to the manufacturer's protocol for 14 cycles for cDNA amplification.
- Approximately 50 ng of cDNA is then used for 14 cycles of gene expression library amplification in parallel with cDNA enrichment and library construction of the TCR library.
- the fragment size of the library is checked with an Agilent 2100 Bioanalyzer (Agilent). Libraries were sequenced on the Illumina NovaSeq6000 in paired-end mode (read1: 28bp; read2: 91bp). Raw reads are processed by Cell Ranger 3.1.0 (10XGenomics). Gene expression-based clustering is performed using the Seurat R package (v3.1, Hafeffle, C., Satija, R. Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. Genome Biol 20 , 296 (2019). https://doi.org/10.1186/s13059-019-1874-1).
- HashTag oligo demultiplexing is performed on CLR-normalized HashTagUMI counts and clonotypes are matched to gene expression data via droplet barcodes using a Python script. Only cells assigned a single hashtag and beta chain clonotype are retained for downstream analysis.
- Tfh cluster is composed of cells expressing Tfh-related genes such as CD200, PDCD1, ICOS, CXCL13, and CD40LG. Furthermore, within the Tfh cluster, we identify over 1100 paired TCRs.
- TCR ⁇ pairs shared between patients These TCR ⁇ pairs are designated clones 1 and 2, derived from patients X1 and X2, which share the same V ⁇ , J ⁇ , V ⁇ , and J ⁇ usage, respectively.
- clones 1 and 2 derived from patients X1 and X2, which share the same V ⁇ , J ⁇ , V ⁇ , and J ⁇ usage, respectively.
- CDR3 ⁇ sequences of clones 1 and 2 are identical and the CDR3 ⁇ s are identical except for one amino acid.
- TCR tumor necrosis factor-associated clonotypes 1 and 2
- TCR ⁇ and ⁇ chains are transfected into TCR-deficient T cell hybridomas to establish TCR-reconstituted CD3+ cells.
- TCR transfectants are stimulated with various antigens in the presence of Epstein-Barr virus (EBV)-transformed B cells from each corresponding patient.
- EBV Epstein-Barr virus
- the HLA alleles that constrain clones 1 and 2 are determined to further reduce the number of peptide candidates for epitopes.
- APCs antigen-presenting cells
- Both clones 1 and 2 respond to S-peptide pool #2 only in the presence of DRA*01:01 and DRB1*15:01, and since DRA is monomorphic, the response is DRB1*15:01. is determined by
- DRB1*15:02 is also the allele responsible for epitope recognition, and tested APC from another individual with DRB1*15:02 but not DRB1*15:01. can be tested. Consequently, DRB1*15:02 can be identified as capable of stimulating both clones 1 and 2 in the presence of this particular peptide.
- clone 1/2 is this virus-specific T cell exhibiting a Tfh profile
- Example 2 Virus case (in the case of SARS-CoV-2)
- SARS-CoV-2-specific T cell subsets and their clonotypes were analyzed using a single cell-based RNA sequencing platform (10xGenomics, Chromium).
- Peripheral blood mononuclear cells were prepared from 6 individuals, including healthy donors and convalescent COVID-19 patients (Tables 1 and 2). Preparation was performed as follows. Whole blood was collected in heparin-coated tubes and centrifuged at 1500 rpm for 10 minutes to separate cell fractions and plasma. Plasma was removed from the cell pellet and stored at -80°C. PBMCs were then separated by density gradient sedimentation and erythrocytes were lysed using ACK lysis buffer. Separated PBMCs were cryopreserved at -80°C in STEM-CELLBANKER (Zenoaq Resource).
- Table 1 Participant Characteristics Table 2: COVID-19 disease severity classification in Japan Cryopreserved PBMCs were thawed and washed with RPMI1640 medium supplemented with 5% human AB serum. 5 x 10 5 PBMCs were immunized with 1 ⁇ g/ml S protein, recombinant S protein (1 ⁇ g/ml), S peptide pool (1 ⁇ g/ml/peptide) or M+N peptide pool (1 ⁇ g/ml). stimulated with activated SARS-CoV-2.
- the inactivated SARS-CoV-2 virus was provided by Dr. Shioda and Dr. Nakayama (Research Institute for Microbial Diseases, Osaka University).
- SARS-CoV-2S protein The recombinant SARS-CoV-2S protein is described in Amanat F, et al. bioRxiv.2020.
- PepMix SARS-CoV-2 (spike glycoprotein) (including pools #1 and #2) was purchased from JPT Peptide Technologies PepTivator SARS-CoV-2 Prot_M and _N from Miltenyi Biotec ) at 37°C for 20 hours followed by staining with anti-human CD3 (HIT3a), CD69 (FN50), CD137 (4B4-1) and TotalSeqTM-C hashtags (all purchased from Biolegend) did.
- CD3+CD69+ or CD3+CD137+ cells were sorted by cell sorter SH-800S cells (SONY) and analyzed for TCR sequences along with RNA expression by single-cell VDJ-RNA-seq analysis as described below. (Single-cell-based transcriptome and TCR repertoire analysis) The following reagents were used for single cell capture and library preparation.
- a single-cell suspension containing approximately 2 ⁇ 10 4 cells was loaded onto a Chromium microfluidic chip and a single-cell gel-bead-in-emulsion was generated using a Chromium controller (10XGenomics) according to the manufacturer's instructions.
- RNA for each sample was then reverse transcribed in a gel bead-in-emulsion using a Veriti Thermal Cycler (Thermo Fisher Scientific), and all subsequent transcriptions to generate single-cell libraries were performed. The steps were performed according to the manufacturer's protocol for 14 cycles for cDNA amplification. Approximately 50 ng of cDNA was then used for 14 cycles of gene expression library amplification in parallel with cDNA enrichment and library construction of the TCR library. The fragment size of the library was confirmed with an Agilent 2100 Bioanalyzer (Agilent). Libraries were sequenced on the Illumina NovaSeq6000 in paired-end mode (read1: 28bp; read2: 91bp).
- Raw reads were processed by Cell Ranger 3.1.0 (10XGenomics). Gene expression-based clustering was performed using the Seurat R package (v3.1, Hafeffle, C., Satija, R. Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. Genome Biol 20 , 296 (2019). https://doi.org/10.1186/s13059-019-1874-1). Briefly, cells with more than 10% mitochondrial content, less than 200 detected genes, or more than 4000 genes were considered outliers (dying cells, empty droplets and doublets, respectively), Filtered out. We used the SeuratSCTransform function for normalization, and because all samples were processed simultaneously, we pooled the data without performing batch effect correction.
- HashTag oligo demultiplexing was performed on CLR-normalized HashTagUMI counts and clonotypes were matched to gene expression data via droplet barcodes using a Python script. Only cells assigned a single hashtag and beta chain clonotype were retained for downstream analysis.
- Tfh clusters were composed of cells expressing Tfh-associated genes, including CD200, PDCD1, ICOS, CXCL13 and CD40LG (Fig. 1A). Furthermore, within the Tfh cluster, 120 paired TCRs were identified (Table 3). Among these, we detected a TCR ⁇ pair shared between patients. These TCR ⁇ pairs were designated clones 1 and 2, derived from patients Ts-017 and Ts-018, which share identical V ⁇ , J ⁇ , V ⁇ , and J ⁇ usage, respectively. Furthermore, the CDR3 ⁇ sequences of clones 1 and 2 were identical and the CDR3 ⁇ s were found to be identical except for one amino acid (Table 4 and Figure 2). Clones 1 and 2 were derived from separate subjects, but were presumed to recognize the same epitope based on sequence similarity. In addition, both were identified from the Tfh cluster, and it was expected that the epitope would easily induce Tfh.
- clone 2 was detected as two different barcode cells sharing the exact same TCR sequence.
- clonotypes 1 and 2 we transfected the respective TCR ⁇ and ⁇ chains into TCR-deficient T-cell hybridomas and established TCR-reconstituted CD3+ cells (Fig. 1B).
- TCR transfectants were stimulated with various antigens in the presence of Epstein-Barr virus (EBV)-transformed B cells from each corresponding patient.
- EBV Epstein-Barr virus
- Clones 1 and 2 responded to the recombinant S protein and S peptide pools, but not to the M+N peptide pool. This was consistent with the initial antigen specificity revealed by single-cell analysis (Fig. 3A).
- HLA alleles constraining clones 1 and 2 were then determined to further reduce the number of peptide candidates for epitopes.
- APCs antigen-presenting cells
- MHC class II alleles shared between Ts-017 and Ts-018, such as DRB1*15:01, DPA1*02:02-DPB1*05:01, DQA1*01:02-DQB1*06 were considered HLA candidates.
- Both clones 1 and 2 respond to S-peptide pool #2 only in the presence of DRA*01:01 and DRB1*15:01, and since DRA is monomorphic, the response is DRB1*15:01. (Fig. 5B).
- the NetMHC server software http://www.cbs.dtu.dk/services/NetMHCIIpan/ was used to search for candidate peptides predicted to bind to DRA-DRB1*15:01 (Fig. 5C). .
- peptide S 864-882 was determined as the epitope for both clones 1 and 2 by synthesizing two peptides to stimulate clones 1 and 2 (Fig. 5E).
- TCRs of clones 1 and 2 differ by one amino acid in CDR3 (Pro and Gln at position 89), both TCRs recognize the same epitope presented by the same MHC molecule and originate from different donors. , suggesting that clones 1 and 2 are public clones. This epitope has low homology with the corresponding amino acid sequence of human coronavirus (HCoV)-OC43.
- clone 1 nor 2 responded at all to the peptide pool and total protein derived from the HCoV-OC43S protein in the presence of APC expressing DRA-DRB1*15:01 (Fig. 6A). Furthermore, none of the other HCoVs, including severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome-associated coronavirus (MERS-CoV), have similar epitopes (Fig. 6B), suggesting that clone It was suggested that 1/2 is unlikely to cross-react with related human coronaviruses.
- SARS-CoV severe acute respiratory syndrome coronavirus
- MERS-CoV Middle East respiratory syndrome-associated coronavirus
- S 864-882 was also predicted as a strong binder to DRB1*15:02 and 15:01 (Fig. 6C). Furthermore, the amino acid sequence identity between DRB1*15:01 and *15:02 is 99.6%. We therefore speculated that DRB1*15:02 is also the allele responsible for epitope recognition, and tested APC from another individual with DRB1*15:02 but not DRB1*15:01. tested. The results showed that DRB1*15:02 was able to stimulate both clones 1 and 2 in the presence of S 864-882 peptide (Fig. 6D).
- clone 1/2 is a SARS-CoV-2-specific T cell exhibiting a Tfh profile
- clone 1/2 was clonally expanded upon infection to promote protective humoral immunity. Assuming that, I investigated as follows.
- the frequency of the clone 1/2 clonotype in recovered patients is greater than the worldwide DRB1*15:01 or 15:02 allele frequency (11.3%), suggesting that clone 1/2 , may recognize other SARS-CoV-2-derived epitopes presented by other HLA alleles.
- Example 3 Restimulation Assay of Peripheral Blood Mononuclear Cells (PBMC) with the Peptide of Example 1 1.0 ⁇ 10 5 cells of PBMC obtained from the experiment participants of Example 1 were suspended in 100 ⁇ l of RPMI1640 medium (containing 5% human serum and penicillin/streptomycin). After turbidity, the Example 1 peptide was added to 1 ⁇ g/ml and cultured in a 96-well plate (U bottom) (Day 0).
- RPMI1640 medium containing 5% human serum and penicillin/streptomycin
- Example 1 As a result of the measurement, it was found that the IL-21 concentration in the medium was higher when stimulated with the peptide of Example 1 compared to when it was not stimulated. These results suggest that the peptide stimulation of Example 1 promotes germinal center formation and anti-affinity antibody production by follicular T cells.
- PBMC Peripheral blood mononuclear cell
- SARS-CoV-2 S 864-882 peptide 1.0 ⁇ 10 5 cells of PBMC obtained from experimental participants in RPMI1640 medium (supplemented with 5% human serum and penicillin/streptomycin) Suspended in 100 ⁇ l, SARS-CoV-2 S 864-882 peptide was added to 1 ⁇ g/ml, and cultured in a 96-well plate (U bottom) (Day 0).
- human IL-2 was added to 10 IU/ml on Days 4 and 7. Passage of medium was performed as appropriate.
- the cells were sorted using the cell sorter SH-800S (SONY) as follows. They were stained with CD3 and CD4 antibodies and PI, and sorted in the order of FSC SSC gating, PI negative gating, CD3 positive gating, and CD4 positive cells. At that time, staining was performed using CXCR5, CD45RA, and PD-1 antibodies, and FCM analysis was also performed.
- SH-800S cell sorter SH-800S
- IL-21 concentration in the medium was found to be higher after stimulation with SARS-CoV-2 S 864-882 peptide compared to non-stimulation. This result suggested that SARS-CoV-2 S 864-882 peptide stimulation promoted germinal center formation and anti-affinity antibody production by follicular T cells.
- Example 5 Evaluation of infection history
- the infection history is evaluated.
- Antibody-based evaluation of infection history is often performed, but since specific immune cells are maintained for a longer period than antibodies, identifying source-specific immune cells is particularly important in examining infection history.
- a T cell detection method using a probe containing an infectious source-specific epitope is useful as a simple method for detecting immune cells established and maintained after infection.
- the presence or absence of probe-reactive T cells can be easily detected by ELISPOT using peripheral blood mononuclear cells (PBMC) or a system using flow cytometry. If probe-reactive T cells are detected, past infection is determined.
- PBMC peripheral blood mononuclear cells
- ELISPOT The presence or absence of infection-specific immune cells in the subject's peripheral blood is examined by ELISPOT assay.
- the ELISPOT assay used here uses plates coated with antibodies capable of detecting IL-21 produced by follicular T cells.
- Peripheral blood mononuclear cells (PBMC) are added to the wells and stimulated with the above antigens for 36 hours.
- Secreted IL-21 binds to capture antibodies in the vicinity of producing cells.
- a cytokine antibody for detection is added to detect the spots.
- an assay without source-derived antigen stimulation is performed. (result) If IL-21 secretion is confirmed, it can be judged that there is a history of infection.
- Example 6 Evaluation of vaccine effectiveness/Evaluation of ability to protect against reinfection
- evaluation of vaccine efficacy and ability to protect against reinfection are performed.
- Infectious source-specific immune cells can be maintained for a longer period of time than antibodies and can respond rapidly upon reinfection, and can be used to assess the protective ability of immune cells.
- follicular T cells are important fractions for the induction and enhancement of humoral immunity (affinity maturation), so they contain epitopes that specifically induce follicular T cells. Subjects with probe-reactive T cells are judged to have a stronger or qualitatively superior defense against infection.
- ELISPOT and flow cytometry can be used for evaluation in the same manner as described above. These methods can detect whether the T cells that reacted to the epitope probe were actually follicular T cells by changing the cytokines to be detected or by combining surface antigen probes, and to what extent they were. It is also possible to design an experimental system according to detection sensitivity and criteria.
- the ELISPOT assay used here uses plates coated with antibodies capable of detecting IL-21 produced by follicular T cells.
- Peripheral blood mononuclear cells (PBMC) are added to the wells and stimulated with the above antigens for 36 hours.
- Secreted IL-21 binds to capture antibodies in the vicinity of producing cells.
- a cytokine antibody for detection is added to detect the spots.
- an assay without source-derived antigen stimulation is performed. (result) If IL-21 secretion is confirmed, it can be judged that the protective ability of immune cells is effective.
- Example 7 Efficacy evaluation of cancer immunodrugs (immune checkpoints, etc.)
- the effectiveness of cancer immunological agents is evaluated. If a humoral immune response against cancer antigens is induced, higher antitumor activity is expected. Therefore, subjects with more follicular T cells that induce anti-tumor humoral immune responses are more likely to activate their anti-tumor immunity, and drugs such as immune checkpoint inhibitors that enhance their anti-tumor immunity are effective. considered to be more effective.
- T cells obtained from tumor biopsy specimens or peripheral blood and epitope probes it is possible to evaluate the activity of the subject's anti-tumor immunity and use it for treatment selection.
- epitope-specific follicular T cells tumor-specific follicular T cells
- flow cytometry to evaluate the activation and exhaustion of epitope-specific follicular T cells (tumor-specific follicular T cells) during drug administration, the activity of anti-tumor immunity is maintained. It is expected to find out if This is effective in determining whether immune checkpoint inhibitors will continue to be effective, or whether treatment should be discontinued and other treatment methods should be sought.
- lung cancer CEA which is a lung cancer marker
- gastric cancer CA19-9 a gastric cancer marker
- ELISPOT assay The presence or absence of antigen-specific immune cells in the subject's peripheral blood is examined by ELISPOT assay.
- the ELISPOT assay used here uses plates coated with antibodies capable of detecting IL-21 produced by follicular T cells.
- Peripheral blood mononuclear cells (PBMC) are added to the wells and stimulated with the above antigens for 36 hours.
- Secreted IL-21 binds to capture antibodies in the vicinity of producing cells.
- a cytokine antibody for detection is added to detect the spots.
- an assay without antigen stimulation is performed.
- Example 8 Risk assessment of autoimmune diseases with autoantibodies (before disease), pathological evaluation)
- risk assessment before disease
- pathological condition assessment of autoimmune diseases accompanied by autoantibodies are performed.
- autoimmune diseases associated with autoantibodies There are many autoimmune diseases associated with autoantibodies. Among them, in diseases in which autoantibodies are thought to be pathogenic (e.g., ANCA-associated vasculitis), follicular T cells that interact with autoantibody-producing B cells are involved. Presence/absence/increase/decrease may lead to onset and aggravation/relapse of pathology associated with maturation of B cells.
- ELISPOT assay The presence or absence of antigen-specific immune cells in the subject's peripheral blood is examined by ELISPOT assay.
- the ELISPOT assay used here uses plates coated with antibodies capable of detecting IL-21 produced by follicular T cells.
- Peripheral blood mononuclear cells (PBMC) are added to the wells and stimulated with the above antigens for 36 hours.
- Secreted IL-21 binds to capture antibodies in the vicinity of producing cells.
- a cytokine antibody for detection is added to detect the spots.
- an assay without antigen stimulation is performed.
- Negative control and IL-21 secretion information and clinical information for each epitope will be shared and stored as data, and used for future diagnostic method development, disease subdivision, and treatment selection method development.
- the present disclosure can be used in fields such as vaccine development, cell therapy, and diagnostic technology.
Abstract
Description
被検体における疾患の疾患関連因子に反応性の濾胞性T細胞のレベルまたは量を測定することを含む、該被検体に対する該疾患を評価するための方法。
(項目2)
前記測定の結果に基づいて、前記疾患の履歴の評価、前記疾患に対する予防剤またはワクチンの有効性の評価、前記疾患に対する治療剤の有効性の評価、前記疾患の再罹患に対する防御能の評価、前記疾患の病態評価および前記疾患の罹患リスク評価からなる群より選択される少なくとも1つを行うことをさらに含む、上記項目のいずれかに記載の方法。
(項目3)
前記被検体における前記疾患を検査または診断することをさらに含む、上記項目のいずれかに記載の方法。
(項目4)
前記被検体の前記疾患の感染履歴の評価をすることをさらに含む、上記項目のいずれかに記載の方法。
(項目5)
前記被検体の前記疾患のワクチン有効性評価・再感染防御能の評価をすることをさらに含む、上記項目のいずれかに記載の方法。
(項目6)
前記被検体の前記疾患のがん免疫薬剤の有効性評価をすることをさらに含む、上記項目のいずれかに記載の方法。
(項目7)
前記疾患関連因子は、自己免疫疾患関連因子であり、前記測定は該自己免疫疾患関連因子に反応性の濾胞性T細胞のレベルまたは量を測定すること、ならびに前記被検体の自己抗体を伴う自己免疫疾患のリスク評価、病態評価をすることをさらに含む、上記項目のいずれかに記載の方法。
(項目8)
前記測定は、ELISPOT、フローサイトメトリー、末梢血単核細胞(PBMC)の再刺激アッセイ、次世代シーケンサー/遺伝子検査(レパトア解析)、免疫染色(病理組織検査)、in situ解析による、上記項目のいずれかに記載の方法。
(項目9)
測定した前記疾患関連因子に反応性の濾胞性T細胞のレベル、空間的分布または量を、疾患に罹患していない被験体における疾患関連因子に反応性の濾胞性T細胞のレベル、空間的分布または量の平均値または中央値と比較することをさらに含む、上記項目のいずれかに記載の方法。
(項目10)
前記疾患は、感染症またはがんである、上記項目のいずれかに記載の方法。
(項目11)
前記疾患はウイルス感染症である、上記項目のいずれかに記載の方法。
(項目12)
前記疾患はアレルギーまたは自己免疫疾患である、上記項目のいずれかに記載の方法。
(項目13)
被検体における疾患の疾患関連因子に反応性の濾胞性T細胞のレベル、空間的分布または量を測定する試薬またはデバイスを含む、該被検体に対する該疾患を評価するための試薬またはデバイス。
(項目14)
前記試薬またはデバイスは、濾胞性T細胞に対して特異的に反応する試薬を含む、上記項目のいずれかに記載の試薬またはデバイス。
(項目15)
前記デバイスは、ELISPOT、フローサイトメトリー、末梢血単核細胞(PBMC)の再刺激アッセイ、次世代シーケンサー/遺伝子検査(レパトア解析)、免疫染色(病理組織検査)、in situ解析を行うためのデバイスである、上記項目のいずれかに記載の試薬またはデバイス。
(項目16)
前記疾患は、感染症またはがんである、上記項目のいずれかに記載の試薬またはデバイス。
(項目17)
前記疾患はウイルス感染症である、上記項目のいずれかに記載の試薬またはデバイス。
(項目18)
前記疾患はアレルギーまたは自己免疫疾患である、上記項目のいずれかに記載の試薬またはデバイス。
(項目19)
被検体における疾患の疾患関連因子に反応性の濾胞性T細胞のレベル、空間的分布または量を測定する試薬またはデバイスと、
該試薬またはデバイスによる測定結果を該疾患について評価する評価部と
を含む、該被検体に対する該疾患を評価するためのシステム。
(項目20)
前記評価部は、前記疾患の履歴の評価、前記疾患に対する予防剤またはワクチンの有効性の評価、前記疾患に対する治療剤の有効性の評価、前記疾患の再罹患に対する防御能の評価、前記疾患の病態評価および前記疾患の罹患リスク評価からなる群より選択される少なくとも1つを行うように構成される、上記項目のいずれかに記載のシステム。
(項目21)
前記被検体における前記疾患を検査または診断する検査・診断部をさらに含む、上記項目のいずれかに記載のシステム。
(項目22)
前記被検体の前記疾患の感染履歴の評価をする感染履歴評価部をさらに含む、上記項目のいずれかに記載のシステム。
(項目23)
前記被検体の前記疾患のワクチン有効性評価・再感染防御能の評価をするワクチン有効性評価・再感染防御能評価部をさらに含む、上記項目のいずれかに記載のシステム。
(項目24)
前記被検体の前記疾患のがん免疫薬剤の有効性評価をするがん免疫薬剤有効性評価部をさらに含む、上記項目のいずれかに記載のシステム。
(項目25)
前記疾患関連因子は、自己免疫疾患関連因子であり、該自己免疫疾患関連因子に反応性の濾胞性T細胞のレベル、空間的分布または量を測定する濾胞性T細胞測定部、ならびに前記被検体の自己抗体を伴う自己免疫疾患のリスク評価、病態評価をする自己免疫疾患リスク評価、病態評価部を含む、上記項目のいずれかに記載のシステム。
(項目26)
前記試薬またはデバイスは、濾胞性T細胞に対して特異的に反応する試薬を含む、上記項目のいずれかのいずれか一項に記載のシステム。
(項目27)
前記デバイスは、ELISPOT、フローサイトメトリー、末梢血単核細胞(PBMC)の再刺激アッセイ、次世代シーケンサー/遺伝子検査(レパトア解析)、免疫染色(病理組織検査)、in situ解析を行うためのデバイスである、上記項目のいずれかに記載のシステム。
(項目28)
測定した前記疾患関連因子に反応性の濾胞性T細胞のレベル、空間的分布または量を、疾患に罹患していない被験体における疾患関連因子に反応性の濾胞性T細胞のレベル、空間的分布または量の平均値または中央値と比較する比較部をさらに含む、上記項目のいずれかに記載のシステム。
(項目29)
前記疾患は、感染症またはがんである、上記項目のいずれかに記載のシステム。
(項目30)
前記疾患はウイルス感染症である、上記項目のいずれかに記載のシステム。
(項目31)
前記疾患はアレルギーまたは自己免疫疾患である、上記項目のいずれかに記載のシステム。
(項目32)
被検体における疾患の疾患関連因子に反応性の濾胞性T細胞のレベル、空間的分布または量に関する情報を提供する工程と、
該濾胞性T細胞のレベル、空間的分布または量に関する情報を該疾患について評価する工程と
を含む、該被検体に対する該疾患を評価するための方法。
(項目33)
前記評価する工程が、前記疾患の履歴の評価、前記疾患に対する予防剤またはワクチンの有効性の評価、前記疾患に対する治療剤の有効性の評価、前記疾患の再罹患に対する防御能の評価、前記疾患の病態評価および前記疾患の罹患リスク評価からなる群より選択される少なくとも1つを行うことをさらに含む、上記項目のいずれかに記載の方法。
(項目34)
前記被検体の前記疾患の感染履歴の評価をすることを含む、上記項目のいずれか記載の方法。
(項目35)
前記被検体の前記疾患のワクチン有効性評価・再感染防御能の評価をすることを含む、上記項目のいずれかに記載の方法。
(項目36)
前記被検体の前記疾患のがん免疫薬剤の有効性評価をすることを含む、上記項目のいずれかに記載の方法。
(項目37)
前記疾患関連因子は、自己免疫疾患関連因子であり、前記測定は該自己免疫疾患関連因子に反応性の濾胞性T細胞のレベルまたは量を測定すること、ならびに前記被検体の自己抗体を伴う自己免疫疾患のリスク評価、病態評価をすることを含む、上記項目のいずれかに記載の方法。
(項目38)
前記情報を提供する工程は、ELISPOT、フローサイトメトリー、末梢血単核細胞(PBMC)の再刺激アッセイ、次世代シーケンサー/遺伝子検査(レパトア解析)、免疫染色(病理組織検査)、in situ解析により行われるものである、上記項目のいずれかに記載の方法。
(項目39)
前記被検体における疾患の疾患関連因子に反応性の濾胞性T細胞のレベル、空間的分布または量に関する情報を、疾患に罹患していない被験体における被検体における疾患の疾患関連因子に反応性の濾胞性T細胞のレベル、空間的分布または量に関する情報の平均値または中央値と比較することをさらに含む、上記項目のいずれかに記載の方法。
(項目40)
前記疾患は、感染症またはがんである、上記項目のいずれかに記載の方法。
(項目41)
前記疾患はウイルス感染症である、上記項目のいずれかに記載の方法。
(項目42)
前記疾患はアレルギーまたは自己免疫疾患である、上記項目のいずれかに記載の方法。
(項目43)
被検体における疾患の疾患関連因子に反応性の濾胞性T細胞のレベル、空間的分布または量に関する情報を提供する工程と、
該濾胞性T細胞のレベル、空間的分布または量に関する情報を該疾患について評価する工程と
を含む、該被検体に対する該疾患を評価するための方法を、コンピュータに実装するコンピュータ読み取り可能なコードを含むプログラム。
(項目44)
前記評価する工程が、前記疾患の履歴の評価、前記疾患に対する予防剤またはワクチンの有効性の評価、前記疾患に対する治療剤の有効性の評価、前記疾患の再罹患に対する防御能の評価、前記疾患の病態評価および前記疾患の罹患リスク評価からなる群より選択される少なくとも1つを行うことをさらに含む、上記項目のいずれかに記載のプログラム。
(項目45)
前記方法が、前記被検体の前記疾患の感染履歴の評価をすることを含む、上記項目のいずれかに記載のプログラム。
(項目46)
前記方法が、前記被検体の前記疾患のワクチン有効性評価・再感染防御能の評価をすることを含む、上記項目のいずれかに記載のプログラム。
(項目47)
前記方法が、前記被検体の前記疾患のがん免疫薬剤の有効性評価をすることを含む、上記項目のいずれかに記載のプログラム。
(項目48)
前記疾患関連因子は、自己免疫疾患関連因子であり、前記方法が、前記測定は該自己免疫疾患関連因子に反応性の濾胞性T細胞のレベルまたは量を測定すること、ならびに前記被検体の自己抗体を伴う自己免疫疾患のリスク評価、病態評価をすることを含む、上記項目のいずれかに記載のプログラム。
(項目49)
前記情報を提供する工程は、ELISPOT、フローサイトメトリー、末梢血単核細胞(PBMC)の再刺激アッセイ、次世代シーケンサー/遺伝子検査(レパトア解析)、免疫染色(病理組織検査)、in situ解析により行われるものである、上記項目のいずれかに記載のプログラム。
(項目50)
前記方法が、前記被検体における疾患の疾患関連因子に反応性の濾胞性T細胞のレベル、空間的分布または量に関する情報を、疾患に罹患していない被験体における被検体における疾患の疾患関連因子に反応性の濾胞性T細胞のレベル、空間的分布または量に関する情報の平均値または中央値と比較することをさらに含む、上記項目のいずれかに記載のプログラム。
(項目51)
前記疾患は、感染症またはがんである、上記項目のいずれかに記載のプログラム。
(項目52)
前記疾患はウイルス感染症である、上記項目のいずれかに記載のプログラム。
(項目53)
前記疾患はアレルギーまたは自己免疫疾患である、上記項目のいずれかに記載のプログラム。
(項目54)
上記項目のいずれかに記載のプログラムを格納したコンピュータ読み取り可能な記録媒体。
(項目55)
上記項目のいずれかに記載のプログラムを格納したコンピュータ読み取り可能な記録媒体。
本開示は、さらに以下の項目も提供する。
(項目A1)
疾患の疾患関連因子に反応性の濾胞性T細胞を惹起する能力を有する、該疾患関連因子またはその一部あるいは機能的等価物を含む、該疾患を治療または予防するための医薬組成物。
(項目A2)
前記疾患関連因子に反応性の濾胞性T細胞を惹起する能力を有する、該疾患関連因子またはその一部あるいは機能的等価物を含む、該疾患に対するワクチン。
(項目A3)
前記組成物またはワクチンは、濾胞性T細胞を優先的に誘導する、前記項目のいずれかに記載の組成物またはワクチン。
(項目A4)
前記疾患関連因子に反応性の濾胞性T細胞を含む、前記疾患を治療または予防するための医薬組成物。
(項目A5)
前記疾患関連因子に反応性の濾胞性T細胞を含む、前記疾患に対する細胞ワクチン。
(項目A6)
前記疾患関連因子に反応性の濾胞性T細胞は、少なくとも前記疾患関連因子に対して反応性である、前記項目のいずれかに記載の組成物またはワクチン。
(項目A7)
前記疾患は、感染症またはがんである、前記項目のいずれかに記載の組成物またはワクチン。
(項目A8)
前記疾患はウイルス感染症である、前記項目のいずれかに記載の組成物またはワクチン。
(項目A9)
前記組成物は、HLAの型特異的に濾胞性T細胞を誘導する、前記項目のいずれかに記載の組成物。
(項目A10)
前記疾患関連因子またはその一部あるいは機能的等価物は、最大で20アミノ酸を含む、前記項目のいずれかに記載の組成物。
(項目A11)
前記濾胞性T細胞は、パブリック濾胞性T細胞である、前記項目のいずれかに記載の組成物。
(項目A12)
前記疾患関連因子に反応性の濾胞性T細胞を惹起する能力を有する、前記疾患関連因子またはその一部あるいは機能的等価物を同定する工程と、
該疾患関連因子またはその一部あるいは機能的等価物を用いて前記疾患に特異的な濾胞性T細胞を惹起させる工程と、
該疾患に反応性の濾胞性T細胞を得る工程と
を含む、前記疾患に反応性の濾胞性T細胞を生産する方法。
(項目A13)
前記疾患に反応性の濾胞性T細胞をスクリーニングする方法であって、
A)濾胞性T細胞の集団を提供する工程と、
B)該濾胞性T細胞の集団と前記疾患関連因子とを接触させる工程と、
C)該濾胞性T細胞の該疾患関連因子への反応性を測定する工程と、
D)該濾胞性T細胞の集団のうち、該疾患関連因子に対して所定値以上の反応性を示す濾胞性T細胞を選択する工程と
を含む、方法。
(項目A14)
前記C)の測定する工程が、ELISPOT、フローサイトメトリー、末梢血単核細胞(PBMC)の再刺激アッセイにより実施される、前記項目に記載の方法。
(項目B1)
前記疾患関連因子に反応性の濾胞性T細胞を惹起する能力を有する、前記疾患関連因子またはその一部あるいは機能的等価物を提示するためのポリペプチド。
(項目B2)
前記ポリペプチドは、濾胞性T細胞を優先的に誘導する、前記項目のいずれかに記載のポリペプチド。
(項目B3)
前記疾患関連因子に反応性の濾胞性T細胞は、少なくとも前記疾患関連因子に対して反応性である、前記項目のいずれかに記載のポリペプチド。
(項目B4)
前記疾患は、感染症またはがんである、前記項目のいずれかに記載のポリペプチド。
(項目B5)
前記疾患はウイルス感染症である、前記項目のいずれかに記載のポリペプチド。
(項目B6)
前記ポリペプチドは、HLAの型特異的に濾胞性T細胞を誘導する、前記項目のいずれかに記載のポリペプチド。
(項目B7)
前記疾患関連因子またはその一部あるいは機能的等価物は、最大で20アミノ酸を含む、前記項目のいずれかに記載のポリペプチド。
(項目B8)
前記濾胞性T細胞は、パブリック濾胞性T細胞である、前記項目のいずれかに記載のポリペプチド。
(項目C1)
前記疾患関連因子に反応性の濾胞性T細胞を惹起する能力を有する、前記疾患関連因子またはその一部あるいは機能的等価物と相互作用するTCRと特異的に結合する抗体。
(項目C2)
前記抗体は、濾胞性T細胞を優先的に誘導する、前記項目のいずれかに記載の抗体。
(項目C3)
前記疾患関連因子に反応性の濾胞性T細胞は、少なくとも前記疾患関連因子に対して反応性である、前記項目のいずれかに記載の抗体。
(項目C4)
前記疾患は、感染症またはがんである、前記項目のいずれかに記載の抗体。
(項目C5)
前記疾患はウイルス感染症である、前記項目のいずれかに記載の抗体。
(項目C6)
前記抗体は、HLAの型特異的に濾胞性T細胞を誘導する、前記項目のいずれかに記載の抗体。
(項目C7)
前記疾患関連因子またはその一部あるいは機能的等価物は、最大で20アミノ酸を含む、前記項目のいずれかに記載の抗体。
(項目C8)
前記濾胞性T細胞は、パブリック濾胞性T細胞である、前記項目のいずれかに記載の抗体。
(項目D1)
前記疾患関連因子に反応性の濾胞性T細胞を惹起する能力を有する、該疾患関連因子またはその一部あるいは機能的等価物を指標とする、該疾患を診断するための医薬組成物。
(項目D2)
前記医薬組成物は、濾胞性T細胞を優先的に誘導する、前記項目のいずれかに記載の医薬組成物。
(項目D3)
前記疾患関連因子に反応性の濾胞性T細胞は、少なくとも前記疾患関連因子に対して反応性である、前記項目のいずれかに記載の医薬組成物。
(項目D4)
前記疾患は、感染症またはがんである、前記項目のいずれかに記載の医薬組成物。
(項目D5)
前記疾患はウイルス感染症である、前記項目のいずれかに記載の医薬組成物。
(項目D6)
前記医薬組成物は、HLAの型特異的に濾胞性T細胞を誘導する、前記項目のいずれかに記載の医薬組成物。
(項目D7)
前記疾患関連因子またはその一部あるいは機能的等価物は、最大で20アミノ酸を含む、前記項目のいずれかに記載の医薬組成物。
(項目D8)
前記濾胞性T細胞は、パブリック濾胞性T細胞である、前記項目のいずれかに記載の医薬組成物。
(項目E1)
前記疾患関連因子に反応性の濾胞性T細胞を含む、前記疾患に対する免疫獲得を強化するための組成物。
(項目E2)
前記疾患関連因子に反応性の濾胞性T細胞は、少なくとも前記疾患関連因子に対して反応性である、前記項目のいずれかに記載の組成物またはワクチン。
(項目E3)
前記疾患は、感染症またはがんである、前記項目のいずれかに記載の組成物またはワクチン。
(項目E4)
前記疾患はウイルス感染症である、前記項目のいずれかに記載の組成物またはワクチン。
(項目E5)
前記濾胞性T細胞は、パブリック濾胞性T細胞である、前記項目のいずれかに記載の組成物。
(項目X1)
被検体における疾患の疾患関連因子に反応性の濾胞性T細胞のレベルまたは量を測定すること、および
該レベルまたは量を所定の基準と比較すること
を含む、該被検体に関する該疾患に関する事項を試験するための方法。
(項目X2)
前記基準が、前記疾患の履歴、前記疾患に対する予防剤またはワクチンの有効性、前記疾患に対する治療剤の有効性、前記疾患の再罹患に対する防御能、前記疾患の病態および前記疾患の罹患リスクからなる群より選択される少なくとも1つに関する基準である、上記項目のいずれかに記載の方法。
(項目X3)
前記基準が、前記被検体における前記疾患に関する基準である、上記項目のいずれかに記載の方法。
(項目X4)
前記基準が、前記被検体の前記疾患の感染履歴に関する基準である、上記項目のいずれかに記載の方法。
(項目X5)
前記基準が、前記被検体の前記疾患のワクチン有効性・再感染防御能に関する基準である、上記項目のいずれかに記載の方法。
(項目X6)
前記基準が、前記被検体の前記疾患のがん免疫薬剤の有効性に関する基準である、上記項目のいずれかに記載の方法。
(項目X7)
前記疾患関連因子は、自己免疫疾患関連因子であり、前記測定は該自己免疫疾患関連因子に反応性の濾胞性T細胞のレベルまたは量を測定することを含み、前記基準が、前記被検体の自己抗体を伴う自己免疫疾患のリスク、病態に関する基準である、上記項目のいずれかに記載の方法。
(項目X8)
前記測定は、ELISPOT、フローサイトメトリー、末梢血単核細胞(PBMC)の再刺激アッセイ、次世代シーケンサー/遺伝子検査(レパトア解析)、免疫染色(病理組織検査)、in situ解析による、上記項目のいずれかに記載の方法。
(項目X9)
前記比較は、測定した前記疾患関連因子に反応性の濾胞性T細胞のレベル、空間的分布または量を、疾患に罹患していない被験体における疾患関連因子に反応性の濾胞性T細胞のレベル、空間的分布または量の平均値または中央値と比較することをさらに含む、上記項目のいずれかに記載の方法。
(項目X10)
前記疾患は、感染症またはがんである、上記項目のいずれかに記載の方法。
(項目X11)
前記疾患はウイルス感染症である、上記項目のいずれかに記載の方法。
(項目X12)
前記疾患はアレルギーまたは自己免疫疾患である、上記項目のいずれかに記載の方法。
(項目X13)
被検体における疾患の疾患関連因子に反応性の濾胞性T細胞のレベル、空間的分布または量を測定する試薬またはデバイスを含む、該被検体に対する該疾患を評価するための試薬またはデバイス。
(項目X14)
前記試薬またはデバイスは、濾胞性T細胞に対して特異的に反応する試薬を含む、上記項目のいずれかに記載の試薬またはデバイス。
(項目X15)
前記デバイスは、ELISPOT、フローサイトメトリー、末梢血単核細胞(PBMC)の再刺激アッセイ、次世代シーケンサー/遺伝子検査(レパトア解析)、免疫染色(病理組織検査)、in situ解析を行うためのデバイスである、上記項目のいずれかに記載の試薬またはデバイス。
(項目X16)
前記疾患は、感染症またはがんである、上記項目のいずれかに記載の試薬またはデバイス。
(項目X17)
前記疾患はウイルス感染症である、上記項目のいずれかに記載の試薬またはデバイス。
(項目X18)
前記疾患はアレルギーまたは自己免疫疾患である、上記項目のいずれかに記載の試薬またはデバイス。
(項目X19)
被検体における疾患の疾患関連因子に反応性の濾胞性T細胞のレベル、空間的分布または量を測定する試薬またはデバイスと、
該試薬またはデバイスによる測定結果を所定の基準と比較する比較部と
を含む、該被検体に関する該疾患に関する事項を試験するためのシステム。
(項目X20)
前記基準は、前記疾患の履歴、前記疾患に対する予防剤またはワクチンの有効性、前記疾患に対する治療剤の有効性、前記疾患の再罹患に対する防御能、前記疾患の病態評価および前記疾患の罹患リスクからなる群より選択される少なくとも1つに関する基準である、上記項目のいずれかに記載のシステム。
(項目X21)
前記基準が、前記被検体における前記疾患に関する基準である、上記項目のいずれかに記載のシステム。
(項目X22)
前記基準が、前記被検体の前記疾患の感染履歴に関する基準である、上記項目のいずれかに記載のシステム。
(項目X23)
前記基準が、前記被検体の前記疾患のワクチン有効性・再感染防御能に関する基準である、上記項目のいずれかに記載のシステム。
(項目X24)
前記基準が、前記被検体の前記疾患のがん免疫薬剤の有効性に関する基準である、上記項目のいずれかに記載のシステム。
(項目X25)
前記疾患関連因子は、自己免疫疾患関連因子であり、該自己免疫疾患関連因子に反応性の濾胞性T細胞のレベル、空間的分布または量を測定する濾胞性T細胞測定部をさらに含み、前記基準は、前記被検体の自己抗体を伴う自己免疫疾患のリスク、病態に関する基準である、上記項目のいずれかに記載のシステム。
(項目X26)
前記試薬またはデバイスは、濾胞性T細胞に対して特異的に反応する試薬を含む、上記項目のいずれかに記載のシステム。
(項目X27)
前記デバイスは、ELISPOT、フローサイトメトリー、末梢血単核細胞(PBMC)の再刺激アッセイ、次世代シーケンサー/遺伝子検査(レパトア解析)、免疫染色(病理組織検査)、in situ解析を行うためのデバイスである、上記項目のいずれかに記載のシステム。
(項目X28)
前記比較部は、測定した前記疾患関連因子に反応性の濾胞性T細胞のレベル、空間的分布または量を、疾患に罹患していない被験体における疾患関連因子に反応性の濾胞性T細胞のレベル、空間的分布または量の平均値または中央値と比較する、上記項目のいずれかに記載のシステム。
(項目X29)
前記疾患は、感染症またはがんである、上記項目のいずれかに記載のシステム。
(項目X30)
前記疾患はウイルス感染症である、上記項目のいずれかに記載のシステム。
(項目X31)
前記疾患はアレルギーまたは自己免疫疾患である、上記項目のいずれかに記載のシステム。
(項目X32)
被検体における疾患の疾患関連因子に反応性の濾胞性T細胞のレベル、空間的分布または量に関する情報を提供する工程と、
該濾胞性T細胞のレベル、空間的分布または量に関する情報を所定の基準と比較する工程と
を含む、該被検体に関する該疾患に関する事項を試験するための方法。
(項目X33)
前記基準が、前記疾患の履歴、前記疾患に対する予防剤またはワクチンの有効性、前記疾患に対する治療剤の有効性、前記疾患の再罹患に対する防御能、前記疾患の病態評価および前記疾患の罹患リスクからなる群より選択される少なくとも1つに関する基準である、上記項目のいずれかに記載の方法。
(項目X34)
前記基準が、前記被検体の前記疾患の感染履歴に関する基準である、上記項目のいずれかに記載の方法。
(項目X35)
前記基準が、前記被検体の前記疾患のワクチン有効性・再感染防御能に関する基準である、上記項目のいずれかに記載の方法。
(項目X36)
前記基準が、前記被検体の前記疾患のがん免疫薬剤の有効性に関する基準である、上記項目のいずれかに記載の方法。
(項目X37)
前記疾患関連因子は、自己免疫疾患関連因子であり、前記測定は該自己免疫疾患関連因子に反応性の濾胞性T細胞のレベルまたは量を測定することを含み、前記基準が、前記被検体の自己抗体を伴う自己免疫疾患のリスク、病態に関する基準である、上記項目のいずれかに記載の方法。
(項目X38)
前記情報を提供する工程は、ELISPOT、フローサイトメトリー、末梢血単核細胞(PBMC)の再刺激アッセイ、次世代シーケンサー/遺伝子検査(レパトア解析)、免疫染色(病理組織検査)、in situ解析により行われるものである、上記項目のいずれかに記載の方法。
(項目X39)
前記比較は、前記被検体における疾患の疾患関連因子に反応性の濾胞性T細胞のレベル、空間的分布または量に関する情報を、疾患に罹患していない被験体における被検体における疾患の疾患関連因子に反応性の濾胞性T細胞のレベル、空間的分布または量に関する情報の平均値または中央値と比較することをさらに含む、上記項目のいずれかに記載の方法。
(項目X40)
前記疾患は、感染症またはがんである、上記項目のいずれかに記載の方法。
(項目X41)
前記疾患はウイルス感染症である、上記項目のいずれかに記載の方法。
(項目X42)
前記疾患はアレルギーまたは自己免疫疾患である、上記項目のいずれかの方法。
(項目X43)
被検体における疾患の疾患関連因子に反応性の濾胞性T細胞のレベル、空間的分布または量に関する情報を提供する工程と、
該濾胞性T細胞のレベル、空間的分布または量に関する情報を所定の基準と比較する工程と
を含む、該被検体に関する該疾患に関する事項を試験するための方法を、コンピュータに実装するコンピュータ読み取り可能なコードを含むプログラム。
(項目X44)
前記基準が、前記疾患の履歴、前記疾患に対する予防剤またはワクチンの有効性、前記疾患に対する治療剤の有効性、前記疾患の再罹患に対する防御能、前記疾患の病態評価および前記疾患の罹患リスクからなる群より選択される少なくとも1つに関する基準である、上記項目のいずれかに記載のプログラム。
(項目X45)
前記基準が、前記被検体の前記疾患の感染履歴に関する基準である、上記項目のいずれかに記載のプログラム。
(項目X46)
前記基準が、前記被検体の前記疾患のワクチン有効性・再感染防御能に関する基準である、上記項目のいずれかに記載のプログラム。
(項目X47)
前記基準が、前記被検体の前記疾患のがん免疫薬剤の有効性に関する基準である、上記項目のいずれかに記載のプログラム。
(項目X48)
前記疾患関連因子は、自己免疫疾患関連因子であり、前記方法が、前記測定は該自己免疫疾患関連因子に反応性の濾胞性T細胞のレベルまたは量を測定することを含み、前記基準が前記被検体の自己抗体を伴う自己免疫疾患のリスク、病態に関する基準である、上記項目のいずれかに記載のプログラム。
(項目X49)
前記情報を提供する工程は、ELISPOT、フローサイトメトリー、末梢血単核細胞(PBMC)の再刺激アッセイ、次世代シーケンサー/遺伝子検査(レパトア解析)、免疫染色(病理組織検査)、in situ解析により行われるものである、上記項目のいずれかに記載のプログラム。
(項目X50)
前記比較が、前記被検体における疾患の疾患関連因子に反応性の濾胞性T細胞のレベル、空間的分布または量に関する情報を、疾患に罹患していない被験体における被検体における疾患の疾患関連因子に反応性の濾胞性T細胞のレベル、空間的分布または量に関する情報の平均値または中央値と比較することをさらに含む、上記項目のいずれかに記載のプログラム。
(項目X51)
前記疾患は、感染症またはがんである、上記項目のいずれかに記載のプログラム。
(項目X52)
前記疾患はウイルス感染症である、上記項目のいずれかに記載のプログラム。
(項目X53)
前記疾患はアレルギーまたは自己免疫疾患である、上記項目のいずれかに記載のプログラム。
(項目X54)
上記項目のいずれかに記載のプログラムを格納したコンピュータ読み取り可能な記録媒体。
本明細書において「濾胞性T細胞」とは、B細胞の成熟と活性化、抗体産生を制御する、共有されるTCRを有するヘルパーT細胞を意味する。濾胞性ヘルパーT細胞ともいい、濾胞性T細胞は濾胞性ヘルパーT細胞はと同じ意味を指すものとして本明細書において互換的に使用される。
以下に本開示の好ましい実施形態を説明する。以下に提供される実施形態は、本開示のよりよい理解のために提供されるものであり、本開示の範囲は以下の記載に限定されるべきでない。したがって、当業者は、本明細書中の記載を参酌して、本開示の範囲内で適宜改変を行うことができることは明らかである。また、本開示の以下の実施形態は単独でも使用されあるいはそれらを組み合わせて使用することができる。
<診断>
被検体に由来する末梢血を、感染源特異的なエピトープを含むプローブと接触させ、プローブに結合する末梢血中の濾胞性T細胞の量をELISPOTやフローサイトメトリーにより測定することができ、ELISPOTやフローサイトメトリーは本明細書において他の場所において例示されている。
1.感染履歴の評価
2.ワクチン有効性評価(Tfh誘導の有無)
3.再感染防御能の評価
4.がん免疫薬剤(免疫チェックポイントなど)有効性評価
5.自己抗体を伴う自己免疫疾患のリスク評価(未病時)、病態評価
抗体による感染履歴評価はよく行われているが、抗体に比べ特異的免疫細胞は長期間維持されるため、感染履歴を調べる上で、感染源特異的な免疫細胞を同定することが有益である。感染源特異的なエピトープを含むプローブを用いたT細胞検出法は、簡便に感染後成立し維持された免疫細胞を検出する方法として有益である。プローブに反応するT細胞の有無は末梢血単核細胞(PBMC)を用いたELISPOTやフローサイトメトリーを用いた系によって容易に検出することが可能である。プローブ反応性のT細胞が検出されれば過去に感染したと判定され得る。それ以外にも、健常者と比較して多くのプローブ反応性のT細胞
が検出されれば過去に感染したと判定することができる。
免疫細胞による特異的応答は感染後数日から2週間程度で成立し、それ以降長期に維持されることが知られている。そのため、選択されたエピトープを用いれば感染後、感染症の病原体が体内から排除された後、あるいは検出できないほど抑制された状態でも、免疫状態から感染履歴を判断することができる。
特定感染症に関連するエピトープと患者または回復者で特定感染症に対する獲得免疫が成立していると考えられる検体を用いて、濾胞性T細胞の反応性を確認し、濾胞性T細胞を誘導するエピトープを同定する。ここで、特定感染症に特異的な免疫細胞による応答であることを担保するため、エピトープの他の感染症抗原や疾患関連抗原との配列保存性、望ましくは実際に検体やエピトープ反応性T細胞を用いて交差反応性を評価し、興味ある特定感染症に特異的なエピトープを選択する。これにより、特定感染症に感染履歴を持つ場合にのみ選択されたエピトープに反応することが担保され、感染履歴の評価に用いることができる。
抗体に比べ感染源特異的免疫細胞は長期間維持され、再感染時に迅速に応答しうる点で免疫細胞の防御能を評価することができる。また、濾胞性T細胞は多くのT細胞分画の中でも液性免疫の誘導と強化(親和性成熟)に重要な分画であるため、特に濾胞性T細胞を誘導する当該感染源エピトープを含むプローブと反応するT細胞を持つ被験者はより強い、あるいは質的に優位な感染防御能を有すると判断される。免疫細胞による特異的応答はワクチン抗原にのみ反応するため、当該エピトープによる反応性を見ることで、ワクチン接種後にワクチン対象疾患に対する免疫の有無や強度が判断できる。
・ワクチン有効性評価・再感染防御能の具体的な手順
ワクチンに含まれるT細胞エピトープの中で、ワクチン対象疾患の患者または回復者でワクチン対象疾患に対する獲得免疫が成立していると考えられる検体を用いて、濾胞性T細胞の反応性を確認し、濾胞性T細胞を誘導するエピトープを同定する。ここで、ワクチン抗原に特異的な免疫細胞による応答であることを担保するため、エピトープの他の感染症抗原や疾患関連抗原との配列保存性、望ましくは実際に検体やエピトープ反応性T細胞を用いて交差反応性を評価し、ワクチンに特異的な濾胞性T細胞エピトープを選択する。これにより、ワクチン対象疾患に感染履歴を持つ場合およびワクチン接種でのみ選択されたエピトープに反応することが担保され、ワクチン有効性の評価に用いることができる。免疫細胞による特異的応答はワクチン抗原にのみ反応するため、当該エピトープによる反応性を見ることで、ワクチン接種後にワクチン対象疾患に対する免疫の有無や強度が判断できる。これにより、ワクチン有効性評価・再感染防御能を評価することができる。
本開示のペプチドなどは、化学合成、遺伝子工学により微生物などにより製造させる方法などの種々の方法を用いて製造することができる。
タンパク質またはペプチドは、標準的な分子生物学的技法によるタンパク質、ポリペプチドまたはペプチドの発現、天然供給源からのタンパク質、インビトロ翻訳、またはペプチドの単離、またはタンパク質またはペプチドの化学合成を含め、当業者に公知の任意の技法によって作製することができる。様々な遺伝子に対応するヌクレオチドおよびタンパク質、ポリペプチド及びペプチド配列は既に開示されており、当業者に公知のコンピュータ化されたデータベースを参照することができる。一つのかかるデータベースは、国立衛生研究所(National Institutes of Health)ウェブサイトにある国立バイオテクノロジー情報センター(National Center for Biotechnology Information)のGenbankおよびGenPeptデータベースである。既知の遺伝子のコード領域は、本明細書に開示される技法を用いて、または当業者に公知であるとおりに増幅しおよび/または発現させることができる。あるいいは、様々な市販のタンパク質、ポリペプチドおよびペプチド調製物が当業者に公知である。
一局面において、本開示は、疾患関連因子に特異的な濾胞性T細胞を惹起する能力を有する、疾患関連因子またはその一部を提示するためのポリペプチドを提供する。このようなポリペプチドは、本開示の検査または診断に用いることができ、プローブとも呼ばれる。
他の局面において、本開示は、疾患関連因子に特異的な濾胞性T細胞を惹起する能力を有する、疾患関連因子またはその一部と相互作用するTCRと特異的に結合する抗体を提供する。このような抗体は、本開示の検査または診断に用いることができ、プローブとも呼ばれる。
本開示は医薬として提供されることができる。医薬または医薬組成物に含まれる成分は、薬剤などと称され得る。本開示の医薬は、ワクチン(細胞ワクチンを含む)またはプローブとして提供され得る。
一局面において、本開示の治療または予防は、
1)同定した濾胞性T細胞エピトープ、もしくはその機能的等価物を含むものを、他のワクチン抗原/核酸に結合させる、またはウイルスベクターもしくはVLPに独立に発現させるステップと、
2)(細胞障害性T細胞エピトープなどの)B細胞またはTfhとは別の免疫惹起を引き起こすものと混合するステップと、
3)2)により得られたものを投与するステップとを
行うことで実施することができる
本開示の一局面において、被検体に対する該疾患を評価するための方法、これを実現するためのコンピュータプログラムもしくはこれを格納する記録媒体、およびシステムあるいはそのシステムの一部を構成するユーザ機器などが提供される。
(一般技術)
本実施例において、単一細胞ベースのRNAシーケンスプラットフォーム(10xGenomics社のChromium)を使用して、SARS-CoV-2特異的T細胞サブセットとそのクローン型を分析する。
末梢血単核球(PBMC)を、健康なドナーおよびウイルス感染患者(例えば、インフルエンザウイルス感染患者)を含む6人の個人から調製する。調製は以下の様に行う。全血をヘパリンコーティングチューブに収集し、1500rpmで10分間遠心分離して、細胞画分と血漿を分離した。血漿を細胞ペレットから除去し、-80℃で保存する。次に、PBMCを密度勾配沈降によって分離し、ACK溶解バッファーを使用して赤血球を溶解する。分離したPBMCを、STEM-CELLBANKER(Zenoaq Resource)で-80℃で凍結保存する。
以下の試薬を使用して、単一細胞の捕捉とライブラリーの調製を行った。Chromium Single Cell 5'Library&Gel Bead Kit、PN-1000165; Chromium Next GEM Chip G Single Cell Kit、PN-1000120; Chromium Single Index Kit T Set A、PN-1000213 ; Chromium Single Cell 5’Feature Barcode Library Kit、PN-1000080;Single Index Kit N Set A、PN-1000212;Chromium シングルセルV(D)J濃縮キット、ヒトT細胞、PN-1000005。約2×104個の細胞を含む単一細胞懸濁液をChromiumマイクロ流体チップにロードし、製造元の指示に従ってChromiumコントローラー(10XGenomics)を使用して単一細胞のゲルビーズインエマルジョンを生成する。続いて、各サンプルのバーコード付き細胞由来のRNAを、Veriti Thermal Cycler(Thermo Fisher Scientific)を使用して、ゲルビーズインエマルジョン内で逆転写し、単一細胞ライブラリーを生成するための後続のすべてのステップを、cDNA増幅のために14サイクルで、製造元のプロトコルに従って実行する。次に、約50ngのcDNAを、TCRライブラリーのcDNA濃縮およびライブラリー構築と並行して14サイクルの遺伝子発現ライブラリー増幅に使用する。ライブラリーのフラグメントサイズは、Agilent 2100 Bioanalyzer(Agilent)で確認する。ライブラリーは、ペアエンドモード(read1:28bp;read2:91bp)としてIllumina NovaSeq6000でシーケンスした。生のリードは、Cell Ranger 3.1.0(10XGenomics)によって処理する。遺伝子発現ベースのクラスタリングは、Seurat Rパッケージを使用した実施する(v3.1、Hafemeister, C., Satija, R. Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. Genome Biol 20, 296 (2019).https://doi.org/10.1186/s13059-019-1874-1)。簡単に説明すると、ミトコンドリア含有量が10%を超える細胞、検出された遺伝子が200未満、または4000を超える細胞を、外れ値(それぞれ、死にかけている細胞、空の液滴、ダブレット)と見なし、フィルターで除外する。正規化にはSeuratSCTransform関数を使用し、すべてのサンプルを同時に処理したため、バッチ効果補正を実行せずにデータを統合する。HashTagオリゴ逆多重化を、CLRで正規化されたHashTagUMIカウントで実行し、クローン型を、Pythonスクリプトを使用して、液滴バーコードを介して遺伝子発現データと照合する。単一のハッシュタグとベータチェーンクロノタイプが割り当てられた細胞のみが、ダウンストリーム分析のために保持する。
1~3×105個のPBMCをQIAzolで溶解し、次に、SMARTerテクノロジー(Takara Bio)を使用して完全長cDNAを合成し、TRAC/TRBC特異的プライマーを使用してTCRαおよびβ遺伝子の可変領域を増幅する。可変領域アンプリコンのシーケンシング後、MiXCRソフトウェアを使用して(Bolotin, D., Poslavsky, S., Mitrophanov, I. et al. MiXCR: software for comprehensive adaptive immunity profiling. Nat Methods 12, 380-381 (2015).https://doi.org/10.1038/nmeth.3364)、リードの各ペアにクローン型(TR(A/B)VおよびTR(A/B)J遺伝子、および相補性決定領域(CDR)3として定義)を割り当てる。各アルファ/ベータクローン型について、拡張を、そのクローンの読み取りの割合をアルファ/ベータ鎖のリードの総数でそれぞれ割ったものとして定義し、プロットと統計分析のために割合をlog10に変換する。
これらのTCRαβペアを、それぞれ同一のVα、Jα、Vβ、およびJβの使用を共有する、患者X1およびX2に由来するクローン1および2として指定する。さらに、クローン1および2のCDR3α配列は同一であり、CDR3βは1つのアミノ酸を除いて同一であることがわかることもある。
クローン1および2は、応答性を確認する。これは、単一細胞分析で明らかになった初期抗原特異性と一致することが確認できる。
クローン1および2のTCRはCDR3内の1つのアミノ酸で異なることが判明したりする。この場合、両方のTCRは、同一のMHC分子によって提示される同じエピトープを認識し、異なるドナーに由来するものであるため、クローン1および2がパブリッククローンであることを示唆すると解釈され得る。このエピトープは、他のインフルエンザウイルスの対応するアミノ酸配列との相同性が低いと解釈することができる。
日本人集団におけるDRB1*15:02(10.6%)および*15:01(7.7%)の頻度を考慮すると(http://hla.or.jp/)、これらのクローン型が存在する場合、人口の18.3%において、クローン1および2はこのペプチドに応答すると予想することができる。他のHLA型についても同様の拘束特異性を検査することができる。
本実施例において、単一細胞ベースのRNAシーケンスプラットフォーム(10xGenomics社のChromium)を使用して、SARS-CoV-2特異的T細胞サブセットとそのクローン型を分析した。
末梢血単核球(PBMC)を、健康なドナーおよび回復期のCOVID-19患者を含む6人の個人から調製した(表1および2)。調製は以下の様に行った。全血をヘパリンコーティングチューブに収集し、1500rpmで10分間遠心分離して、細胞画分と血漿を分離した。血漿を細胞ペレットから除去し、-80℃で保存した。次に、PBMCを密度勾配沈降によって分離し、ACK溶解バッファーを使用して赤血球を溶解しした。分離したPBMCを、STEM-CELLBANKER(Zenoaq Resource)で-80℃で凍結保存した。
表1:参加者の特徴
表2:日本におけるCOVID-19疾患重症度分類
凍結保存したPBMCを解凍し、5%ヒトAB血清を添加したRPMI1640培地で洗浄した。5×105個のPBMCを、1μg/mlのSタンパク質、組換えSタンパク質(1μg/ml)、Sペプチドプール(1μg/ml/ペプチド)またはM+Nペプチドプール(1μg/ml)を含む不活化SARS-CoV-2で刺激した。(不活化SARS-CoV-2ウイルスは塩田氏と中山氏(大阪大学微生物病研究所)から提供された。組換えSARS-CoV-2Sタンパク質はAmanat F, et al. bioRxiv.2020.に記載されたように調製された。PepMix SARS-CoV-2(スパイク糖タンパク質)(プール#1および#2を含む)は、JPT PeptideTechnologiesから購入した。PepTivator SARS-CoV-2 Prot_Mおよび_Nは、MiltenyiBiotecから購入した。)37℃で20時間、続いて抗ヒトCD3(HIT3a)、CD69(FN50)、CD137(4B4-1)およびTotalSeq(商標)-Cハッシュタグ(全て、バイオレジェンド社から購入)で染色した。CD3+CD69+またはCD3+CD137+細胞を、セルソーターSH-800Sセル(SONY)によってソートし、以下に記載するようにシングルセルVDJ-RNA-seq分析によってRNA発現とともにTCR配列を分析した。
(シングルセルベースのトランスクリプトームおよびTCRレパトア分析)
以下の試薬を使用して、単一細胞の捕捉とライブラリーの調製を行った。Chromium Single Cell 5'Library&Gel Bead Kit、PN-1000165; Chromium Next GEM Chip G Single Cell Kit、PN-1000120; Chromium Single Index Kit T Set A、PN-1000213 ; Chromium Single Cell 5′ Feature Barcode Library Kit、PN-1000080;Single Index Kit N Set A、PN-1000212 ; Chromium シングルセルV(D)J濃縮キット、ヒトT細胞、PN-1000005。約2×104個の細胞を含む単一細胞懸濁液をChromiumマイクロ流体チップにロードし、製造元の指示に従ってChromiumコントローラー(10XGenomics)を使用して単一細胞のゲルビーズインエマルジョンを生成した。続いて、各サンプルのバーコード付き細胞由来のRNAを、Veriti Thermal Cycler(Thermo Fisher Scientific)を使用して、ゲルビーズインエマルジョン内で逆転写し、単一細胞ライブラリーを生成するための後続のすべてのステップを、cDNA増幅のために14サイクルで、製造元のプロトコルに従って実行した。次に、約50ngのcDNAを、TCRライブラリーのcDNA濃縮およびライブラリー構築と並行して14サイクルの遺伝子発現ライブラリー増幅に使用した。ライブラリーのフラグメントサイズは、Agilent 2100 Bioanalyzer(Agilent)で確認した。ライブラリーは、ペアエンドモード(read1:28bp;read2:91bp)としてIllumina NovaSeq6000でシーケンスした。生のリードは、Cell Ranger 3.1.0(10XGenomics)によって処理した。遺伝子発現ベースのクラスタリングは、Seurat Rパッケージを使用した実施した(v3.1、Hafemeister, C., Satija, R. Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. Genome Biol 20, 296 (2019). https://doi.org/10.1186/s13059-019-1874-1)。簡単に説明すると、ミトコンドリア含有量が10%を超える細胞、検出された遺伝子が200未満、または4000を超える細胞を、外れ値(それぞれ、死にかけている細胞、空の液滴、ダブレット)と見なし、フィルターで除外した。正規化にはSeuratSCTransform関数を使用し、すべてのサンプルを同時に処理したため、バッチ効果補正を実行せずにデータを統合した。HashTagオリゴ逆多重化を、CLRで正規化されたHashTagUMIカウントで実行し、クローン型を、Pythonスクリプトを使用して、液滴バーコードを介して遺伝子発現データと照合した。単一のハッシュタグとベータチェーンクロノタイプが割り当てられた細胞のみが、ダウンストリーム分析のために保持した。
1~3×105個のPBMCをQIAzolで溶解し、次に、SMARTerテクノロジー(Takara Bio)を使用して完全長cDNAを合成し、TRAC/TRBC特異的プライマーを使用してTCRαおよびβ遺伝子の可変領域を増幅した。可変領域アンプリコンのシーケンシング後、MiXCRソフトウェアを使用して(Bolotin, D., Poslavsky, S., Mitrophanov, I. et al. MiXCR: software for comprehensive adaptive immunity profiling. Nat Methods 12, 380-381 (2015).https://doi.org/10.1038/nmeth.3364)、リードの各ペアにクローン型(TR(A/B)VおよびTR(A/B)J遺伝子、および相補性決定領域(CDR)3として定義)を割り当てた。各アルファ/ベータクローン型について、拡張を、そのクローンの読み取りの割合をアルファ/ベータ鎖のリードの総数でそれぞれ割ったものとして定義し、プロットと統計分析のために割合をlog10に変換した。
これらの中で、患者間で共有されるTCRαβペアを検出した。
これらのTCRαβペアを、それぞれ同一のVα、Jα、Vβ、およびJβの使用を共有する、患者Ts-017およびTs-018に由来するクローン1および2として指定した。さらに、クローン1および2のCDR3α配列は同一であり、CDR3βは1つのアミノ酸を除いて同一であることがわかった(表4および図2)。クローン1、2は別々の被験者由来であるが、配列類似性から同一エピトープを認識すると推定された。また、共にTfhクラスターから同定されており、当該エピトープはTfhを誘導しやすいエピトープであることが期待された。
患者Ts-017とTs-018との両方からの抗原提示細胞(APC)がクローン1と2を活性化できることを見出した。これは、APCが相互に交換可能であることを示している(図3E)。)
したがって、DRB1*15:01、DPA1*02:02-DPB1*05:01、DQA1*01:02-DQB1*06など、Ts-017とTs-018との間で共有されるMHCクラスII対立遺伝子のそれぞれを、HLAの候補とした。次いで、クローン1および2によるSペプチドの認識を調べるために、これらの対立遺伝子を個別にトランスフェクトした。
実施例1のペプチドによる末梢血単核細胞(PBMC)の再刺激アッセイ
実施例1実験参加者から得たPBMC 1.0×105cellsをRPMI1640培地(5%human serum、penicillin/streptomycin添加)100μlに懸濁し、実施例1 ペプチドを1μg/mlになるよう添加し、96well plate(U底)で培養する(Day0)。
SARS-CoV-2 S864-882ペプチドによる末梢血単核細胞(PBMC)の再刺激アッセイ
実験参加者から得たPBMC1.0×105cellsをRPMI1640培地(5%human serum、penicillin/streptomycin添加)100μlに懸濁し、SARS-CoV-2 S864-882ペプチドを1μg/mlになるよう添加し、96well plate(U底)で培養した(Day0)。
24時間後、培地の上清を回収し、ELISAを用いてhuman IL-21の測定を行った。測定結果を図7に示す。
本実施例では、感染履歴の評価を行う。
抗体による感染履歴評価はよく行われているが、特異的免疫細胞は、抗体に比べて長期間維持されるため、感染履歴を調べる上で、感染源特異的な免疫細胞を同定することは特に有益である。感染源特異的なエピトープを含むプローブを用いたT細胞検出法は、感染後成立し維持された免疫細胞を簡便に検出する方法として有益である。プローブに反応するT細胞の有無は末梢血単核細胞(PBMC)を用いたELISPOTやフローサイトメトリーを用いた系によって容易に検出することが可能である。プローブ反応性のT細胞が検出されれば過去に感染したと判定される。
(材料)
インフルエンザウイルスの場合
抗原として、Influenza A,Hemagglutinin,Brisbane(funakoshi)を用いる。
腸管出血性大腸菌感染症の場合
抗原として、大腸菌O157由来リポポリサッカリド(Wako)を用いる。
真菌性肺炎の場合
抗原として、標準菌株(KWIK-STIK 2pack)Aspergillus fumigatus derived from ATCC 204305 01021P(アズワン)を用いる。
被検体の末梢血中の感染源特異的な免疫細胞の有無をELISPOTアッセイで調べる。ここで使用されるELISPOTアッセイでは、濾胞性T細胞が産生するIL-21を検出できる抗体をコートしたプレートを用いる。末梢血単核細胞(PBMC)をウェルに加え、上記の抗原を用いて36時間刺激する。分泌されたIL-21は、産生細胞の周辺にあるキャプチャー用抗体と結合する。洗浄により細胞を除去した後、検出用のサイトカイン抗体を添加し、スポットを検出する。ネガティブコントロールとして、感染源由来抗原による刺激を行わないアッセイを行う。
(結果)
IL-21の分泌が確認された場合、感染歴があると判断できる。
本実施例では、ワクチン有効性評価・再感染防御能の評価を行う。
感染源特異的免疫細胞は、抗体に比べて長期間維持され、再感染時に迅速に応答しうるため、免疫細胞の防御能を評価に用いることができる。また、濾胞性T細胞は多くのT細胞分画の中でも液性免疫の誘導と強化(親和性成熟)に重要な分画であるため、特に濾胞性T細胞を誘導する当該感染源エピトープを含むプローブと反応するT細胞を持つ被験者はより強い、あるいは質的に優位な感染防御能を有すると判断される。そのため、感染後やワクチン摂取後に成立した免疫評価法として、PBMCにおいて、プローブ反応性の細胞の有無を調べることが有効であると考えられる。評価法は上記と同様にELISPOTやフローサイトメトリーを用いることができる。これらの方法は、検出するサイトカインを変更したり、表面抗原プローブを組み合わせることで、エピトーププローブに反応したT細胞が実際に濾胞性T細胞であったか、どの程度の割合がそうであったかを検出することもでき、検出感度や判定基準に応じて実験系を設計することができる。
(材料)
インフルエンザウイルスの場合
抗原として、InfluenzaA,Hemagglutinin,Brisbane(funakoshi)を用いる。
腸管出血性大腸菌感染症の場合
抗原として、大腸菌O157由来リポポリサッカリド(Wako)を用いる。
真菌性肺炎の場合
抗原として、標準菌株(KWIK-STIK 2pack) Aspergillus fumigatus derived from ATCC 204305 01021P(アズワン)を用いる。
(プロトコール)
被検体の末梢血中の感染源特異的な免疫細胞の有無をELISPOTアッセイで調べる。ここで使用されるELISPOTアッセイでは、濾胞性T細胞が産生するIL-21を検出できる抗体をコートしたプレートを用いる。末梢血単核細胞(PBMC)をウェルに加え、上記の抗原を用いて36時間刺激する。分泌されたIL-21は、産生細胞の周辺にあるキャプチャー用抗体と結合する。洗浄により細胞を除去した後、検出用のサイトカイン抗体を添加し、スポットを検出する。ネガティブコントロールとして、感染源由来抗原による刺激を行わないアッセイを行う。
(結果)
IL-21の分泌が確認された場合、免疫細胞の防御能が有効であると判断できる。
本実施例では、がん免疫薬剤(免疫チェックポイントなど)有効性評価を行う。
がん抗原に対する液性免疫応答が惹起されれば、より高い抗腫瘍性が期待される。そのため、抗腫瘍液性免疫応答を誘導する濾胞性T細胞がより多く検出される被験者は、被験者の抗腫瘍免疫が活性化しやすく、免疫チェックポイント阻害剤など被験者の抗腫瘍免疫を強化する薬剤がより有効であると考えられる。
腫瘍生検検体や末梢血から得たT細胞とエピトーププローブとの反応性を評価することで、被験者の抗腫瘍免疫の活動度を評価し、治療法選択に役立てることが考えられる。また、エピトーププローブとフローサイトメトリーを組み合わせ、薬剤投与中のエピトープ特異的濾胞性T細胞(腫瘍特異的濾胞性T細胞)の活性化や疲弊度を評価することで、抗腫瘍免疫の活動が維持されているかどうか調べることが期待される。これは免疫チェックポイント阻害剤が今後も有効であるか、治療を中断し別の治療法を模索すべきか等の判断に有効である。
(材料)
肺がんの場合
抗原として、肺がんマーカーであるCEAを用いる。
胃がんの場合
抗原として、胃がんマーカーであるCA19-9を用いる。
被検体の末梢血中の抗原特異的な免疫細胞の有無をELISPOTアッセイで調べる。ここで使用されるELISPOTアッセイでは、濾胞性T細胞が産生するIL-21を検出できる抗体をコートしたプレートを用いる。末梢血単核細胞(PBMC)をウェルに加え、上記の抗原を用いて36時間刺激する。分泌されたIL-21は、産生細胞の周辺にあるキャプチャー用抗体と結合する。洗浄により細胞を除去した後、検出用のサイトカイン抗体を添加し、スポットを検出する。ネガティブコントロールとして、抗原による刺激を行わないアッセイを行う。
ネガティブコントロールと比較してIL-21の分泌の増加が確認された場合、がん免疫薬剤が有効に作用すると判断することができる。
本実施例では、自己抗体を伴う自己免疫疾患のリスク評価(未病時)、病態評価を行う。
自己抗体を伴う自己免疫疾患は多いが、その中でも自己抗体が病原性を持つと考えられる疾患(例えばANCA関連血管炎)においては、自己抗体を産生するB細胞と相互作用する濾胞性 T細胞の有無・増減が、B細胞の成熟に伴う発症や病態悪化/再燃につながることが考えられる。そのため、疾患特異的な自己抗原由来のエピトープを提示する濾胞性T細胞を検出することにより、疾患リスク(発症前)や疾患活動度を評価することができると考えられる。
試験方法としては被験者から採取したPBMCに対しプローブ反応性の細胞をELISPOTやフローサイトメトリーを用いて調べることが考えられる。
(材料)
アトピー性皮膚炎の場合
アトピー性皮膚炎を引き起こす自己抗体を、抗原として用いる。
アレルギー性鼻炎の場合
アレルギー性鼻炎を引き起こす自己抗体を、抗原として用いる。
喘息の場合
喘息を引き起こす自己抗体を、抗原として用いる。
被検体の末梢血中の抗原特異的な免疫細胞の有無をELISPOTアッセイで調べる。ここで使用されるELISPOTアッセイでは、濾胞性T細胞が産生するIL-21を検出できる抗体をコートしたプレートを用いる。末梢血単核細胞(PBMC)をウェルに加え、上記の抗原を用いて36時間刺激する。分泌されたIL-21は、産生細胞の周辺にあるキャプチャー用抗体と結合する。洗浄により細胞を除去した後、検出用のサイトカイン抗体を添加し、スポットを検出する。ネガティブコントロールとして、抗原による刺激を行わないアッセイを行う。
ネガティブコントロールと比較してIL-21の分泌の増加が確認された場合、疾患リスク(発症前)や疾患活動度が高いと判断できる。
これまでの実施例で述べてきたように、エピトープ特異的濾胞性T細胞応答は様々な疾患に適用しうる。一方で、エピトープや抗原自身が不明な疾患があることも事実であり、そのためにもさまざまな患者における既知の疾患関連エピトープを含む様々なエピトープに対する濾胞性T細胞応答のデータを研究期間内で共有し、ビッグデータとして新たな知見を得るための基盤として運用することが考えられる。試験方法としては被験者から採取したPBMCに対しプローブ反応性の細胞をELISPOTやフローサイトメトリーを用いて調べることが考えられる。
(材料および方法)
(材料)
明確な抗原が不明な全身性エリテマトーデスを対象疾患として考える。
これに対し、既知の感染症等の抗原由来エピトープやランダムに準備したエピトープをパネル化して用いて、濾胞性T細胞の個々のエピトープに対する応答やレベルを評価する。
(プロトコール)
被検体の末梢血中の抗原特異的な免疫細胞の有無をELISPOTアッセイで調べる。ここで使用されるELISPOTアッセイでは、濾胞性T細胞が産生するIL-21を検出できる抗体をコートしたプレートを用いる。末梢血単核細胞(PBMC)をウェルに加え、上記の抗原を用いて36時間刺激する。分泌されたIL-21は、産生細胞の周辺にあるキャプチャー用抗体と結合する。洗浄により細胞を除去した後、検出用のサイトカイン抗体を添加し、スポットを検出する。ネガティブコントロールとして、抗原による刺激を行わないアッセイを行う。
ネガティブコントロールと各エピトープのIL-21の分泌量の情報と臨床情報をデータとして共有・保管し、将来の診断法開発や疾患の細分化・治療法選択法の開発に用いる。
以上のように、本開示の好ましい実施形態を用いて本開示を例示してきたが、本開示は、この実施形態に限定して解釈されるべきものではない。本開示は、特許請求の範囲によってのみその範囲が解釈されるべきであることが理解される。当業者は、本開示の具体的な好ましい実施形態の記載から、本開示の記載および技術常識に基づいて等価な範囲を実施することができることが理解される。本明細書において引用した特許、特許出願および文献は、その内容自体が具体的に本明細書に記載されているのと同様にその内容が本明細書に対する参考として援用されるべきであることが理解される。本出願は、日本国特許庁に、2021年3月16日に出願された特願2021-42670に対する優先権主張を伴うものであり、その内容は、その全体が本願において参考として援用される。
Claims (56)
- 被検体における疾患の疾患関連因子に反応性の濾胞性T細胞のレベルまたは量を測定すること、および
該レベルまたは量を所定の基準と比較すること
を含む、該被検体に関する該疾患に関する事項を試験するための方法。 - 前記基準が、前記疾患の履歴、前記疾患に対する予防剤またはワクチンの有効性、前記疾患に対する治療剤の有効性、前記疾患の再罹患に対する防御能、前記疾患の病態および前記疾患の罹患リスクからなる群より選択される少なくとも1つに関する基準である、請求項1に記載の方法。
- 前記基準が、前記被検体における前記疾患に関する基準である、請求項1または2に記載の方法。
- 前記基準が、前記被検体の前記疾患の感染履歴に関する基準である、請求項1に記載の方法。
- 前記基準が、前記被検体の前記疾患のワクチン有効性・再感染防御能に関する基準である、請求項1に記載の方法。
- 前記基準が、前記被検体の前記疾患のがん免疫薬剤の有効性評価に関する基準である、請求項1に記載の方法。
- 前記疾患関連因子は、自己免疫疾患関連因子であり、前記測定は該自己免疫疾患関連因子に反応性の濾胞性T細胞のレベルまたは量を測定することを含み、前記基準が、前記被検体の自己抗体を伴う自己免疫疾患のリスク、病態に関する基準である、請求項1に記載の方法。
- 前記測定は、ELISPOT、フローサイトメトリー、末梢血単核細胞(PBMC)の再刺激アッセイ、次世代シーケンサー/遺伝子検査(レパトア解析)、免疫染色(病理組織検査)、in situ解析による、請求項1~7のいずれか一項に記載の方法。
- 前記比較は、測定した前記疾患関連因子に反応性の濾胞性T細胞のレベル、空間的分布または量を、疾患に罹患していない被験体における疾患関連因子に反応性の濾胞性T細胞のレベル、空間的分布または量の平均値または中央値と比較することをさらに含む、請求項1~8のいずれか一項に記載の方法。
- 前記疾患は、感染症またはがんである、請求項1~6および8~9のいずれか一項に記載の方法。
- 前記疾患はウイルス感染症である、請求項1~6および8~9のいずれか一項に記載の方法。
- 前記疾患はアレルギーまたは自己免疫疾患である、請求項1~9のいずれか一項に記載の方法。
- 被検体における疾患の疾患関連因子に反応性の濾胞性T細胞のレベル、空間的分布または量を測定する試薬またはデバイスを含む、該被検体に対する該疾患を評価するための試薬またはデバイス。
- 前記試薬またはデバイスは、濾胞性T細胞に対して特異的に反応する試薬を含む、請求項13に記載の試薬またはデバイス。
- 前記デバイスは、ELISPOT、フローサイトメトリー、末梢血単核細胞(PBMC)の再刺激アッセイ、次世代シーケンサー/遺伝子検査(レパトア解析)、免疫染色(病理組織検査)、in situ解析を行うためのデバイスである、請求項13に記載の試薬またはデバイス。
- 前記疾患は、感染症またはがんである、請求項13~15のいずれか一項に記載の試薬またはデバイス。
- 前記疾患はウイルス感染症である、請求項13~15のいずれか一項に記載の試薬またはデバイス。
- 前記疾患はアレルギーまたは自己免疫疾患である、請求項13~15のいずれか一項に記載の試薬またはデバイス。
- 被検体における疾患の疾患関連因子に反応性の濾胞性T細胞のレベル、空間的分布または量を測定する試薬またはデバイスと、
該試薬またはデバイスによる測定結果を該疾患について評価する評価部と
を含む、該被検体に対する該疾患を評価するためのシステム。 - 前記評価部は、前記疾患の履歴の評価、前記疾患に対する予防剤またはワクチンの有効性の評価、前記疾患に対する治療剤の有効性の評価、前記疾患の再罹患に対する防御能の評価、前記疾患の病態評価および前記疾患の罹患リスク評価からなる群より選択される少なくとも1つを行うように構成される、請求項19に記載のシステム。
- 前記被検体における前記疾患を検査または診断する検査・診断部をさらに含む、請求項19または20に記載のシステム。
- 前記被検体の前記疾患の感染履歴の評価をする感染履歴評価部をさらに含む、請求項19に記載のシステム。
- 前記被検体の前記疾患のワクチン有効性評価・再感染防御能の評価をするワクチン有効性評価・再感染防御能評価部をさらに含む、請求項19に記載のシステム。
- 前記被検体の前記疾患のがん免疫薬剤の有効性評価をするがん免疫薬剤有効性評価部をさらに含む、請求項19に記載のシステム。
- 前記疾患関連因子は、自己免疫疾患関連因子であり、該自己免疫疾患関連因子に反応性の濾胞性T細胞のレベル、空間的分布または量を測定する濾胞性T細胞測定部、ならびに前記被検体の自己抗体を伴う自己免疫疾患のリスク評価、病態評価をする自己免疫疾患リスク評価、病態評価部を含む、請求項19に記載のシステム。
- 前記試薬またはデバイスは、濾胞性T細胞に対して特異的に反応する試薬を含む、請求項19~25のいずれか一項に記載のシステム。
- 前記デバイスは、ELISPOT、フローサイトメトリー、末梢血単核細胞(PBMC)の再刺激アッセイ、次世代シーケンサー/遺伝子検査(レパトア解析)、免疫染色(病理組織検査)、in situ解析を行うためのデバイスである、請求項19~25のいずれか一項に記載のシステム。
- 測定した前記疾患関連因子に反応性の濾胞性T細胞のレベル、空間的分布または量を、疾患に罹患していない被験体における疾患関連因子に反応性の濾胞性T細胞のレベル、空間的分布または量の平均値または中央値と比較する比較部をさらに含む、請求項19~27のいずれか一項に記載のシステム。
- 前記疾患は、感染症またはがんである、請求項19~24および26~28のいずれか一項に記載のシステム。
- 前記疾患はウイルス感染症である、請求項19~24および26~28のいずれか一項に記載のシステム。
- 前記疾患はアレルギーまたは自己免疫疾患である、請求項19~24および26~28のいずれか一項に記載のシステム。
- 被検体における疾患の疾患関連因子に反応性の濾胞性T細胞のレベル、空間的分布または量に関する情報を提供する工程と、
該濾胞性T細胞のレベル、空間的分布または量に関する情報を所定の基準と比較する工程と
を含む、該被検体に関する該疾患に関する事項を試験するための方法。 - 前記基準が、前記疾患の履歴の有無、前記疾患に対する予防剤またはワクチンの有効性、前記疾患に対する治療剤の有効性、前記疾患の再罹患に対する防御能の有無、前記疾患の病態評価および前記疾患の罹患リスクからなる群より選択される少なくとも1つに関する基準である、請求項32に記載の方法。
- 前記基準が、前記被検体の前記疾患の感染履歴の有無に関する基準である、、請求項32に記載の方法。
- 前記基準が、前記被検体の前記疾患のワクチン有効性・再感染防御能の有無に関する基準である、請求項32に記載の方法。
- 前記基準が、前記被検体の前記疾患のがん免疫薬剤の有効性に関する基準である、請求項32に記載の方法。
- 前記疾患関連因子は、自己免疫疾患関連因子であり、前記測定は該自己免疫疾患関連因子に反応性の濾胞性T細胞のレベルまたは量を測定することを含み、前記基準が、前記被検体の自己抗体を伴う自己免疫疾患のリスク、病態に関する基準である、請求項32に記載の方法。
- 前記情報を提供する工程は、ELISPOT、フローサイトメトリー、末梢血単核細胞(PBMC)の再刺激アッセイ、次世代シーケンサー/遺伝子検査(レパトア解析)、免疫染色(病理組織検査)、in situ解析により行われるものである、請求項32~37のいずれか一項に記載の方法。
- 前記比較は、前記被検体における疾患の疾患関連因子に反応性の濾胞性T細胞のレベル、空間的分布または量に関する情報を、疾患に罹患していない被験体における被検体における疾患の疾患関連因子に反応性の濾胞性T細胞のレベル、空間的分布または量に関する情報の平均値または中央値と比較することをさらに含む、請求項32~38のいずれか一項に記載の方法。
- 前記疾患は、感染症またはがんである、請求項32~36および38~39のいずれか一項に記載の方法。
- 前記疾患はウイルス感染症である、請求項32~36および38~39のいずれか一項に記載の方法。
- 前記疾患はアレルギーまたは自己免疫疾患である、請求項32~41のいずれか一項に記載の方法。
- 被検体における疾患の疾患関連因子に反応性の濾胞性T細胞のレベル、空間的分布または量に関する情報を提供する工程と、
該濾胞性T細胞のレベル、空間的分布または量に関する情報を該疾患について評価する工程と
を含む、該被検体に対する該疾患を評価するための方法を、コンピュータに実装するコンピュータ読み取り可能なコードを含むプログラム。 - 前記評価する工程が、前記疾患の履歴の評価、前記疾患に対する予防剤またはワクチンの有効性の評価、前記疾患に対する治療剤の有効性の評価、前記疾患の再罹患に対する防御能の評価、前記疾患の病態評価および前記疾患の罹患リスク評価からなる群より選択される少なくとも1つを行うことをさらに含む、請求項43に記載のプログラム。
- 前記方法が、前記被検体の前記疾患の感染履歴の評価をすることを含む、請求項43に記載のプログラム。
- 前記方法が、前記被検体の前記疾患のワクチン有効性評価・再感染防御能の評価をすることを含む、請求項43に記載のプログラム。
- 前記方法が、前記被検体の前記疾患のがん免疫薬剤の有効性評価をすることを含む、請求項43に記載のプログラム。
- 前記疾患関連因子は、自己免疫疾患関連因子であり、前記方法が、前記測定は該自己免疫疾患関連因子に反応性の濾胞性T細胞のレベルまたは量を測定すること、ならびに前記被検体の自己抗体を伴う自己免疫疾患のリスク評価、病態評価をすることを含む、請求項43に記載のプログラム。
- 前記情報を提供する工程は、ELISPOT、フローサイトメトリー、末梢血単核細胞(PBMC)の再刺激アッセイ、次世代シーケンサー/遺伝子検査(レパトア解析)、免疫染色(病理組織検査)、in situ解析により行われるものである、請求項43~48のいずれか一項に記載のプログラム。
- 前記方法が、前記被検体における疾患の疾患関連因子に反応性の濾胞性T細胞のレベル、空間的分布または量に関する情報を、疾患に罹患していない被験体における被検体における疾患の疾患関連因子に反応性の濾胞性T細胞のレベル、空間的分布または量に関する情報の平均値または中央値と比較することをさらに含む、請求項43~49のいずれか一項に記載のプログラム。
- 前記疾患は、感染症またはがんである、請求項43~47および49~50のいずれか一項に記載のプログラム。
- 前記疾患はウイルス感染症である、請求項43~47および49~50のいずれか一項に記載のプログラム。
- 前記疾患はアレルギーまたは自己免疫疾患である、請求項43~50のいずれか一項に記載のプログラム。
- 請求項43~53のいずれか一項に記載のプログラムを格納したコンピュータ読み取り可能な記録媒体。
- 被検体における疾患の疾患関連因子に反応性の濾胞性T細胞のレベルまたは量を測定することを含む、該被検体に対する該疾患を評価するための方法。
- 被検体における疾患の疾患関連因子に反応性の濾胞性T細胞のレベル、空間的分布または量に関する情報を提供する工程と、
該濾胞性T細胞のレベル、空間的分布または量に関する情報を該疾患について評価する工程と
を含む、該被検体に対する該疾患を評価するための方法。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22771446.6A EP4310171A1 (en) | 2021-03-16 | 2022-03-15 | Novel medical technique using follicular t-cells |
CN202280022067.8A CN117441103A (zh) | 2021-03-16 | 2022-03-15 | 使用滤泡性t细胞的新型医疗技术 |
JP2023507138A JPWO2022196701A1 (ja) | 2021-03-16 | 2022-03-15 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021-042670 | 2021-03-16 | ||
JP2021042670 | 2021-03-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022196701A1 true WO2022196701A1 (ja) | 2022-09-22 |
Family
ID=83322131
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/011710 WO2022196701A1 (ja) | 2021-03-16 | 2022-03-15 | 濾胞性t細胞を用いた新規医療技術 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP4310171A1 (ja) |
JP (1) | JPWO2022196701A1 (ja) |
CN (1) | CN117441103A (ja) |
WO (1) | WO2022196701A1 (ja) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998037919A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
WO1998040100A1 (en) | 1997-03-10 | 1998-09-17 | Ottawa Civic Loeb Research Institute | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT |
WO1998052581A1 (en) | 1997-05-20 | 1998-11-26 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
WO1998055495A2 (en) | 1997-06-06 | 1998-12-10 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
WO1999011241A1 (en) | 1997-09-05 | 1999-03-11 | Smithkline Beecham Biologicals S.A. | Oil in water emulsions containing saponins |
WO2016186154A1 (ja) * | 2015-05-19 | 2016-11-24 | 国立研究開発法人国立精神・神経医療研究センター | 多発性硬化症(ms)患者の新規治療適用判断方法 |
JP2021042670A (ja) | 2016-11-07 | 2021-03-18 | パナソニック株式会社 | 密閉型電動圧縮機及びこれを用いた冷凍装置 |
-
2022
- 2022-03-15 WO PCT/JP2022/011710 patent/WO2022196701A1/ja active Application Filing
- 2022-03-15 EP EP22771446.6A patent/EP4310171A1/en active Pending
- 2022-03-15 JP JP2023507138A patent/JPWO2022196701A1/ja active Pending
- 2022-03-15 CN CN202280022067.8A patent/CN117441103A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998037919A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
WO1998040100A1 (en) | 1997-03-10 | 1998-09-17 | Ottawa Civic Loeb Research Institute | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT |
WO1998052581A1 (en) | 1997-05-20 | 1998-11-26 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
WO1998055495A2 (en) | 1997-06-06 | 1998-12-10 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
WO1999011241A1 (en) | 1997-09-05 | 1999-03-11 | Smithkline Beecham Biologicals S.A. | Oil in water emulsions containing saponins |
WO2016186154A1 (ja) * | 2015-05-19 | 2016-11-24 | 国立研究開発法人国立精神・神経医療研究センター | 多発性硬化症(ms)患者の新規治療適用判断方法 |
JP2021042670A (ja) | 2016-11-07 | 2021-03-18 | パナソニック株式会社 | 密閉型電動圧縮機及びこれを用いた冷凍装置 |
Non-Patent Citations (20)
Title |
---|
ALTSCHUL ET AL., J. MOL. BIOL, vol. 215, 1990, pages 403 - 410 |
BATZE ET AL., NUCLEIC ACID RES, vol. 19, 1991, pages 5081 |
BOLOTIN, D.POSLAVSKY, S.MITROPHANOV, I ET AL.: "MiXCR: software for comprehensive adaptive immunity profiling", NAT METHODS, vol. 12, 2015, pages 380 - 381, Retrieved from the Internet <URL:https://doi.org/10.1038/nmeth.3364> |
CHEN, Y.-ZLIU, G.SENJU, SWANG, Q.IRIE, A.HARUTA, M.NISHIMURA, Y: "Identification of SARS-COV Spike Protein-Derived and HLA-A2-Restricted Human CTL Epitopes by Using a New Muramyl Dipeptide-Derivative Adjuvant", INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2010, pages 165 - 177, Retrieved from the Internet <URL:https://doi.org/10.1177/039463201002300115> |
CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, Retrieved from the Internet <URL:http://onlinelibrary.wiley.com/book/10.1002/0471142727> |
IWAMOTO, YAYIO; UENO, HIDEKI: "Differentiation and functions of human T follicular helper cells", RINSHO MENEKI ARERUGIKA = CLINICAL IMMUNOLOGY & ALLERGOLOGY, JP, vol. 74, no. 6, 25 December 2020 (2020-12-25), JP , pages 637 - 645, XP009539782, ISSN: 1881-1930 * |
KRIEG, CURROPINMOLTHER, vol. 3, 2001, pages 15 - 24 |
KRIEG, VACCINE, vol. 19, 2000, pages 618 - 622 |
MARK ET AL., PROC NATL ACAD SCI USA, vol. 81, no. 18, September 1984 (1984-09-01), pages 5662 - 5666 |
MERRIFIELD RB: "Solid phase peptide synthesis I. Synthesis of tetrapeptides", J. AM. CHEM. SOC, vol. 85, 1963, pages 2149 - 54, XP002257754, DOI: 10.1021/ja00897a025 |
NEEDLEMANWUNSCH, J. MOL. BIOL, vol. 48, 1970, pages 443 - 453 |
OHTSUKA ET AL., J. BIOL. CHEM, vol. 260, 1985, pages 2605 - 2608 |
PEARSONLIPMAN, PROC. NATL. ACAD. SCI., USA, vol. 85, 1988, pages 2444 - 2448 |
ROSSOLINI ET AL., MOL. CELL. PROBES, vol. 8, 1994, pages 91 - 98 |
SAMBROOK ET AL.: "A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY, article "Molecular Cloning" |
SHIGENARI ISHIZUKA, MASAMICHI NAGAE, SHO YAMASAKI: "Analysis on T cells specific for SARS-CoV-2 in recovered patients", JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, BIOMEDICAL DRUGS PUBLICATION, JP, vol. 279, no. 10, 4 December 2021 (2021-12-04), JP , pages 947 - 952, XP009539776, ISSN: 0039-2359 * |
SMITH AND WATERMAN, BIOL, vol. 147, 1981, pages 195 - 197 |
WANG ET AL., SCIENCE, vol. 224, no. 4656, 29 June 1984 (1984-06-29), pages 1431 - 1433 |
Y. LONG; X. ZHAO; CHANG LIU; C. XIA; CHEN LIU: "Activated inducible co‐stimulator‐positive programmed cell death 1‐positive follicular helper T cells indicate disease activity and severity in ulcerative colitis patients", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, WILEY-BLACKWELL PUBLISHING LTD., GB, vol. 202, no. 1, 28 July 2020 (2020-07-28), GB , pages 106 - 118, XP071082538, ISSN: 0009-9104, DOI: 10.1111/cei.13485 * |
ZOLLER ET AL., NUCLEIC ACIDS RES, vol. 10, no. 20, 25 October 1982 (1982-10-25), pages 6487 - 6500 |
Also Published As
Publication number | Publication date |
---|---|
CN117441103A (zh) | 2024-01-23 |
EP4310171A1 (en) | 2024-01-24 |
JPWO2022196701A1 (ja) | 2022-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI816702B (zh) | 利用熱點識別新抗原之方法及電腦系統 | |
JP6661107B2 (ja) | T細胞受容体およびb細胞受容体レパトアの解析のための方法およびそのためのソフトウェア | |
Roberts et al. | Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells | |
JP2023162369A (ja) | T細胞療法用の新生抗原の特定法 | |
Wullner et al. | Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics | |
Muehling et al. | Circulating memory CD4+ T cells target conserved epitopes of rhinovirus capsid proteins and respond rapidly to experimental infection in humans | |
KR20200127001A (ko) | 범-대립유전자 모델을 갖는 신생항원 동정 | |
Martinuzzi et al. | acDCs enhance human antigen–specific T-cell responses | |
TWI733719B (zh) | 改善的組合物及用於新表位之病毒遞送的方法及其應用 | |
AU2015314776A1 (en) | Personalized cancer vaccines and methods therefor | |
CN113711239A (zh) | 利用ii类mhc模型鉴别新抗原 | |
CN109081867B (zh) | 癌症特异性tcr及其分析技术和应用 | |
WO2014098012A1 (ja) | ヘルパーt細胞の活性化方法 | |
CN110627895B (zh) | 肺癌特异性tcr及其分析技术和应用 | |
JPWO2017159686A1 (ja) | 免疫療法のためのモニタリングまたは診断ならびに治療剤の設計 | |
CA3131766A1 (en) | Cancer biomarkers for durable clinical benefit | |
CA3132028A1 (en) | Compositions and methods for preparing t cell compositions and uses thereof | |
BR112019021094A2 (pt) | Peptídeos e combinações dos mesmos para uso na imunoterapia contra leucemias e outros cânceres | |
WO2020252145A1 (en) | Neoantigen immunotherapies | |
Kasatskaya et al. | Functionally specialized human CD4+ T-cell subsets express physicochemically distinct TCRs | |
Liu et al. | Single-cell analysis reveals macrophage-driven T cell dysfunction in severe COVID-19 patients | |
Valentini et al. | Identification of neoepitopes recognized by tumor-infiltrating lymphocytes (TILs) from patients with glioma | |
JP6778932B2 (ja) | 免疫実体クラスタリングソフトウェア | |
CA3189269A1 (en) | Ras neoantigens and uses thereof | |
WO2019036043A2 (en) | METHOD FOR GENERATING A COCKTAIL OF PERSONALIZED ANTICANCER VACCINES FROM TUMOR DERIVED GENETIC MODIFICATIONS FOR THE TREATMENT OF CANCER |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22771446 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023507138 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022771446 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022771446 Country of ref document: EP Effective date: 20231016 |